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I declare that I have written this thesis based on my own work, and the contribution 
of others has been clearly indicated. 
Margaret L. Opsahi 
ABSTRACT 
Transgenic animals harbour exogenous DNA, which is transmitted to their 
progeny. Many transgenes exhibit appropriate spatio-temporal patterns of expression. 
However, expression levels often differ between individuals of the same transgenic 
line. This thesis investigates expression instability, focusing on mice carrying a 
transgene encoding sheep 3-lactoglobu1in (BLG), the major whey protein. BLG 
transgenes inserted as multicopy arrays within the mouse genome are robustly 
expressed in mammary epithelium and the product is exported into milk (Simons et 
al 1987). In two of the three lines studied, milk BLG levels differed markedly 
between individuals. This was attributed to mosaic expression due to stochastic 
inactivation of the transgene (Dobie et a! 1996), and suggestive of position effect 
variegation as seen in Drosophila. The highly variegating line, BLG/7, was chosen 
for further studies. 
The original line was created on a mixed genetic background. First, to address a 
possible link between genetic background and variegation, BLG/7 animals were 
backcrossed to inbred mouse strains CBA and C57BL/6. Transgene expression 
continued to variegate after 13 backcross generations. However, inbreeding reduced 
the absolute expression levels: the mean and variance differed significantly from the 
parental population. Levels were restored by intercrossing inbred strains. Second, 
homozygous BLG/7 mice were studied. Variegated expression was maintained, but 
maximum expression levels were indistinguishable from heterozygote levels. 
Fluorescent in situ hybridisation for nuclear BLG transcription revealed that only one 
transgene locus is active per cell. This is suggestive of a trans-homology effect for 
the BLG/7 transgene. Previously, similar events have only been reported in plants 
and insects. 
Finally, mosaic expression could reflect clonal expansion of committed 
progenitor cells. To address this issue, we sought to exploit X-inactivation. A lacZ 
reporter gene under BLG promoter control was targeted to the X-linked 
hypoxanthine- phosophoribosyl transferase (HPRT) gene of ES cells. To date, 
chimeric animals have been obtained; progeny reporter mice should address the issue 
of clonality of mosaic expression in BLGI7 mice. 
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TO A MOUSE 
Wee, slekit, cowrin, tim'rous beastie, 
0, what a panic's in thy breastie! 
Thou need na start awa sae hasty, 
Wi' bickering brattle! 
I wad be laith to rin an' chase thee, 
Wi' murd'ring pattle! 
I'm truly sorry man's dominion, 
Has broken nature's social union, 
An' justifies that ill opinion, 
Which makes thee startle 
At me, thy poor, earth-born companion, 
An' fellow-mortal! 
I doubt na, whiles, but thou may thieve; 
What then? poor beastie, thou maun live! 
A daimen icker in a thrave, 
'S a sma' request; 
I'll get blessin wi' the lave, 
An' never miss't! 
Thy wee bit housie, too, in ruin! 
It's silly wa's the win's are strewin! 
An' naething, now, to big a new ane, 
0' foggage green! 
An' bleak December's winds ensuing, 
Baith snell an' keen! 
Thou saw the fields laid bare an' waste, 
An' weary winter comin fast, 
An' cozie here, beneath the blast, 
Thou thought to dwell, 
Till crash! the cruel coulter past 
Out thro' thy cell. 
That wee bit heap o'leaves an' stibble, 
Has cost thee mony a weary nibble! 
Now thou's turn'd out, for a' thy trouble, 
But house or hald, 
To thole the winter's sleety dribble, 
An' cranreuch cauld! 
But Mousie, thou art no thy lane, 
In proving foresight may be vain; 
The best-laid schemes o' mice an' men, 
Gang aft agly, 
An' lea'e us nought but grief an' pain, 
For promis'd joy! 
V 
Still thou art blest, compar'd wi' me; 
The present only toucheth thee: 
But och! I backward cast my e'e, 
On prospect drear! 
An' forward, tho' I canna see, 
I guess an' fear! 
Robert Burns 
To the mice (mercifully few), to whom I owe so much: without whose contribution 
and sacrifice this thesis could not exist 
(Paraphrased from Winston Churchill) 
Also, to my family for continued support and encouragement throughout my studies: 
in return, you get a unique coffee table book with which to bore the neighbours and 
concuss burglars. 
Finally, to Graham, who has been there for me throughout, in the good times and the 
bad, with excellent advice from someone who has travelled this path before me 
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Transgenic technology has revolutionised biological research, its applications 
spanning a wide field of interest covering both industry and academia. During the 
past two decades, a large number of different transgenic plant and animal lines have 
been created. Although they differ widely with regards to transgene content or 
endogenous gene modification, successful transgenic lines require that any 
modification display certain key properties. Crucial to all transgenic applications is 
stability of integration, expression and inheritance of the transgene or endogenous 
gene modification (for an overview, see Jablonka 1992). With the increasing 
numbers of transgenic lines created, it has become evident that not all the transgenes 
are behaving as expected. One of these phenomena is transgene silencing. Silencing 
can be progressive, with reports of both endogenous and transgene silencing as a 
function of time, age or generation (see 1.5). All systems examined to date exhibit 
silencing phenomena, as the examples in this chapter clearly demonstrate. This 
suggests that the ability to silence gene expression is an ancient and possibly 
conserved mechanism. 
The loss of expression could be caused by transgene deletion, but recent 
investigations indicate that most transgenes remain stably integrated and inherited 
once a line has been established (Aigner et al 1999). Silencing must therefore be by 
some mechanism whose action can be maintained without changing the underlying 
genetic blueprint. Changes in gene expression without sequence modification is 
termed epigenetics, a term first introduced almost 60 years ago (Waddington 1942). 
Although the exact definition of the term is debated (Wu & Morris 2001), I believe 
that the most generally used and accepted definition derives from Holliday's 
definitions (1987, 1996), where epigenetics is explained as the study of changes in 
gene expression/function that are mitotically and can also be meiotically inherited 
without changing the DNA sequence (Wu & Morris 2001). Methylation (Assaad eta! 
1993, Koetsier et a! 1996, Schweizer et a! 1998) and histone acetylation (Cavalli & 
Paro 1999, Kim eta! 1999) are two examples of epigenetic marks. 
1 
Vector design, copy number, methylation status and site of integration are all known 
to influence transgene expression. Transgene silencing is now frequently reported, as 
is variable levels of expression from transgenic lines. Variations in transgene product 
yields are being observed both within and between some transgenic lines containing 
the same transgene inserted at different genomic locations (Palmiter et al 1982 & 
1984, Pittius et al 1988, Assaad et al 1993, Kunz et al 1996, Dobie et a! 1996, 
Festenstein et a! 1996, Gutierrez et a! 1996, Cerutti et al 1997, Guy et a! 1997, 
Kieffer et a! 1997, Ogilvy et a! 1998, Matzke et a! 2001). Although several of the 
published papers on variable transgene expression report differences in expression 
levels between lines (Pittius et a! 1988, Robertson et al 1996, Kieffer et al 1997), in 
many cases there is no mention of any investigation into the relative expression 
levels between different transgenic lines (Morley et a! 1996). There are increasing 
reports of variable expression levels within lines as well (Palmiter et al 1982, Bleck 
& Bremel 1994, Dobie et a! 1996 & 1997, Matzke et a! 2001). In addition to this 
being an interesting question regarding gene silencing, variable transgene expression 
has serious implications for the viability of commercial transgenics using plants and 
animals as bioreactors, as well as the future of effective gene therapy and academic 
investigations into gene function. 
1.1 The influence of vector design on transgene expression 
Vector design and delivery can have a profound effect on the expression potential of 
a transgene. The choice of delivery system and carrier construct determines the 
amount of DNA that can be transferred into the host system. The size limitations will 
in turn influence transgene design. Three elements are each credited with increasing 
the frequency of generation of lines harbouring expression competent transgenes. 
1.1.1 Intronic sequences required for correct nuclear processing of transcripts 
The first transgene constructs contained cDNA driven by minimal promoters. 
Despite good in vitro results, in vivo performances were disappointing (Whitelaw et 
a! 1991). Inclusion of intronic sequences was found to enhance in vivo expression by 
2 
increasing the probability of expression (Whitelaw et al 1991, Shani et al 1992, 
Clark et al 1993, Clark et al 1997). 
Intronic sequences may serve a function crucial to transgene expression potential: 
breaking up the coding sequences, contributing to correct chromatin conformation of 
the transgene locus (1.2) and avoiding homologous interactions with pseudogenes 
(Kricker et al 1992). A second function has been uncovered by studies on the - 
globin locus transcription control, where transcription from the intergenic regions is 
required to keep the locus open through and accessible to the transcriptional 
machinery (Gribnau et a! 2000). This may not be a general function of intronic 
sequences at other loci. 
Additionally, 5' and 3' regulatory sequences are also important for transcript 
processing (Custodio et a! 1999). This, and other aspects of RNA processing were 
not investigated as part of this thesis, and will therefore not be discussed further. 
1.1.2 Cis regulatory sequences required 5' & 3' of coding sequence 
Flanking sequences may play a large role in determining expression patterns of many 
transgenes, in particular the transgene locus investigated as part of this thesis 
Inclusion of locus control regions (LCRs) is reputed to confer position independent 
transcription and increased transcription rates (Festenstein et a! 1996, Kioussis & 
Festenstein 1997), although later reports suggest that not all negative effects imposed 
by the genome itself or associated transgenic sequences can be overcome by an LCR 
(Guy et a! 1996 & 1997, Alami et a! 2000). LCRs increase the proportion of 
expressing recovered transgenic lines, enabling expression by establishing an open 
chromatin configuration (Grosveld et a! 1997, Kioussis & Festenstein 1997), which 
requires the inclusion of the entire LCR (Kioussis & Festenstein 1997). In addition, 
an LCR can convey tissue specificity (Santoso et a! 2000). 
LCRs should not be confused with enhancers, another regulatory control element 
often included in transgene constructs. Enhancer elements can increase the number 
3 
of expressing cells (Walters et al 1995, Sutherland et al 1997, Blackwood & 
Kadonga 1998, Francastel et al 1999), acting cumulatively in cis to increase the 
probability of correct spatial and temporal expression (Blackwood & Kadonga 1998) 
by establishing an open chromatin configuration (Kioussis & Festenstein 1997). 
Inclusion of functional enhancers have been linked with non-centromerjc location of 
transgene integration in cell culture. Mutated enhancers increase transgene silencing 
and localisation to centromeric heterochromatin (Francastel et al 1999). 
Enhancers in turn should not be confused with insulators, also known as boundary 
elements. Insulators protect the transgene from position effects in single copy inserts 
(Dorer 1997). A putative boundary element has been identified in mammals: it is 
speculated that the chromatin structure of the maternally derived 5' H19 locus may 
contain an epigenetic mark that prevents access by Igf2 to the 3' enhancer elements 
present on the maternal chromosome. These sequences function as silencers in 
Drosophila, supporting their role as a boundary element (Hark & Tilghman 1998). 
Inclusion of matrix attachment regions (also known as scaffold attachment regions), 
thought to influence the nuclear localisation of the gene, is also reported to enhance 
expression from transgene constructs (Porter & Meyer 1994, Dorer 1997, Ulker et al 
1999, Vain et al 1999). Another reported effect is increased stability of expression 
over generations (Ulker et a! 1999, Vain et a! 1999). A plant-derived SAR works 
perfectly in mammalian cells (Dietz et a! 1994), suggesting functional conservation. 
The inclusion of all cis-regulatory sequences connected to a transgene in its natural 
environment appears to be able to confer (in most instances), position independent 
expression. This is reported for the chicken lysozyme locus (Bonifer et a! 1996, 
Huber et a! 1996), human gp9l-phox (Lien et a! 1997), -casein (Persuy et a! 1992) 
and some metallothionein fusion constructs (Palmiter et a! 1993). The success of 
large vectors, such as YACs and BACs, may in part be due to inclusion of all 
regulatory sequences associated with a gene (Giraldo & Montoliu 2001). 
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1.1.3 Promoter choice is important 
The promoter used in a transgene construct is chosen based on several criteria. 
Promoter strength, specificity and availability are three major factors that govern 
promoter choice. The choice of an inappropriate promoter can have disastrous 
consequences, with plants providing a notorious example. Viral promoters are widely 
used in transgenic plants, unfortunately, they can trigger the genome defence system, 
which identifies the promoter and all associated sequences as viral and proceeds to 
inactivate expression (Vaucheret 1993, Assaad et a! 1993, Ratcliff et a! 1997, 
McCabe et a! 1999). The serendipitous discovery of the plant genome defence 
mechanism has been exploited to engineer crops resistant to viral attack, with as little 
as 90 bp of homology (Vaucheret 1993) sufficient to induce specific resistance (Guo 
et a! 1998, Waterhouse et a! 1999, Baulcombe 1999, Kooter et a! 1999). In animals, 
a recent paper has demonstrated that the use of endogenous promoters decreases the 
variability of expression and increases stability and reproducibility when the 
construct is re-used, as opposed to retroviral promoters (DeAngioletti et a! 2001). 
1.1.4 Sequence composition can also influence expression 
Checking for cryptic splice sites or start codons can prevent unwanted expression or 
processing of the transgene (Al-Shawi et a! 1991, Yull et a! 1995, Haseloff et a! 
1997), whilst codon use can be as influential as promoter choice in determining 
transgene expression potential since prokaryotic and eukaryotic amino acid triplet 
codon preferences differ. By changing the codon usage in a sequence to match that of 
the intended host species, the efficiency of protein production from the mRNA is 
significantly enhanced, as demonstrated for the green fluorescent protein reporter 
derived from jellyfish (Zolotukhin et a! 1996). Ensuring that the nucleotide 
composition of the transgene construct resembles the profile of the host genome is 
also important for a successful transgene. In plants, transgene sequences with a base 
content whose pattern diverges from the host are vulnerable to targeted silencing by 
the host genome defence system (Meyer et a! 1993, tenLohuis et a! 1995). The 
sequence divergence may cause an identifiable structural abnormality. 
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Evidence for operational genome defence systems in animals 
Plant transgenics has suffered from the prevalence of viral promoters in their 
constructs (1.1.3). Viral and bacterial derived material is also used in animal 
transgenics, although the sequences used are more commonly reporter genes or 3' 
processing signals. Although there is little evidence for viral sequences triggering 
silencing events in mammals, there are growing numbers of articles reporting 
silencing by prokaryotic reporter sequences such as chloramphenicol 
acetyltransferase (Clark et a! 1997) and -galactosidase (Cohen-Tannoudji et al 2000 
a & b, Montoliu et a! 2000, Ramirez et a! 2001). There is also evidence for an 
alternative "policing" system in mammals that can identify and eliminate foreign 
sequences (Scrable & Sambrook 1999). Lacl sequences of bacterial, but not 
mammalian, origin were targeted for somatic elimination (Scrable & Sambrook 
1999). This highlights the desirability of using mammalian promoters and gene 
sequences. The presence in both plants and animals of a genome surveillance system 
suggests an ancient shared mechanism responsible for protecting genome integrity 
(Matzke et a! 2000). 
1.2 How homologies within and between exogenous and 
endogenous gene sequences can affect expression 
Transgenes are frequently present as multicopy arrays inserted at one or more loci in 
the genome and often exhibit silencing in one form or another. This silencing 
phenomenon is termed homology-dependent gene silencing (HDGS). Under the 
umbrella heading of HDGS, a number of widely different functional silencing routes 
take shelter (Wu & Morris 1999). HDGS encompasses all epigenetic inactivation 
based on sequence recognition at either the DNA or RNA level, with silencing taking 
place at the transcriptional (TGS = transcriptional gene silencing) or post-
transcriptional (PTGS = post-transcriptional gene silencing) stages (see Hsieh & Fire 
2000 for review). Homologies leading to gene silencing can be found: 
A) 	Within a multi-copy array at a single site (Assaad et a! 1993, 
Garrick et a! 1998, Birchier et a! 2000) (see 1.3 for further detail), 
B) 	Between a transgene and endogenous genes (Davies et al 1997, 
Jorgensen 1995, Seo et a! 1995, Smith et a! 1990, tenLohuis et a! 
1995, van Blokland et al 1994) and 
C) 	Between transgenes at linked or unlinked loci (Jorgensen 1990, 
English et al 1997, Neuhuber et a! 1994, Park et a! 1995, 
Vaucheret 1993). 
The amount of homology and level of silencing varies. Plants dominate reported 
HDGS phenomena, both by the sheer bulk of reports, and also because only plants 
have so far given multiple confirmed results of HDGS covering every sub-category 
of the umbrella term. 
1.2.1 Homology dependent gene silencing in plants 
Gene silencing in plants can be triggered by sequence homologies between the 
transgene and endogenous genes, or between homologous transgenes at separate loci 
(Flavell 1994, Matzke & Matzke 1995, Itoh et a! 1997, Matzke & Matzke 1998). 
This phenomenon is clearly connected, at least mechanistically, to the virally induced 
silencing phenomenon mentioned in 1.1.3 (Waterhouse et a! 1999, Baulcombe 
1999). Promoter homology is sufficient to induce silencing (Park et a! 1996), which 
can occur at the transcriptional or post-transcriptional level (Kooter et a! 1999), the 
latter believed restricted to plants and fungi. Transcriptional gene silencing is shared 
with animals and insects, and will be discussed together. Post-transcriptional gene 
silencing is unique, and will therefore be discussed in detail below. 
Post-transcriptional gene silencing (PTGS) 
Natural occurrence of PTGS to control gene expression has only been demonstrated 
in plants and fungi (Maessen 1997,Cogoni et a! 1996). In plants, PTGS is believed to 
be part of an endogenous "immune-system" that fights viral infections and other 
assaults on cellular and genome integrity (Matzke et a! 2000) and is also used to 
control endogenous gene expression (Maessen 1997). A threshold level of mRNA 
production probably has to be reached before the silencing machinery becomes 
7 
activated, and may explain why homologies to certain endogenous genes only trigger 
silencing of gene expression in certain cell types or developmental stages (Smith et 
a! 1990, Boerjan et al 1994, Meyer & Saedler 1996). Aberrant or overly abundant 
mRNA sequences are capable of triggering silencing (Smith et a! 1990, Vaucheret 
1993, Boerjan et a! 1994, Mueller et a! 1995, Meyer & Saedler 1996), a combination 
of a strong transgene promoter and abundant endogenous transcripts triggering the 
sensing system that targets excessive transcripts of any mRNA species for 
degredation. This system may be used to both combat viral infection and control 
endogenous gene expression through a negative feedback loop 
The first report of transgene PTGS was for a chalcone synthase (CHS) gene in 
Petunia (de Carvalho et al 1992, Jorgensen 1995). PTGS has helped explain the 
inherent instability of many plant transgenes, and provided scientists with an 
excellent tool to generate crops resistant to viral infection (Mueller et a! 1995). This 
method can also target endogenous genes, successfully demonstrated by the double 
silencing of tomato polygalacturonase and pectinerase (Simons & Tucker 1999). 
PTGS can be inherited 
Despite using a post-transcriptional silencing route, there is evidence that this 
silencing phenomenon can be inherited. Resistance to potato virus Y infection is 
maintained through 4 generations of inbreeding (Han et al 1999). The same stability 
is seen in rice with engineered resistance to rice yellow mottle virus (Pinto et al 
1999). Others have been less successful. Homozygocity for the transgene locus is 
need to provide complete resistance to pepper mild mottle tobamovirus, with 
unstable inheritance of the phenotype typical (Tenllado & Diaz-Ruiz 1999) whilst 
Brome mosaic virus resistance phenotypes are variable in progeny from RI resistant 
parents (Iyer & Hall 2000). Evaluating the use transgenes to generate resistance to 
plant viruses is difficult as all the examples test different viruses, with target choice, 
vector design and delivery influencing effectiveness. Importantly, virus ability to 
circumvent the induced resistance mechanism will also differ. 
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Maintenance is either through continued degradation of transcripts or transcriptional 
silencing following the initial PTGS event. The former precludes meiotic inheritance 
of the resistance phenotype. The latter can initiate inherited resistance (Vaucheret 
1993; 1994), where initial transcription from the transgenic locus silences the locus 
and all associated loci in trans. The transcriptional silencing following PTGS may be 
initiated by the RNA transcripts themselves interacting with the DNA locus, possibly 
initiating methylation at the homologous sites (Van Houdt et a! 2000). A mammalian 
equivalent is the involvement of Xist RNA in X-chromosome inactivation (Willard 
& Salz 1997). Drosophila provide an alternative suggestion, where RNA-protein 
complexes are implicated in dosage compensation (Willard & Salz 1997). 
Post-transcriptional gene silencing can be induced in mammalian cells 
Although confirmed natural PTGS is currently limited to plants and fungi, there is 
some suggestion that mammalian systems may be capable of PTGS in a manner not 
induced by antisense-RNA (Bahramian & Zarbl 1999, Sharp 1999). 
All silencing pathways may share a common ancestral link, which has evolved into 
the multitude of silencing phenomena seen today. Some of the pathways may no 
longer be used in all organisms, but the components remain present and capable of 
reactivation. The prevalence of PTGS in plants and fungi may relate to their more 
sedentary lifestyle, which renders them particularly susceptible to viral attack. Late 
germline segregation may also render the genetic blueprint vulnerable and in need of 
extra protection from viruses and transposable elements. Identification and silencing 
of aberrant sequence transcription may be crucial to maintenance of species identity 
and survival, and has thus been retained through the forces of natural selection. 
Animals segregate their germline early in development, protecting integrity of 
transmission. Mobility and a complex efficient immune system may explain why 
PTGS was not maintained in animals. The resurfacing of this phenomenon (albeit in 
an in vitro environment) through transgenic manipulation processes suggests that the 
mechanism lies dormant but can be activated when normal defence barriers against 
an assault on the genome are bypassed. 
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1.2.2 Diploid genomes have 2 copies of most genetic loci: are both expressed 
and is this the norm for both endogenous and transgenic loci? 
Endogenous autosomal genes are normally present in a double dose in diploid 
genomes. Expression from both copies of the gene is presumed, though I am unaware 
of any study that has investigated this in great depth. Imprinted genes (Tilghman 
1999) and those linked to the sex chromosomes (Panning & Jaenisch 1998) are the 
general exceptions known to exhibit mono-allelic expression. Recently, proof that 
autosomal genes can also be monoallelically expressed has emerged (Hollander et al 
1998, Rhoades et a! 2000). Both papers report apparent regulation of interleukin 2 
(IL-2) expression levels through random inactivation of one of the two alleles. 
Few transgenic loci are made homozygous, and most of the examples are transgenic 
plants were homozygocity is a relatively easy state to achieve through selfing. In 
plants, silencing phenomena are quite diverse and transgenes can exhibit different 
phenotypes within a single line (Tenilado & Diaz-Ruiz 1999, Iyer & Hall 2000). 
Homozygocity can induce increased silencing (Tenilado & Diaz-Ruiz 1999), or 
epigenetic mosacism (Iglesias et a! 1997). The silent phenotype can be transmitted 
through the germline (Iglesias et a! 1997), and reactivation of gene expression once 
the gene loci are separated can in certain cases take several generations (Jakowitsch 
et a! 1999). One paper even reports probable monoallelic expression in homozygous 
transgenes, where a silent allele is transmitted to 50% of the progeny (Matzke et a! 
2001). Investigations into the effects of gene knockout and connected applications 
appear to be the predominant reason for generating homozygous transgenic animals 
(Kabra et al 2001, Adam et al 2000, Philbrick et a! 1998, Urbanek et a! 1997). When 
a functional transgene has been generated in a homozygous state, few investigators 
appear to have investigated comparative expression levels of the transgene (at any 
rate, there is no mention of it in most papers). Two of the few authors to address this 
are the Matzkes (Matzke et a! 2001). By extrapolation from their work on transgenic 
plants, one could estimate that up to 3/4  of stably expressing lines should give rise to a 
doubling in expression level when compared to hemizygotes. This does not include 
variegating lines (see 1.7). 
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1.2.3 Paramutation and transvection: two unique cases of homology-driven 
regulation of gene expression 
Paramutation and transvection are two similar phenomena reported in plants and 
Drosophila respectively (Henikoff & Comai 1998, Wu & Morris 1999). Each 
involves the interaction of two (usually) homologous gene loci, leading to a 
modification in gene expression. Somatic pairing between homologous genes is a 
requirement of both paramutation and transvection. The pairing enables the one site 
to influence the transcriptional activity of the other site (Scholz et al 1993, Dernburg 
et a! 1996, Matzke et a! 2001), possibly through transfer of activating or silencing 
complexes and/or changing nuclear localisation of the loci (Sass & Henikoff 1999). 
Transvection 
Transvection is a rare phenomenon that can mediate complementation between 
paired alleles, with the promoter region apparently important for the regulation of the 
interaction (Morris et a! 1999). Transvection was first used to describe some 
unexpected interactions between mutant alleles belonging to the bithorax complex 
(E.B. Lewis 1954, Judd 1988, Tartof & Henikoff 1991). The term transvection was 
used to define the process of homologue pairing leading to altered gene activity. 
Transvection in Drosophila has as its most notable example certain mutations of the 
brown gene (Henikoff & Dreesen 1989, Dreesen et al 1991, Martin-Morris & 
Henikoff 1995, Csink & Henikoff 1996, Dernburg et a! 1996, Sass & Henikoff 
1999). Other genes subject to transvection phenomena have also been reported in 
Drosophila (Georgiev & Corces 1995, Gdula et a! 1996, Donaldson & Karpen 1997, 
Dorer & Henikoff 1997, Morris et al 1999). Studies of the pointed gene indicate that 
both trans-activation and trans-inactivation can occur (Scholz et a! 1993). One of the 
few transgenic examples of transvection has been reported for white gene (Martin-
Morris et a! 1997). The trans-inactivation of a paired homologue can also inactivate 
genes in close proximity to the insertion site. Despite the vast numbers of reports on 
silencing, dominant trans-inactivation remains a rare phenomenon, even in 
Drosophila, the most studied of genetic tools. 
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Paramutation 
First described 70 years ago for the maize ri gene (Winkler 1930), paramutation 
involves interactions between two gene alleles. The paramutable allele is the 
sensitive allele, and upon interaction with the dominant paramutagenic allele adopts 
the paramutagenic transcriptional status (Matzke & Matzke 1995). Separation of the 
two loci can lead to reversion of the paramutable allele to "wildtype" expression, or 
permanent transformation to a functional paramutagenic allele. This indicates that 
there are at least two pathways in operation, with epigenetic modifications that can 
be maintained through meiosis. Transgenic paramutation was first described in 
Petunia (Meyer et a! 1993), and can involve homologous sequences at non-
homologous sites, with pairing essential as trisomies led to inactivation of only one 
of the two paramutable alleles. These results suggest that pairing and "information 
exchange" occurs during a limited window of the cell cycle. The cell cycle, 
especially length of 5- and GuS-phase transition, may influence silencing of genes 
subjected to phenomena such as position effect variegation (Fox & Rhine 1996, 
Seum et a! 1996), indicating that "decisions" on gene activation status occur only at 
certain time points. 
The influence of pairing 
Somatic pairing is proposed to be a prerequisite for trans-interactions (Henikoff & 
Dreesen 1989, Meyer et al 1993, Golic & Golic 1996, Henikoff 1997) and may play 
a role in the control of some human genes (Tartof & Henikoff 1991). In fungi, 
pairing of alleles of an endogenous gene has been demonstrated to be essential for 
the correct regulation of expression and thus sexual sporulation (Aramayo & 
Metzenberg 1996). The first article suggesting the possibility of a trans-sensing 
mechanism in fungi was published a year earlier (Woloshuk et a! 1995), describing 
the dominant inactivation of an aflatoxin biosynthetic pathway gene. 
Many examples of pairing dependent changes in transcription have been documented 
in Drosophila, with the subsequent emergence of a large number of similar terms: 
such as transvection, trans-interaction, pairing—sensitive repression and trans-
repression (Henikoff 1997). Many describe silencing of gene expression, with 
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interactions between allelic and non-allelic loci. Transvection is sometimes described 
as a directional interaction between two unlike mutant alleles, trans-inactivation is a 
directional interaction between two normal identical alleles, whereas pairing-
dependent repression is described as a reciprocal interaction between two similar 
alleles (Henikoff & Comai 1998). Henikoff and Comai (1998) suggest the use of 
the general term trans-sensing effects. I would prefer to use the term of trans-
homology interactions, which indicates some sequence similarity but does not 
presume inactivation or changes in transcription levels of both alleles. 
The effects of pairing interactions may, in some examples be perpetuated through the 
germline (Hollick et al 1997, Matzke et al 2001). Circumstantial evidence suggests 
that this may be the cause of certain unexplained phenotypes in human diseases (Sabl 
& Laird 1992, Bennett et a! 1997). It is not known how the activational history of a 
gene may be transmitted, but with a confirmed role in imprinting (1.4.2), methylation 
has been implicated as a possible candidate. As methylation is not implicated in all 
paramutation events and Drosophila lack methyltransferases, other candidates 
include transfer of heterochromatic proteins and/or histone deacetylases between 
paired loci (Henikoff & Dreesen 1989, Ronsseray et al 1998). Alternatively, pairing 
may localise the genes to a different part of the nucleus (Dernburg et a! 1996, Sass & 
Henikoff 1999). Nuclear localisation can play a crucial role in determination of gene 
activity (Henikoff 1997, Brown 1999, Francastel et al 2000, Wallrath 2000), even 
prokaryotes appear to organise their cells into distinct domains (Kim & Wang 1999). 
As current experimental data indicate genomic location and availability of 
heterochromatic proteins are major factors determining PEV (Wakimoto & Hearn 
1990, Talbert et a! 1994, Gerasimova & Corces 1998, Gerasimova et al 2000, 1.7), a 
combination the two is therefore a strong candidate for the basic machinery 
governing trans-homology interaction events. Additionally, sequence elements 
within the gene may be able to convey epigenetic signals. One such candidate is the 
Fab-7 element of Drosophila (Cavalli & Paro 1998). 
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The evidence in 1.1 and 1.2 suggests that inclusion of cis-regulatory- and intronic 
sequences may increase the probability of transgene expression, but cannot always 
overcome the vulnerability of multi-copy integration (Simon & Knowles 1993). 
1.3 The influence of copy number on transgene expression 
Repeated sequences are vulnerable to heterochromatin formation (Dorer 1997, Dorer 
& Henikoff 1997) and silencing (Wolffe 1998). Heterochromatin is most commonly 
associated with the centromeric and telomeric chromosomal regions, rich in repeated 
sequences and poor in functional genes. A recent paper (Ahmad & Henikoff 2001) 
using a conditional system to probe for heterochromatin at a reporter gene site 
suggests that variegated expression is caused by heterochromatin inhibiting exposure 
of transcription factor binding sites. The exact nature of repeat susceptibility to 
heterocbromatin formation, and how clusters of multiple rRNA genes avoid silencing 
is unknown. rRNA gene clusters may contain sequences that attract protective 
protein complexes, keeping the sites open (Munakata et a! 2000) and preventing 
pairing and loop formation whose structural anomalies may attract the protein 
complexes that form heterochromatin. The heat shock protein loci in Drosophila are 
an analogous system where binding of GAGA and RNA Pol II keep the site open at 
all times (Cryderman et al 1999, Thomas & Elgin 1988). Alternatively, controlled 
nuclear localisation may hold the key (Akhmanova et al 2000). 
1.3.1 Transgene repeat arrays are susceptible to silencing 
Pronuclear injection of DNA is a widely used method for making transgenic animals. 
The resulting animals usually contain the transgene integrated as a multicopy array. 
Copy number dependent expression was hoped for, the data suggested otherwise 
(Wolffe 1997, Birchler et a! 2000). High copy number integration is more often 
associated with transgene silencing or variable expression (1.6 & 1.7), thought to be 
the result of heterochromatin formation at the transgene array (Dorer & Henikoff 
1994). Multicopy plant transgenes are also silenced (Assaad et a! 1993, tenLohuis et 
a! 1995), with timing and extent of silencing linked to copy number (Bucherna et a! 
1999) or expression levels (Chareonpornwattana et a! 1999). Documentation of 
rescued expression through copy number reduction confirmed that the array itself can 
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be responsible for silencing or variable expression of the transgene in mammals 
(Garrick et a! 1998), although subsequent papers suggest that this may be dependent 
on additional factors such as site of integration (Ramirez et al 2001) (1.6). 
Fungi possess a unique sensing system capable of identifying and inactivating 
duplicated sequences. Two related mechanisms both involve methylation of 
homologous sequences. One is methylation induced premeiotically (MIP) in 
Ascobulus immerses (Meyer & Saedler 1996), where duplicated sequences are 
silenced through methylation. This system can also identify and silence artificially 
duplicated sequences (Flavell 1994). The other is repeat induced point mutation 
(RIP) in Neurospora crassa, where repeats trigger methylation and subsequent CG - 
AT mutation, reducing homologies (Cambareri et al 1990, Foss et a! 1991, Singer et 
a! 1995). Silencing of duplicated sequences takes place in haploid nuclei during the 
sexual cycle (Selker 1997). MIP and RIP may have evolved to combat assault on 
genome integrity from transposable elements and other exogenous mobile elements. 
Although efficient in fungi, such a mechanism does not appear to be operational in 
higher eukaryotes. 
14 The influence of methylation status on transgene expression 
Methylation is undeniably linked to repression of gene transcription (Boyes & Bird 
1991, Bird & Woiffe 1999, Ng & Bird 1999, Fuks et a! 2000), though the debate still 
rages as to its exact role. Does the epigenetic modification initiate changes in 
chromatin conformation, or is methylation a secondary event (Ng & Bird 1999, Fuks 
et a! 2000) in a manner analogous to that of the polycomb group of regulatory 
proteins? (see 1.6). The evidence is conflicting and reminiscent of the "chicken & 
egg" scenario. CpG methylation may also be important in the evolution and 
stabilisation of chromosomal structure, marking duplicated sequences for 
diversification and protecting against homologous recombination that could disrupt 
the functional structure of the genome (Kricker et a! 1992). The RIP and MIP of 
fungi are examples of this (1.3.1). 
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Methylation is implicated as a part of the genome defense system, and also controls 
the temporal & spatial expression of certain genes (Meyer eta! 1993, Flavell 1994, 
tenLohuis et a! 1995, Selker 1997, Bird & Wolffe 1999). Organisms that have 
adopted methylation as part of their gene control system are apparently incapable of 
managing without. Mice lacking methyltransferases never survive (Jaenisch 1997, 
Okano et a! 1999). Conversely, introduction of a mammalian methyltransferase with 
subsequent genomic methylation is lethal in Drosophila (Lyko et a! 1999). The 
problems of Large Animal Syndrome and other defects associated with nuclear 
transfer are attributed, in part, to incorrect patterns of gene methylation that may be 
caused by the experimental procedure (Sinclair et a! 2000, Young et a! 2001). 
1.4.1 Methylation & Transgene Expression 
Methylation is also implicated in the unstable expression of some transgenes. 
Methyltransferases can recognize foldback DNA, the tandem repeats of multicopy 
transgene arrays susceptible to methylation and thus silencing due to their propensity 
to form such secondary structures through pairing (Meyer & Saedler 1996, Stam et a! 
1998). This is seen even for transgenes containing a housekeeping gene promoter 
(Mehtali et a! 1990), although the CAT reporter may have contributed to the reduced 
expression seen in high copy number lines. 
Transgene expression and methylation levels are inversely correlated in both 
plants and animals 
Despite the MOM paper (Amedeo et a! 2000), methylation is implicated as a major 
cause of epigenetic silencing in plants. Disruption of the DNA methylation locus 
(DDM 1) leads to partial reversal of silencing of a previously methylated tryptophan 
biosynthetic transgene in Fl homozygote Arabidopsis (Jeddeloh et a! 1998). Full 
reversion to transcriptional activity in the 3rd  generation of inbreeding is correlated 
with a loss of transgene methylation. Loss of methylation leads to transcriptional 
reactivation of a previously silenced hygromycin phosphotransferase transgene 
(Scheid et a! 1998), whereas increased methylation results in progressive silencing of 
a kanamycin resistance transgene over 4 generations of inbreeding (Kilby et al 
1992). Methylation silences expression in three rice lines containing transgenic 
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chalcone synthase genes (Davies et al 1997). Outcrossing results in variegated 
expression, even in the absence of the transgene locus, with methylation maintained 
at the endogenous gene locus. 
Correlations between mouse transgene expression and methylation status have been 
reported (Palmiter et a! 1982, Mehtali et al 1990, Hayashizaki et a! 1994), with some 
evidence that transgene hypermethylation only occurs when the transgene is 
completely silenced in the line (Sutherland et a! 1997). This supports the hypothesis 
that methylation is a secondary event that "locks" the site into a more permanent 
non-permissive state. Transgenic zebrafish are also vulnerable to methylation-
induced silencing (Collas 1998), confirming that this is not a phenomenon confined 
to mammals in the animal kingdom. Histone acetylation may be an accessory to 
methylation-led silencing, with deacetylation associated with inactive loci (De 
Rubertis et a! 1996, Ekwall et a! 1997, Svensson et a! 1998, Cavalli & Paro 1999, 
Kim et a! 1999). 
Hypomethylation and hypermethylation of transgene loci have been linked to active 
and inactive transgenes respectively (van Blokland et a! 1997, Jeddeloh et a! 1998, 
Scheid et a! 1998). Heterogeneous methylation levels of a transgene in periferal 
blood T-cells have been linked to heterogeneity in expression (Zhu et a! 1999) with 
oscillations in methylation associated with oscillating transcription in cell culture 
(Feng et a! 2001), strongly implicating methylation as a player in control of gene 
expression. Even post-transcriptional silencing events have been associated with 
subsequent nuclear methylation (Ingelbrecht et a! 1994, Wassenegger et a! 1994), 
linking post-transcriptional and transcriptional gene silencing. 
1.4.2 Methylation & Imprinting 
Imprinting is a well-documented case of using methylation to mark epigenetically 
and inactivate loci dependent on parent of origin. The best-studied imprinted locus is 
the Igf2r and H19 locus (Reeve 1996). Parent of origin has been shown to influence 
transgene methylation state (Allen et a! 1990), possibly in conjunction with the 
transgene sequence and its integration site (Hayashizaki et a! 1994). Genomic 
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imprinting in Drosophila (Bishop & Jackson 1996, Lloyd et al 1999) indicates that 
methylation is not the only epigenetic mark capable of meiotic propagation. 
1.4.3 Methylation & Background 
Different genetic backgrounds can display significant qualitative and quantitative 
differences in proteins affecting gene expression. Combined with mode of germline 
transmission, background can influence transgene expression potential (Schweizer et 
a! 1998, Morgan et al 1999). Single modifier loci can convey strain-specific 
methylation of transgenes and surrounding sequences in cis (Engler et a! 1998), 
different backgrounds increasing or decreasing methylation (Engler et al 1991). This 
is not exclusive to mammals, with reports of zebrafish displaying genotype specific 
modification to methylation patterns of a transgene, with sex and environment 
contributing to the phenotypic outcome (Martin & McGowan 1995). 
1.4.4 Other candidate epigenetic marks involved in gene silencing 
The Drosophila genome is not methylated, but is capable of being imprinted. Other 
epigenetic modifications therefore exist that are capable of both mitotic and meiotic 
propagation. Histone acetylation can maintain gene silencing through a repressed 
chromatin state (Ekwall et al 1997). Both methylation and acetylation may ultimately 
work through recruitment of heterochromatic protein components to the site. A 
recent paper reports discovery of a histone methyltransferase and the stable 
methylation of Lys 9 at the N termini of histones H3 & H4, a modification that 
creates a binding site for heterochromatin-associated proteins (Jenuwein 2001). This 
epigenetic mark could be used to transmit chromatin states. 
Another candidate is the MOM gene product. Silenced transgenes have been 
reactivated through disrupting MOM (mutation in a "morpheus" molecule) 
expression in Arabidopsis (Amedeo et al 2000). MOM is required for transcriptional 
gene silencing, has no effect on methylation, but shares similarities with the ATPase 
region of the SWI2/SNF2 complex, suggesting that MOM can influence chromatin 
conformation. Conservation of these proteins argues for a functional link between 
mammalian, Drosophila, yeast and plant silencing phenomena. 
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1.5 The influence of age, germline transmission and genetic 
background on both endogenous and transgene expression 
Silencing phenomena described in this section are found in both plants and animals, 
despite the many differences between them. Could basic gene regulation mechanisms 
remain conserved or are the observed similarities the result of convergent evolution? 
1.5.1 Age—Related Silencing 
Ageing may trigger methylation changes that can be both gene and tissue-specific. 
Increased age appears to be a major contributing factor in hypermethylation and 
silencing of certain genes in cancers (Ahuja et a! 1998, Toyota & Issa 2000). 
Conversely, upregulation of gene expression is also linked to ageing (Villeponteau 
1997). This article suggests that heterochromatin loss occurs with increased age and 
with it the loss of heterochromatin—induced silencing. Yeast systems corroborate 
Villeponteau's theory, documenting age-dependent loss of transcriptional silencing at 
heterochromatic sites (Jazwinski 1999), and suggest a possible role for histone 
deacetylases in ageing control (Kim et a! 1999). This silencing is not confined to 
endogenous genes. Cohn et a! (199 1) report progressive silencing of a mouse colon-
specific transgene, each crypt functioning as a single expression unit. Silencing has 
also been reported for globin transgenes in mice, the proportion of expressing cells 
decreasing with age (Robertson et a! 1996, Sutherland et a! 1997). In plants, 
silencing of an S-Adenosyl-L-methionine synthetase transgene in tobacco occurs first 
in the veins of leaves and later in the whole leaf in new leaves on plants already 
exhibiting silencing (Boerjan et a! 1994). In an in vitro system, retroviral vectors 
used to target haematopoietic stem cells and improve oxygen production are silenced 
over time. Evidence suggests that this silencing is also progressive, with each 
silencing event apparently irreversible (Zentillin et a! 2000). Methylation is a 
suggested silencing event, either as the primary silencer or a secondary epigenetic 
"lock" (Antequera et al 1990, Dieguez et a! 1998, Sutherland et a! 1997). 
The common theme in the articles above is deregulation of gene expression with 
increasing age. Perhaps this is a reflection of an organism's finite lifespan. One of 
the signs of ageing could be loss of regulatory control, leading to a breakdown of cell 
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function followed by death. Human cancers are more prevalent in older individuals, 
and could be interpreted as the manifestation of a general degeneration of cellular 
function. In my study, the BLG/7 mice (1.8) are sampled in their prime. Serial 
lactations indicate that BLG protein expression does not differ significantly between 
individual lactations (Dobie et al 1996), suggesting that the observed variegation is 
not age-related. BLG/7 transgene expression is lactation specific, whereas other 
studies use transgenes containing constitutively active promoters, at least for their 
cell type (Cohn et al 1991, Robertson et al 1996, Sutherland et al 1997). The limited 
window of expression differentiates our mice from the others, and may render our 
transgene immune to time or age-related repression effects. 
1.5.2 Meiotic Inheritance of Epigenetic Silencing 
Maintenance of epigenetic marks through the germline defies the principle that DNA 
alone conveys the blueprint of life to the next generation. Research outlined below 
suggests inheritance can be infinitely more complex. For ease of presentation, the 
next section has been divided into units that broadly cover the main species used in 
transgenic research. Such a discussion will eventually focus on plants due to the 
large amount of data for this phylum. 
Drosophila 
The Fab-7 trithorax cis-regulatory element is a recent Drosophila example where the 
epigenetic expression state can be inherited. Meiotic inheritance of the active state 
may reflect inheritance of transcriptionally competent chromatin at the gene locus, 
with H4 hyperacetylation a putative epigenetic tag (Cavalli & Paro 1999). A different 
example involves the I-element transposon, where complete suppression takes up to 
10 generations (Jensen et a! 1999). This phenomenon is reminiscent of PTGS in 
plants: transcription is needed to induce silencing; success is proportionally linked to 
I-element sequence transcript length and dosage. Silencing is cumulative over the 
generations and transferred through the maternal germline, even non—transgenic 
offspring display silencing if the maternal parent is a silenced transgene carrier. This 
suggests the maintenance/transfer of an epigenetic mark that is established very early 
in embryonic development, before the degradation of maternal mRNA. Paternal 
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transmission erases genomic silencing, strengthening speculation that maternal 
mRNA could be the catalyst for silencing of I-element associated sequences. 
Fish 
Transgene expression can remain stable in zebrafish (Caldovic et a! 1999). Others 
have been less successful, silencing of transgenic green fluorescent protein seen by 
F2 in 20% of zebrafish lines (Amsterdam et al 1995). 
Plants 
Even non-transgenic plants exhibit silencing phenomena; some may be caused by 
mixed genotypes, with a recent description of the domination of one parental set of 
rRNA over the other in a hybrid plant after two generations (Chen et a! 1998). The 
direction of dominance can be switched in this example, suggesting that the balance 
of parental factors probably determines the direction of dominance rather than the 
rRNA. The progressive silencing of a kanamycin resistance gene over 4 generations 
of inbreeding may be linked to a parental genotype (Kilby et a! 1992). 
A single gene is able to generate several phenotypes. An investigation into the 
segregation of drug resistance phenotypes through 7 generations in Arabidopsis 
reports resistant parents consistently segregating 3 offspring phenotypes: sensitive, 
partially resistant or resistant (Assaad et a! 1993). Silencing could be progressive 
over the generations, coinciding with increased methylation, but was also reversible. 
The most varied example is reported for a transgenic construct containing a 
kanamycin resistance gene (Schmulling & Rohrig 1995). The locus generated 
antisense transcripts that silenced expression with progressive severity over the 
generations, but never exhibits complete penetrance. Two different types of silencing 
were observed. The first was early silencing with methylation and meiotic resetting. 
The second was a slow stochastic onset of silencing without methylation, exhibiting 
stable meiotic transmission and with reactivation capable of being sustained over 
several generations. Some plants exhibited mosaic expression patterns with different 
intensities reflecting different levels of transgene expression. Introduction of a 
second transgene, sharing homologies with the kanamycin gene, induced increased 
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silencing over the generations. Re-establishment of kanamycin expression required 
separation of the two transgenes for 3 generations. Genetic background could 
influence silencing, which varied from 24-46% in the F2 backcrosses. 
That a single transgene locus can cause multiple phenotypes argues for the presence 
of complex silencing mechanisms in plants. Some of these mechanisms may be 
unique to plants; perhaps a consequence of the plasticity that can support polyploidy, 
aneuploidy and hybrid plants in a manner not seen in animals. 
Mammals 
Plants segregate their germline later in development than animals. This increases the 
probability that epigenetic mutations are passed on to future generations. This may 
provide plants with an evolutionary advantage, but no such advantages are apparent 
for animals (John & Surani 1999). 
Most papers on epigenetic inheritance in mammals describe imprinted loci. Parent of 
origin determines expression, with methylation the apparent epigenetic mark 
involved. Work has suggested that there are allelic variations in methylation between 
homologous human chromosomes, which are both tissue specific and capable of 
germline transmission (Silva & White 1988). Could this indicate that epigenetic 
inheritance and differentiation between homologous sites is widespread? In humans, 
the inheritance of epigenetic modification is well known for imprinted loci, as are the 
conditions that occur when the imprinting process malfunctions. There is now 
intense speculation that inheritance of epigenetically modified, but otherwise fully 
functional gene loci, may explain some inexplicable occurrences of disease in 
genotypically normal individuals. This is the hypothesis put forward to account for 
cases of Huntingdon disease (Sabl & Laird 1992). 
Coat colour is an easy phenotype to study. An early report on putative epigenetic 
inheritance involves the star coat-marking gene in foxes (Belyaev et a! 1981). 
Transmission of the active gene was linked to selection for domestic behaviour in 
females. In mice, the inheritance of epigenetic changes linked to the agouti coat 
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colour has been extensively studied. Offspring phenotype is linked not only to the 
maternal phenotype, but also to that of the maternal grandmother. It is suspected that 
epigenetic marks are incompletely erased during germline formation, giving rise to a 
variegated expression pattern resulting in coat colours and patterns covering the 
entire colour spectrum (Morgan et al 1999). 
Nuclear transfer has enjoyed success in large animals, but side effects are associated 
with the technique (Young et al 2001). The same phenotypes are now being seen in 
mice generated by nuclear transfer, with changed expression profiles for a range of 
genes that are transferred through the germline to the next generation. One line 
exhibits progressive methylation with increasingly severe phenotypes with each 
generation. The epigenetic inheritance lasts at least two generations, with studies 
continuing (Roemer et a! 1997). These reports raise serious questions over the safety 
of future cloning ventures, and provide the definite argument against human cloning. 
1.5.3 The influence of genotype on phenotype 
In plants, genotype influencing gene expression is suggested for hermaphrodite 
mutants containing mutations in the gynoecium-suppressing function region in white 
campion (Lardon et a! 1999). Additionally, studies into hybrids and their inbred 
parental strains have revealed both qualitative and quantitative differences in gene 
expression (Sun et al 1999). 
More information is available for mammals, where genetic background has long 
been suspected to play a part in influencing expression levels. Dominant strain 
specific modifiers are documented (McGowan et a! 1989, Elliot et a! 1995), with 
over-expression of a single heterochromatic protein component capable of modifying 
the extent of transgene variegation in mice (Festenstein et a! 1999). Genetic 
background can influence methylation and expression of a variegating transgene 
(Koetsier et a! 1996), with increased levels of methylation and silencing associated 
with a C57BL/6 background. This background was also associated with de novo 
methylation of a hepatitis B virus surface antigen (HBsAg) transgene (Schweizer et 
a! 1998). HB5Ag expression levels differed depending on the strain, backcrossing 
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enhancing the effects. Segregation of strain-specific factors meant that crosses 
produced offspring exhibiting both up- and downregulation of expression, due to the 
cooperative effects of different combinations of modifier proteins. Intriguingly, 
background effects were only observed when the transgene was transmitted through 
the male germline. Silent transgenes can also be reactivated by crossing into a 
background conducive to expression (Sutherland et al 2000), with a C57BL16 
background increasing reactivation of the transgene by decreasing methylation. The 
authors could select for high expressors, but the overall trend was for progessive 
silencing with continued variegation. Even high expressors generated low- and non-
expressing progeny. 
The transgene behaviour reported above suggest that strain specific factors do not act 
in isolation. Integration site with associated site-specific factors, as well as residual 
effects derived from the background on which the line originated, probably combine 
with strain-specific factors to determine the transgene expression profile. 
1.6 The influence of integration site on transgene expression 
Injected transgene constructs are supposedly integrated at random into the genome, 
although there is suggestive evidence that integration may be less random than 
previously thought. Some genomic sites appear more "accessible" than others 
(Rijkers et al 1994) with 5' and 3' sequences capable of targeted insertions 
(McFarlane & Wilson 1996). Homologies to endogenous sequences can drive 
targeted insertions; a property exploited in embryonic stem (ES) cell work to 
generate animals with single copy transgene integrations at defined genomic loci 
(Bronson et a! 1996). The limitation is a lack of available ES cells for species other 
than mouse; therefore, pronuclear injection is still extensively used despite the 
associated problems of multilocus multicopy random integration. 
Random integration can render a transgene vulnerable to what is termed position 
effects. These effects are either stable, where expression levels are reduced but is 
seen in all relevant cells; or variegated, where expression levels are maintained but 
only a proportion of cells are active. "Defensive" structures, such as LCRs, can 
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increase the probability of transgene expression (1.1.2), but cannot protect against 
strong position effects (Guy et al 1996). Sex chromosomes integration will lead to 
variable expression due to dosage compensation mechanisms such as X-inactivation 
(Haller & Woodruff 2000), as will integration into an imprinted region (Duvillie et al 
1998). Strong endogenous enhancers or silencers close to the integration site may 
also induce aberrant transcription (Milot et al 1996). The effects of neighbouring 
sequences are believed to cause many human diseases, such as cancers, where 
chromosomal translocations have been linked to the disease phenotype (Brock 1993). 
A widely studied phenomenon of site-dependent control of gene expression is 
Position Effect Variegation (PEV), where translocation or insertion of a transgene 
array inside or close to endogenous heterochromatin leads to mosaic transgene 
expression at the cellular level due to variable spread of heterochromatin. 
1.7 Position Effect Variegation 
The first description of Position Effect Variegation (PEV) was published over 70 
years ago (Muller 1930). This paper and the follow up report (Muller 1932) describe 
a mutation-induced translocation of the white eye colour gene of Drosophila from its 
normal euchromatic site to a position close to centromeric heterochromatin. This 
juxtaposition led to patchy white gene expression where the physical manifestation is 
a mottled eye colour, combining patches of the usual red eye colour with patches of 
white (Figure 1.1). Since then, variegating gene expression has been found in many 
other organisms. Variegation has been reported in plants, insects, yeast, fungi, fish 
and mammals (Muller 1930, McGowan et al 1989, Stuart et al 1990, Allshire et al 
1994, Tartof 1994, Cogoni et al 1996, Dobie et al 1996, Festenstein et al 1996, 
Meyer & Saedler 1996, Robertson et a! 1996, Collas et al 1999, Giraldo et al 1999, 
Benedict et al 2000, Sutherland et al 2000, Matzke et al 2001). 
PEV has two distinct physical manifestations: the mosaic pattern of gene expression 
visible at the cellular level and the cytological observation of heterochromatin 
spreading into the variegating gene locus. This increased heterochromatinisation is 
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Figure 1.1 	Position Effect Variegation (PEV) in Drosophila 
Reproduced with the kind permission of P.B. Singh (from Singh 1994) 
Schematic illustration of chromosome inversion leading to variegation of the 
white (w+) gene due to new position close to constitutive heterochromatin. 
PEV can be affected by a number of factors that are able to modify 
determination and degree of variegation within a given tissue. These can be 
environmental conditions, protein modifiers or other factors that determine 












McCall & Bender 1996). Mosaic expression is explained as the manifestation of 
variable heterochromatin spreading, with discrete patches of cells sharing the same 
expression profile due to clonal expansion after "fixation" of the expression state 
(Paro & Hogness 1991). A large number of variegating genes have been studied and 
factors that can modify their expression have been identified. Many modifiers are 
chromatin components (Singh 1994), strengthening the theory that variable spread of 
heterochromatin causes variegation. Homologues of these modifier genes have been 
identified in several systems, and experimental evidence suggests that many are 
probably capable of functional substitution between systems (Stankunas et al 1998, 
Aagaard et a! 1999, Festenstein et a! 1999, McMorrow et a! 2000). In order to 
understand PEV, it is necessary to have an understanding of heterochromatin. 
1.7.1 Heterochromatin function and composition 
Heterochromatin is a term used to describe a densely packed higher order chromatin 
structure. Morphologically, heterochromatin describes deeply staining compact 
bodies of nuclear material that remain condensed and visible throughout the cell 
cycle (Heitz 1928, from Weiler & Wakimoto 1995) and are the last to undergo 
replication (Holmquist 1987). Heterochromatin is a heterogeneous component of 
higher order chromatin structure (Lloyd et a! 1997, Wallrath 2000), with some 
shared features. The tails of histories H3 & H4 are hypoacetylated compared to their 
euchromatic counterparts (Braunstein et a! 1996), and nucleosome spacing patterns 
are more regular (Wallrath & Elgin 1995). Hypermethylation is associated with 
heterochromatin (Bongiorni et a! 1999), and there is speculation that 
hypermethylation may act to stabilise the chromatin state, either by itself or through 
recruitment of chromatin remodelling complexes (Henikoff 2000). 
Although structurally similar, centromeric and telomeric heterochromatin protein 
composition is different (Wallrath 2000) and thus can react differently to external 
influences. Common to both is the presence of repeated sequences, although the 
repeats themselves differ (Cryderman et a! 1999B).  Introduced repeats can induce 
heterochromatin formation, and may in part explain the propensity of transgenes to 
become silenced (1.3.1). That constitutive heterochromatin remains confined to a 
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defined area of the genome in the absence of structural alteration argues for the 
presence of structural boundary elements. Such putative boundary elements have 
been identified and their role experimentally verified (1.7.6). Facultative 
heterochromatin is formed at discrete genomic sites and may not remain 
cytologically visible throughout the cell cycle, and include sites occupied by the 
Polycomb family of regulatory proteins (1.7.3). Heterochromatin structural 
components remain conserved, with heterochromatic protein 1 (Singh et al 1991, 
Cowell & Austin 1997, Wang et al 2000) currently the best characterised. 
How repeat structures initiate heterochromatin formation is unknown, but a 
mechanism capable of identifying repeated structures could exist. Transgenic 
experiments may have uncovered a hitherto unknown branch of the genome defence 
system against exogenous attack. Whilst the immune system protects the host body 
from micro-organisms, a genomic defence system defends the genome at both the 
somatic and germline level against retroviral, transposon and other assaults on host 
genome integrity. Heterochromatinisation would prevent both sequence activation 
and pairing leading to trans-activation. Methylation epigenetically marks the 
sequences, maintaining the heterochromatic state of the locus and aid in c -> t 
mutations (Henikoff & Matzke 1997, Yoder et a! 1997, Dimitri & Junakovic 1999). 
That a large proportion of the human genome is comprised of retrotransposons and 
repeat elements provides supportive evidence for such a functional role for 
heterochromatin in genome defence (Smit 1996, Henikoff et a! 1997). 
The use of heterochromatin in silencing endogenous genes reveals a role in 
controlling gene expression as well as protecting genome integrity (Brown et a! 
1997, Brown et al 1999). Terminal differentiation of many cell types is associated 
with progressive genomic heterochromatinisation (Lundgren et a! 2000), suggesting 
a role for heterochromatin in determining and maintaining cellular fate and identity. 
The discovery of cross-species conservation of some heterochromatin proteins, or 
their functional domains, has encouraged speculation that these proteins may have an 
even wider function. Yeast silencing proteins appear to have conserved homologues 
from bacteria to humans (Sherman & Pillus 1997). Swi6 is a Yeast protein 
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homologous to HP 1 (Wang et al 2000) involved in imprinting of the mating-type 
locus and contributing to the cellular memory responsible for maintenance of the 
silenced state (Grewall 2000). Could mammalian HP  have a similar functional role? 
1.7.2 PEV and heterochromatin 
The discovery of PEV and subsequent investigations has ensured that 
heterochromatin is no longer considered merely an "inert" packaging material. 
Heterochromatin is now known to play a role in chromosome pairing and centromere 
function during cell division (Demburg et a! 1996, Renauld & Gasser 1997). This 
ties with earlier observations that heterochromatic regions are late replicating 
(Holmquist 1987). The pairing capabilities of heterochromatin may also explain the 
rare cases of dominant PEV, with pairing driving heterochromatinisation of both loci 
and/or physical removal to a heterochromatic area of the nucleus (Henikoff & 
Dreesen 1989, Ronserray et al 1998, Sass & Henikoff 1999). Functional genes do 
reside within constitutive heterochromatin (Sinclair et a! 2000), with this chromatin 
environment needed for their correct expression (Lu et a! 2000, Wakimoto & Hearn 
1990). Translocations into euchromatic parts of the genome leads to disruption of 
gene expression in a manner not dissimilar to the position effect variegation 
displayed by euchromatic genes in a heterochromatic environment (Weiler & 
Wakimoto 1995). Heterochromatic genes subjected to PEV may also be sensitive to 
pairing; in this case pairing can rescue expression (Weiler & Wakimoto 1995). 
1.7.3 Links between PEV and control of endogenous genes through 
modification of chromatin conformation 
Development from fertilisation through to adulthood is a strictly controlled process 
of gene activation and silencing. The pattern of gene expression defines a cell and 
determines its fate. What controls the patterns of expression, changing cells from 
totipotent to terminally differentiated? The field of developmental biology has some 
pieces of the puzzle, but the picture is by no means complete. 
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The pattern of gene expression is determined early in development, but the factors 
that lay down the initial patterning are not responsible for the long-term maintenance 
of these patterns; that is the job of a secondary set of controlling factors (Mahmoudi 
& Verrijzer 2001). The best-studied group of secondary developmental regulators are 
the Polycomb group (PcG) and trithorax group (trxG) families of regulatory proteins. 
They control homeotic gene expression in Drosophila. Polycomb proteins act as 
repressors whilst trithorax proteins are activators (Epstein 1992, Kennison 1995). 
The trxG and PcG complexes serve as a cellular memory of earlier regulatory factor 
binding (Orlando & Paro 1995). It is believed that many of the binding sequences 
involved in homeotic gene control may be bound by either PcG or trxG complexes, 
with the Fab-7 element a prime example (Cavalli & Paro 1998). The site is capable 
of binding both Pc and GAGA factor (a trxG protein), enabling switching of 
expression states as well as conveying a memory of past activation that can survive 
female germline meiosis. A functional link has been established between PEV and 
homeotic gene expression control through the identification of some of the enhancers 
and suppressors of variegation as members of either the trx or PeG families. Other 
modifiers of PEV contain structural similarities to trx & PcG functional domains 
(Hazelrigg et a! 1984, Paro & Hogness 1991, Bhadra & Birchler 1996, Carrington & 
Jones 1996, Larsson et al 1996, Platero et a! 1996, Bhadra et al 1997A & B, Laible et 
a! 1997, Meyer 1999). 
Although many PcG proteins do not modulate PEV, their binding creates repressive 
chromatin complexes that aggregate in subnuclear domains coincident with neither 
heterochromatin nor transcriptional activety (Buchenau et al 1998). Pc-mediated 
repression blocks pol II transcription, but allows T7 RNA polymerase access 
(McCall & Bender 1996). This links with heterochromatin-mediated silencing where 
trans-acting factors are blocked from cis-acting regulatory sequences (Cryderman et 
al 1999A & B), suggesting that PEV and PcG mediated repression involves similar 
higher order chromosomal structuring (Boivin & Dura 1998). 
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1.7.4 A diverse range of modifiers of PEV have been identified 
PEV was first described in Drosophila, with much information arising from 
experiments in this system, especially concerning factors that can modify PEV. With 
homologues identified in other animal and plant systems, PEV could be a powerful 
tool for unravelling the complex process of gene expression control in higher 
eukaryotes. Modifiers are now counted in their hundreds (Bhadra et al 1997A),  and 
whilst many are components of heterochromatin, increasing numbers are not. 
Modifiers can be grouped into different classes, which are outlined below: 
• Components of heterochromatin; e.g. 
• HP1 (Clark & Elgin 1992, Eissenberg et al 1992) 
• Su(var)3-7 (Reuter et al 1990, Cleard et al 1997) 
• Enhancer of zeste (Carrington & Jones 1996) 
• Modifiers of transcription of heterochromatin components; e.g. 
• Lom (Bhadra et al 1997A) 
• Dmrnahel (Eberl et a! 1997) 
• Transcriptional regulators; e.g. 
• Regena (Frolov et al 1998) 
• Zeste (Scum et al 1996, Gubb et al 1997) 
• E(var)3-trl (=GAGA factor) (Seum et al 1996, 
Walirath 2000) 
• Histone deacetylases, HDAC 1 (Mottus et al 2000) 
• EBF (Lundgren et al 2000) 
• Enzymatic protein modifiers; e.g. 
• Ubiquitin (Henchoz et al 1996) 
PP 1 phosphatase (Seum et a! 1996) 




The majority of modifiers act in a dosage dependent fashion, with a few exhibiting 
opposing effects when present in limiting or excessive dosages (Reuter et a! 1990, 
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Eissenberg et al 1992, Henikoff 1996, Cleard et a! 1997, Gubb et a! 1997, Sass & 
Henikoff 1998, Festenstein et a! 1999, McMorrow et a! 2000, Lundgren et al 2000). 
External factors may also affect variegation, examples being temperature (during 
critical windows of development) and proximity to MARs/SARs (Girard et a! 1998). 
1.7.5 Theoretical explanations proposed to explain PEV 
Three main theories have been advanced to account for PEV of transgenes: 
Somatic mutation or elimination of the transgene causes the variegated 
expression profile (Karpen & Spradling 1990) 
Altered chromatin packaging causes PEV through variable spread of the 
silencing heterochromatic chromatin (Ananiev & Gvozdev 1974, Tartof et a! 
1984, Wallrath & Elgin 1995) 
Altered nuclear compartmentalisation of the transgene due to its 
chromosomal position causes PEV, due to limited supplies of factors needed 
for expression (Wakimoto & Hearn 1990, Talbert et a! 1994, Gerasimova & 
Corces 1998) 
Theory 1 is disputed by several groups (Ahmad & Golic 1996, Wallrath et a! 1996). 
Experiments that refute this theory include examples where a variegating or silent 
transgene construct has been excised as expression competent ectopic circular DNA 
(Ahmad & Golic 1996), or re-integrated into the genome and successfully expressed 
(Al-Shawi et a! 1990). Although it cannot be wholly ruled out that a rare example of 
variegation is caused by somatic mutation/elimination (Scrable & Stambrook 1999), 
I believe the majority of examples have a different underlying cause. 
Cytogenetic observations of heterochromatin spread, different nuclease accessibility 
of active and silent genes, as well as characterisation of modifiers of PEV 
encompassing heterochromatic proteins and modifiers supports the validity of theory 
2 (Clark & Elgin 1992, Belyaeva et a! 1993, Wallrath & Elgin 1995, Garrick et a! 
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1996, Gdula et al 1996, Henchoz et a! 1996, Seum et al 1996, Bhaddra et al 1997A, 
Cleard et al 1997, Frolov et a! 1998, Festenstein et al 1999, McMorrow eta! 2000). 
Evidence for nuclear compartmentalisation, with delineation of transcriptionally 
active and repressed areas, support the third theory of PEV (Brown et a! 1999, 
Wallrath 2000). Even different chromosomes appear to occupy distinct nuclear 
positions in mammalian interphase cells (Haaf & Schmid 1991). In addition, 
numerous papers report that nuclear localisation can play a crucial role in 
determination of gene activity (Henikoff 1997, Brown 1999, Francastel et a! 2000, 
Walirath 2000). Even prokaryotes appear to organise their cells into distinct domains 
(Kim & Wang 1999). There is thus plenty of evidence to support theory 3. 
Theories 2 & 3 are not mutually exclusive as there is experimental evidence 
supporting both (Cryderman et a! 1999J3). Two connected phenomena link both 
chromatin structure and nuclear localisation with control of gene expression: 
transvection and paramutation (1.2.3). Transfer of heterochromatic components 
and/or histone deacetylases during pairing is a prime candidate for the mechanism 
operating in these phenomena (Henikoff & Dreesen 1989, Ronserray et a! 1998). An 
alternative mechanism is localisation of the genes to a different nuclear compartment 
as a result of the pairing interaction (Dernburg et a! 1996, Sass & Henikoff 1999). 
Changes in chromatin structure can influence nuclear localisation of a gene in 
interphase cells, with circumstantial evidence linking paramutation and repressive 
chromatin structures. Efficiency of paramutable allele silencing by the 
paramutagenic allele is apparently influenced by chromosomal location (Meyer 
1999). Heterochromatic gene variegation can also be eliminated/reduced through 
pairing with the untranslocated homolog, enabling correct nuclear localisation to a 
heterochromatic compartment (Weiler & Wakimoto 1995). Similarly, insertion of 
heterochromatin into a eukaryotic gene induces PEV and association of both the 
mutated and normal gene with heterochromatin through transvection (Csink & 
Henikoff 1996). The best-known example of transvection is the brown' mutation in 
Drosophila (Dreesen et a! 1991). Studies suggest that associations with 
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heterochromatin and nuclear localisation change during development, both brown' 
and wildtype associating with centromeric heterochromatin due to homology and 
chance pairing during interphase (Csink & Henikoff 1996, Dernberg et al 1996). 
Heterochromatin involvement in chromosomal pairing and segregation during 
mitosis confirms the pairing properties of heterochromatin (Kellum & Alberts 1995, 
Elgin 1996, Csink & Henikoff 1996) and may explain how cell cycle can influence 
PEV. 
Current experimental data indicate that two of the major factors determining PEV are 
genomic location of the transgene and heterochromatic protein availability 
(Wakimoto & Hearn 1990, Talbert et a! 1994, Gerasimova & Corces 1998, 
Gerasimova et a! 2000). Dissociation of silencing and nuclear localisation (Sass & 
Henikoff 1999, Francastel et a! 1999, Lundgren et a! 2000) suggests that control of 
gene expression is much more sophisticated than the current theories propose, with 
nuclear localisation only one event in a multi-step process involving many factors. 
Several layers of complexity are involved in gene silencing, with some genes 
controlled by "simple" mechanisms such as formation of heterochromatin at the site 
and/or nuclear localisation to a silencing compartment. Other genes may require 
more complex regulation through a pathway containing several checkpoints. It is 
speculated that nuclear repositioning of a gene to centromeric heterochromatin may 
be a feature of heritable gene silencing (Brown et a! 1999), possibly controlling 
terminal differentiation? 
An alternative hypothesis suggests that a silent state is the default state, with genes 
destined for activation epigenetically marked during metaphase (Michelotti et a! 
1997), with DNA transcriptional start sites conformationally distorted in genes due to 
be expressed. Maintenance of this distortion, or use of it in epigenetic tagging may 
be through protein binding to ssDNA. Transcription factor dosage can influence 
expression and nuclear localisation of a variegating gene (Lundgren et a! 2000), 
suggesting that promoter potentiation could influence localisation of the gene to a 
nuclear position where activation is possible. Alternatively, genes destined for 
silencing may be marked by a conformational distortion during metaphase. The 
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identification of an ssDNA binding protein associated with pericentromeric 
heterochromatin (Cortes et a! 1999) adds weight to this hypothesis. 
1.7.6 Regulation of PEV 
I cannot envision any reason why several mechanisms cannot operate in the control 
of gene expression. Shared components and overlapping pathways could account for 
the bewildering and occasionally conflicting reports on the causes and influences of 
PEV. Two papers have investigated the effects of introducing two different 
variegating loci into the same genome (Belyaeva et a! 1993, Lloyd et al 1997). Both 
used Drosophila as the experimental system. If the two loci are subjected to the same 
constraints, competition for limiting factors should disrupt the usual expression 
profile of one or both genes. Independent regulation of the two loci would lead to the 
continuation of the normal expression profiles. Both outcomes were observed, 
depending on the combinations of loci used, confirming that PEV can be regulated 
by several different pathways that may or may not overlap. HP  is a prime candidate 
protein that may be involved in all PEV pathways as it is a component of both 
telomeric and centromeric heterochromatin and able to modify PEV at both locations 
(Festenstein et al 1999, McMorrow et al 2000). Telomeres and centromeres also 
support non-overlapping pathways operating in PEV (Talbert et a! 1994, Walirath & 
Elgin 1995, Cryderman eta! 199913). It is therefore difficult to decide whether to treat 
centromeric and telomeric variegation as separate phenomena, or focus on shared 
traits in the hope that these are the keys to understanding PEV. 
1.7.7 Mechanistic Models proposed to explain heterochromatic spread in PEV 
There is currently much debate concerning the precise mechanism(s) involved in the 
manifestation of PEV, and if it is possible to predict the outcome of harbouring two 
variegating loci in the same system. Whilst PEV is frequently described as the 
variable spread of heterochromatin into a normally euchromatic translocated close to 
or inside a heterochromatic site (Epstein 1992, Orlando & Paro 1995, McCall & 
Bender 1996), it is not strictly accurate, as PEV is also observed when 
heterochromatic genes are translocated to a euchromatic site (Schultz & Dobzansky 
1934, Wakimoto & Hearn 1990). Loss of heterochromatin is probably responsible for 
35 
the instability in this case. As this latter example of PEV is relatively rare, all the 
mechanisms below discuss the former example of PEV. 
Although great progress is being made unravelling the protein composition of 
heterochromatin, the manner in which spreading of heterochromatin from a 
euchromatic/heterochromatic breakpoint junction occurs remains open to 
speculation. Why are some sequences more susceptible than others to position 
effects? What determines how far heterochromatin can spread into adjacent 
euchromatin? How are the euchromatic and heterochromatic boundaries defined and 
maintained in normal cells? Two similar models have been proposed to explain and 
predict the spread of PEV into transgenes inserted into heterochromatic areas 
(Balasov & Makunin 1996, Clarke et al 1996). Both models assume that there are 
"binding/initiation" sites for heterochromatic complexes distributed across the whole 
genome, with proximity of binding sites and availability of heterochromatin 
components determining the spread of heterochromatin and thus silencing. 
Balasov & Makunin's Model 
Balasov & Makunin (1996) have proposed a theory that can account for all the 
questions regarding susceptibility to position effects, heterochromatin spread and 
delineation. The theory, as I interpret it, is an expansion upon the "Spreading Effect 
Rule" proposed by Spofford (1976). Spofford suggests that heterochromatin spreads 
progressively into the euchromatic site at the break junction (a presumed boundary 
element delineating heterochromatic and euchromatic areas having been removed by 
the translocation), with the likelihood of variegating expression decreasing with 
increased distance from the breakpoint junction. It has been noted that 
heterochromatin can spread up to 1000 Kb from a breakpoint, in either a continuous 
or discontinuous pattern (Belyaeva & Zhimulev 1991). Local concentrations of 
heterochromatin components would determine the length of spread, and this would 
vary between cells, giving rise to the characteristic "speckled" expression pattern of 
PEV. This theory does not explain discontinuous spread of heterochromatin, which is 
where Balasov & Makunin (1996) expand. Their PEV model is based on the 
statistical distribution of compactisator protein (CP) molecules around presumed 
compactisation initiation centres (CIC5). The CP molecules and CICs probably vary 
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in composition, giving rise to distinct combinatorial subsets conferring both tissue-
and stage-specificity to heterochromatin formation. There are four basic assumptions 
made in this model: 
CICs are found in both euchromatin and heterochromatin 
CP molecules are heterogeneous and bind both to CICs and to each 
other, forming multimeric complexes. 
There are many different CICs, with differint affinities for the 
different CP molecules. CIC distributions vary across the genome and 
account for the differences in heterochromatin protein composition 
between different heterochromatic domains. 
Levels of CP molecule binding and distances between the CICs 
determine the level of cooperation between sites and also determine if 
the threshold level for heterochromatin formation is reached. 
At a euchromatic-heterochromatic breakpoint, CPs spread into the euchromatic area, 
as there is no longer a boundary element present to prevent it (see Sun & Elgin 1999 
for a review on boundary elements, and van der Viag et a! 2000 for experimental 
testing of boundary element strength). The relative concentrations of CICs and CPs, 
in conjunction with the distances between the CICs, will act to determine where and 
when heterochromatinisation takes place. Some parts of the euchromatic locus may 
not have CICs close enough together for formation of heterochromatin, but if there 
are CIC sites located distally which are closer together and can be reached by the 
CPs, then they could spread there and give rise to discontinuous compaction. 
Experimental results, mainly in Drosophila, bolster the validity of this theory. Most 
convincing are the Polycomb response elements (PREs). Initially identified as part of 
the Bithorax—C regulatory domains (Simon et a! 1990), PREs are targets for 
Polycomb group (PcG) proteins (Simon et a! 1993). The elements appear diverse in 
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composition, exhibiting different preferences for PcG complexes, and can easily be 
equated with CICs alongside PcG proteins as the CPs. PREs act to maintain correct 
expression patterns via the action of bound PcG and possibly also trithorax group 
(trx) complexes (Busturia & Bienz 1993, Chan et al 1994, Chiang et a! 1995, 
Gindhart & Kaufman 1995, Muller & Bienz 1991, Simon et al 1993), with several of 
the sequences identified as putative PRE's (or associated with them) apparently 
combining both a silencer and a boundary function. The Fab-7 element (Hagstrom et 
a! 1996 + 1997) and Mcp element (Muller et a! 1999) are two examples. In addition, 
they also contain properties that can convey an active chromatin configuration upon 
associated sequences (Cavalli & Paro 1999, Muller et al 1999). This indicates 
strongly that trx complexes can bind the recognition site as well. Yeast experiments 
reinforce the universality of the theory, Sherman & Pillus (1997) suggesting that 
competition between loci and availability of protein complexes may explain variable 
silencing at different genomic loci. 
The Markov Model 
Clarke et a! (1996) proposed a mathematical model based on conditional 
probabilities with which to calculate the assembly of heterochromatin into a 
euchromatic region at a given heterochromatic-euchromatic breakpoint. The model is 
known as: "A Markov Model for the Assembly of Heterochromatic Regions in 
Position Effect Variegation" and appears to share the same basic assumptions as 
Balasov & Makunin. An attempt is made to create a mathematical model upon which 
to predict the behaviour of one or more variegating loci in the same system. The 
design is for only one allele of a pair to be variegating, two variegating loci are 
presumed to be two separate genes at different loci. The model's central tenet is also 
that the relative concentrations of CICs and CPs together determine the outcome for 
a given locus' expression state. 
1.7.8 PEY and X-inactivation: a case of shared properties and pathways? 
A PEV model involving sites responsible for binding/initiation of heterochromatin 
formation is reminiscent of the spread of heterochromatin during X-inactivation. 
Both PEV and X-inactivation share many similarities: both determine the activation 
state of a defined site. This determination is reputed to take place early in 
development and maintained in a clonal fashion (Lu et al 1998), leading to the 
speculation that both processes may share some structural if not mechanistic 
components. Although the mosaic pattern of expression seen for genes subject to 
PEV is highly suggestive of a clonal route of signal propagation, some reports 
suggest that this may not be the case in all examples (Kunz et al 1996, Voinnet & 
Baulcombe 1997). A partial relaxation in the silencing structure of heterochromatin 
(Lu et al 1996) that is cell independent may be one explanation. This is seen for the 
Smcx gene on the X-chromosome, where variable levels of expression and non-
clonal release from silencing can be observed (Sheardown et al 1996). 
1.7.9 PEV and Mice 
Although Drosophila are excellent and extensively used tools for genetic 
investigations, they have their limitations, especially when mammalian disease 
models or proteins are needed. The mouse is a natural choice to complement and 
extends the research done in Drosophila and single celled organisms such as Yeast. 
Transgenic technology has been used to create mouse models of human disease and 
also model methods of producing therapeutic proteins for harvesting (Andres et a! 
1987, Archibald et al 1990, Matsuoka et a! 2000). Other mice have been created in 
order to investigate the function of specific proteins or gene regulatory sequences 
(Caterina et a! 1994, Bonifer et a! 1996, Festenstein et al 1996, Corcoran et al 1998). 
In the course of the generation of all these mice, many of the transgenes have 
displayed unexpected behaviour linked to any one or a combination of the 
abovementioned sources of gene expression disruption (1.1-1.7). A chromosomal 
position effect was demonstrated as the cause of aberrant expression of a HSV-TK 
transgene, though without mapping of the insertion site classical PEV could not be 
confirmed (Al-Shawi et a! 1990). The same transgene contained a cryptic promoter 
responsible for aberrant tissue expression (Al-Shawi et a! 1991). Position effects 
were also deemed to cause the variable expression of lacZ reporter under 3-globin 
promoter and LCR control, with the unusual observation of qualitative and 
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quantitative expression differences within both lines and individual mice (Guy et al 
1997). 
Mammalian transgenic papers are still rare compared with Drosophila and Plants, 
with PEV phenomena in mammals only reported and acknowledged five years ago 
(Dobie et a! 1996, Festenstein et al 1996). 18 000 hits are generated by a literature 
search using transgenic animals as the key, shrinking to 55 when the additional terms 
PEV or copy number are included. The majority of mammalian PEV papers have 
until recently not addressed the mechanism(s) surrounding PEV. The identification 
of mammalian homologues of Drosophila proteins known to modulate PEV (Singh 
et a! 1991, Cowell & Austin 1997) have generated two papers which investigate the 
effects that changing modifier concentration has on variegating transgenes in mice 
(Festenstein et a! 1999, McMorrow et a! 2000). PEV studies in mammals have also 
investigated copy number effects by generating multicopy transgene array inserts 
that induce variegation, and then reducing the copy number in order to study the 
effects of reduction of the array size. The first paper reported that reduction in copy 
number abolished PEV and led to even expression in all cells (Garrick et al 1998), 
resulting in the current mantra: "More is Less". The second paper reports the exact 
opposite (Ramirez et al 2001). Variegation still prevailed and the level of variegation 
generally remained unchanged, with only an occasional incidence of quantitative 
reduction in expression from the cells that were expressing the transgene. 
With few reports of confirmed classical position effect variegation in mice 
(variegation within a line, with integration close to constitutive heterochromatin), the 
first such reported line (Dobie et a! 1996, containing a milk protein transgene) 
remains an important source of information, combining the means to study a 
phenomenon impacting on both commercial production of therapeutic proteins and 
human diseases where position effects are implicated in the phenotype. 
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j 	Transgenic Mouse line BLG/7 
BLG/7 is a unique transgenic resource 
In variably expressing transgenic mouse lines, silencing is frequently seen at the 
cellular level, with the extent of silencing variable between related individuals for 
lines exhibiting within line variations in expression levels (Dobie et a! 1996, 
Sutherland et a! 2000), and between individuals of different lines when the variation 
in expression is between two lines (Robertson et al 1996). In many of the reported 
cases, the relative transgene expression levels from individual cells will not vary 
(Graubert et al 1998), differences in the number of cells expressing the transgene are 
responsible for the variable amount of protein production. These qualitative, rather 
then quantitative, differences in transgene expression generate a mosaic pattern of 
expression when in situ hybridisations for mRNA are performed (Dobie et al 1996). 
This phenomenon therefore bears at least a superficial resemblance a position and/or 
copy number effect known as Position Effect Variegation (PEV) in Drosophila. 
BLG/7 is one such line exhibiting this phenomenon where centromeric integration 
has been linked to the variegated phenotype, this being the first report linking 
genomic location and variegated expression in a mirror image of that reported for 
PEV in Drosophila. 
Other mice expressing transgenes under milk promoter control exhibit within line 
variegation (Bleck & Bremel 1994, Gutierrez et a! 1996, Barash et al 1999), without 
linking it to insertions close to constitutive heterochromatin, although there was the 
suggestion that high copy number decreased expression (Barash et al 1999). Even in 
transgenic terms, BLG/7 are a unique resource as the variegation observed may be 
the result of both copy number and position effects, justifying a more in-depth study. 
These mice have formed the central focus of the work described in this thesis. 
BLG/7 creation and initial characterisation 
BLG/7 is a line of transgenic mice created over a decade ago (Simons et al 1987). 
The line contains approximately 25 copies of an ovine milk protein gene called - 
lactoglobulin (BLG) (Dobie et al 1996). BLG is the major whey protein in ruminants 
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and has no rodent counterpart. The transgene array has integrated as a single block 
close to centromeric heterochromatin of mouse chromosome 15 (Dobie et al 1996). 
BLG/7 was created as part of a study into the feasibility of creating transgenic 
animals able to secrete pharmaceutically important proteins in their milk, a process 
known as "pharming". Three transgenic mouse lines containing BLG displayed 
correct temporal and spatial expression of the transgene. Unexpectedly, two of the 
lines displayed considerable within line variation in expression levels. This was 
demonstrated to be due to mosaic expression, with variable numbers of expressing 
and silent cells correlating with the variable amount of transgenic protein produced 
in the milk. Correlation between integration near centromeric heterochromatin and 
high transgene copy number with variegated expression was established (Dobie et al 
1996). Images presented in the following chapters may be easier to interpret if a brief 
description of the mammary gland is given at this point. 
1.8.1 Mammary Gland Function and Composition 
The mammary gland is a complex organ whose basic structure is laid down in the 
foetus. Hormonal cues delivered during puberty and pregnancy ensures development 
of a functional organ. Both gland development and protein expression is under the 
control of placental lactogens, growth factors and signals emanating from the 
extracellular matrix (ECM). There are differences in expression between the various 
proteins that comprise the milk, and these differences are attributed to differences in 
cis-regulatory elements and interactions with the hormones and ECM signals. 
The gland contains a large number of different cell types, only a subset of which are 
responsible for the production and secretion of milk proteins. These specialised cells 
are known as the secretory epithelial cells, and their numbers increase enormously in 
rodents between parturition and mid-lactation. This increase in cell number is needed 
to enhance the milk yield and feed the growing litter. Believed to originate from a 
modified sweat gland, the parts of the mammary gland that comprise the secretory 
pathway include the aforementioned secretory epithelial cells that line individual 
alveoli, into which the milk proteins are secreted. The alveoli drain into secretory 
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tubules that in turn drain into lobular ducts that eventually connect to the teat. 
Structural cells and other vital components needed to contain the gland and ensure an 
adequate supply of nutrients and hormonal signal cues to all cells surround the 
alveoli. A simple example is to liken the structural composition of the mammary 
gland to a bunch of grapes. Each alveolus can be equated to a single grape in the 
bunch; with the secretory epithelial cells the skin of the grape. The stems represent 
the secretory network, congregating in the teat represented by the main stem that 
connects the entire bunch (see Figure 1.2). 
Investigations into expression at the cellular level involve sectioning the mammary 
tissue and probing for milk gene expression. As only secretory epithelial cells 
express milk protein genes, the probe used identify no other cell types. In situ 
hybndisations for milk protein gene expression therefore generate images of 
circularish structures with only the outside edges visible (see Figure 1.2). The 
mammary gland is infinitely more complex than described here, but this simplified 
explanation is sufficient for my purposes. I am only concerned with expression from 
secretory epithelial cells, and provided the endogenous milk genes are expressed 
normally, I do not consider further examination of the intricacies of mammary gland 
biology part of the scope of this thesis. Suffice to say that previous investigations 
into transgene expression in BLG/7 mice revealed a link between the variable 
amount of protein secreted into the milk and mosaic mRNA expression at the cellular 
level. This phenotype was further correlated with the transgene multicopy array and 
its integration close to centromeric heterochromatin (Dobie et al 1996). This is 
analogous to the effects of Position Effect Variegation seen in Drosophila. 
1.8.2 BLG/7 lines of investigation 
Three lines of mice carrying a -lactoglobulin transgene integrated at different 
genomic locations with varying numbers of gene copies at those sites have been 
investigated (Dobie et a! 1996). Despite evidence that the integrations remained 
stable without any obvious signs of rearrangements, two of the three lines exhibited 
variegated levels of expression within the line. Both lines had the transgene 























Figure 1.2 	Mammary gland development during pregnancy and lactation 
Representation of mammary gland expansion during pregnancy. The grapes represent 
the individual alveoli (courtesy of Lothar Henninghausen, NIH). 
Morphology of mammary gland changes between virgin, pregnant, lactating and post-
lactational stages (courtesy of Lothar Henninghausen, NIH). 
Fluorescent in situ hybridisation of a wax embedded mammary gland from BLG/7 
hemizygous female taken at mid lactation and probed for BLG (Red/Orange) and 3-
casein (green) mRNA expression. Bright yellow fluorescence is caused by 
autofluorescence of wax residues, easily distinguished from mRNA signals. 
44 
(BLG/7) as multicopy arrays of approximately 17 (BLG/45) and 25 (BLG/7) copies, 
with the variegation in milk expression evident as mosaic expression at the cellular 
level. The third line exhibited even expression, both in milk and mammary tissue, 
with two copies of the gene integrated mid-arm on chromosome 7 (BLG/14). 
As BLG/7 was the line with the highest level of variegation, it was investigated 
further. Backcrosses were performed to two different genetic backgrounds for three 
generations to check if the variegated expression was caused by segregation of 
genotype-specific modifier alleles (the mice were created on a mixed Fl 
background). No significant evidence was found, although there was a weak trend 
evident in one of the backgrounds (CBA) for reduced expression and variance 
compared to the original samples. Serial lactations showed that the levels of BLG 
expression do not vary between lactation, and must therefore be fixed and maintained 
at some point in advance of the first sampling (1 l" day of lactation). Location of the 
transgene close to the centromere suggested that the mosaic expression pattern seen 
at the cellular level was due to an analogous mechanism that is responsible for 
position effect variegation in Drosophila, with the multicopy nature of the 
integration site playing a probable additional role (Dobie et al 1996). 
Taking the project further 
The investigation into the variegated expression profile of BLG/7 mice uncovered 
more questions than it answered. Three natural lines of investigation were 
incorporated into this project, attempting to answer three specific questions: 
• Are multiple recessive modifier loci responsible for BLG/7 variegation? 
The observation that the CBA background exhibited a weak trend towards a 
lowered level and spread of expression initiated maintenance of the 
backcrossing regime for a further 10 generations to investigate the possible 
presence of minor modifier loci affecting BLG/7 expression (Chapter 3) 
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• Would an increase in copy number through breeding to homozygocity 
uncover limiting factors involved in variegation control? 
The phenotypic links to PEV and copy number dependent silencing 
phenomena suggested that this would be a good source of information. The 
behaviour of two identical variegating loci could indicate whether the 
variegation is subject to any constraints, such as availability of modifier 
proteins, and if the two loci can interact and affect each other. Homozygous 
BLG/7 mice were sampled and transgenic milk protein content and cellular 
expression compared to hemizygous BLG/7 mice (Chapter 4) 
• Are the mosaic patterns of expression clonally or instructionally derived? 
The discrete patches of cells expressing BLG/7, and similar expression 
patterns seen for PEV affected genes, are assumed to be clonally derived. An 
alternative explanation is that the pattern is the result of an instructional state 
derived from inter-cellular communication (a distinct possibility in mammary 
tissue, where expression of milk proteins is hormonally controlled). The 
origin of the expression pattern of BLG/7 was therefore chosen as a third area 
for investigation. Mice with a lactation specific marker of clonality do not 
exist, and would have to be made before further investigations (Chapter 5.) 
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Chapter 2 
Materials & Methods 
Chemicals are from BDH (Sigma if not stocked by BDH) unless otherwise indicated. 
2.1 DNA manipulation 
Bacterial Based Manipulations 
2.1.1 Miniprep Protocol 
Grow up 3m1 culture over night at 37 °C, or temperature suited to bacteria 
(D115a were generally used). 
Spin 1.4 ml in eppendorf at 8000 rpm for 5 mm. 
Remove supernatant and resuspend pellet in 100 tl TE for bacteria (25 mM 
Tris.HC1, 10 mM EDTA pH 8). 
Add 200 j.iI alkaline SDS (0.25 M NaOH, 1% SDS), mix gently, solution should 
become clear and viscous. 
Add 150 j.il 3M Na or K acetate pH 5, mix by inversion. A white precipitate 
should appear. 
Centrifuge 10 minutes at 13000 rpm. 
Remove supernatant (approx. 400 tl) and extract once with an equal volume of 
1:1 phenol: chloroform (centrifuge 3 min at 13000 rpm). 
Add 1 ml EtOH, mix, precipitate in —20 °C freezer for 30 - 60 minutes. 
Centrifuge 10 minutes at 13000 rpm, remove supernatant. 
Wash pellet with 70% EtOH and leave to airdry for 10 minutes. 
Rehydrate in 50 t1 TE with RNase (20 l 10 mg/ml Ribonuclease Aa  in 0.5 ml). 
(a = Sigma) 
2.1.2 50 ml Scale-up of Miniprep Protocol 
Centrifuge culture in falcons for 10 minutes at 4000 rpm 
Resuspend pellet in 4 ml TE (25 mM Tris, 10 mM EDTA pH 8) 
Add 8 ml Alkaline SDS (0.25 M NaOH, 1% SDS) 
Add 6 ml 3M Na or K acetate 
Centrifuge 10 min at 4000 rpm 
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Filter through sterile fishwool at bottom of 20m1 syringe with plunger removed 
Extract with an equal volume 1:1 phenol: chloroform (here 15 ml) 
Precipitate 30 min at -70 °C with 2.5 volumes EtOH. 
Centrifuge down 10 minutes at 4000 rpm 
Rinse pellet in 70% EtOH and leave to dry, resuspend in 0.5-1 ml TE with RNase 
(20 tl 10 mg/ml Ribonuclease Aa  in 0.5 ml TE). 
(a = Sigma) 
2.1.3 Modified Qiagen Maxiprep Protocol 
(To maximise DNA yield. Kit catalogue number 121 63) 
Grow up large (250 ml x 3) cultures at appropriate temperatures overnight 
Centrifuge 10 minutes 5000 rpm at room temperature 
Resuspend pellet in 10 ml buffer P1 which contains RNase A 
Add 10 ml buffer P2 at 37 °C for 5 minutes (invert tube to mix, do not vortex). 
Add 10 ml chilled buffer P3, mix gently and leave on ice for 20 minutes. 
Centrifuge 30 min 13 000 rpm at 4 °C 
Filter supernatant through miracloth 
Equilibrate Qiagen tip 500 adding 10 ml buffer QBT, allow to empty by gravity 
(use 4 tips to maximise yield and minimise loss through column blockage). 
Add supernatant to equilibrated tips and wait until it has flowed through 
Fill to top with Buffer QC (approx. 15 ml) allow to flow through, then repeat. 
Elute DNA with 15 ml of Buffer QF. 
Collect the eluate in 10 or 30 ml small baked glass centrifuge tubes (corex). 
Add 0.7 volume isopropanol to the eluate (10.5 ml), mix and centrifuge for 30 
minutes using a fixed rotor set for 7 - 8000 rpm at 4 °C. 
Wash pellet with 5 ml 70% EtOH and recentrifuge as above. 
Dry pellet briefly, then resuspend using 0.5 ml TE buffer. 
Buffer P1: 	50 mM Tns.Cl (pH 8), 10 mM EDTA, 100 ig/ml Rnase A. 
Buffer P2: 200 mM NaOH, 1% SDS 
Buffer P3: 	3 M potassium acetate, pH 5.5 
Buffer QBT: 750 mM NaCl, 50 mM MOPS pH 7,15% isopropanol 
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Buffer QC: 750 mM NaCl, 50 mM MOPS pH 7, 15% isopropanol, 0.15% 
TritonX- 100 
Buffer QF: 	1.25 M NaCl, 50 mM Tris.Cl pH 8.5,15% isopropanol 
2.1.4 Transformations 
(Insertion of plasmid DNA into new host bacteria) 
Thaw competent cells slowly on ice 
Add 100 p1 of the cells into a clean eppendorf, add 5 p.1 of a ligation mix (or 
appropriate amount of plasmid DNA) and mix gently (include no DNA controls) 
Leave on ice for 20 minutes 
Heat shock for 90 seconds at 37 or 42 °C 
Ice for 2 minutes 
Add 400 p.1 Luria-Bertani (LB) medium (no drugs), incubate on shaker at 37 °C 
for 20 - 30 minutes 
Centrifuge slowly for 1 minute (8000 rpm) 
Remove nearly all supernatant, leaving approx. 50 p.1 for resuspension 
Plate on agar plates with appropriate drug resistance 
Incubate overnight at 37 °C 
Luria-Bertani (LB) medium 
Tryptone 	 10 g/L 
Yeast Extract 	5 g/L 
NaCl 	 lOg/L 
Agar 
Bacterial grade agarose in LB medium 15 g/L 
Ampicillin plates made to concentration of 1 mg/L (100 p.1 of 100mg/mi stock) 
Kanamycin plates made to a concentration of 0.3 mg/L 
Same concentrations of antibiotics used in LB medium. 
Glycerol stocks for transformed bacteria 
Mix glycerol and bacteria in a ratio of 300: 700 in 1 ml. 
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In vitro based DNA manipulations 
2.1.5 DNA digests 
General Digests 
Enzymes: 1 Vg of (clean) DNA should be digested completely by 1 unit of enzyme 
in an hour. Enzyme volume should not exceed 10% of total digest volume. Enzymes 
were usually sourced from Boehringer, with New England Biolabs the next choice if 
the enzyme needed was not available from Boehringer. 
Buffers: Use buffer appropriate for enzymes in reaction. Buffers usually supplied 
with enzyme as lOx strength, so constitute 11101h  of total reaction volume 
DNA: 	1-2 i.tl for diagnostic test of miniprep DNA, 0.5 - 1 tg for plasmid DNA. 
Volume: Diagnostic reactions can be as little as 10 p1, depending on quality of 
DNA and complexity of reaction (larger volumes are recommended if several 
enzymes are used, especially if a buffer change is needed). 
Blunt ending: Use Klenow enzyme to create blunt ends from previously cut DNA. 
Southern Blot Digests 
Larger reactions and high concentration enzymes needed when using genomic DNA. 
25 tl reactions: 
10 tg DNA 
2.5 jtl High Conc. Enzyme (40 U/mi) 
2.5 p110 X Buffer 
Incubate at relevant temperature (usually 37 °C) overnight 
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Buffer Changes 
Equilibrate a 0.025 .tm VS Millipore paper by floating on distilled water for 10 
minutes (shiny surface facing up) 
Place digest on surface for 20-30 minutes, salts should be drawn into the water 
Remove droplet containing digestion divested of salt buffer and proceed with 
second digestion, adding required buffer and enzyme. 
Can also use to remove small DNA fragments from a digest by dialysing overnight. 
2.1.6 Ligation Reactions 
Heat inactivate any digestion enzymes for 10 minutes at 65 °C to avoid interference 
with ligation reaction. Large fragments (15 Kb and above) are difficult to clone. 
10 t1 reactions: 
Vector: Insert 
	
(vary ratio from 1:0 to 1:4) 
10 X Buffer 
	
1 jt1 
10 mM ATP 
	
1 p.1 100 mM stock, final concentration 1 mM 
T4 DNA Ligase 
	
1 p.! 
1-120(di still ed,autoc laved) 	make up to total volume of 10 p.1 
Ligate overnight at approximately 14 T. 
Insert concentrations needed for cloning dependent on insert and vector sizes: 
Insert size (Kb) Vector concentration (p.g/ml) 	Insert concentration (Mg/ml) 
4 Kb vector 8 Kb vector 
1 	 125 	250 	 30 
2 	 30 	60 	 25 
6 	 12 	25 	 20 
9 	 6 	 12 	 15 
15 	 2 	 4 	 10 
20 	 1 	 2 	 5 
When cloning linker additions, use a 10:1 molar ratio of linker sequence to vector, 
heat denature at 70 °C for 10 minutes, then ice 2 minutes before adding ligase. 
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2.1.7 DNA purification methods 
Dialysis Method 
(suited to high molecular weight DNA) 
Cut out desired DNA band from gel 
Wash dialysis tube (approx. 10cm) in distilled water and seal one end with a clip. 
Add 400 tl of buffer to the tube (vary it depending on size of gel band) 
Add gel to tubing, seal other end with clip and ensure no air bubbles or leakage. 
Return to gel tank, keep tube immersed using glass plate, dialyse 2 hrs at 100V. 
Reverse current for 1 minute to remove any DNA clinging to sides of tubing. 
Remove liquid, avoid including agarose remnants, transfer to fresh eppendorf. 
Extract with an equal volume phenol: chloroform, then ethanol precipitate DNA 
Rehydrate in a suitable volume TE. 
Dialysis tubing: 10 cm cut tubes in 5 mM EDTA (5 ml 0.5 M EDTA pH 8 in 500 
ml distilled water), autoclave before use and store at 4 T. 
Freeze Method 
(suitable for small to medium molecular weight DNA) 
Cut out desired band from the gel. 
Place in an eppendorf and put in - 70 °C freezer overnight 
Centrifuge for 10 minutes at 14000 rpm 
Remove liquid and extract with an equal volume phenol: chloroform 
Ethanol precipitate DNA and resuspend in a suitable volume TE 
Fishwool Gel Extraction Method 
(suited to smaller molecular weight DNA) 
Cut out desired DNA band from agarose gel and place in a petridish 
Remove cap from PCR tube 
Puncture bottom with fine needle, place fishwool at the bottom using fine forceps 
Cut gel on petridish into very small pieces and stuff into PCR tube 
Place in 1.5ml eppendorf with lid removed, centrifuge 13000 rpm for 10 minutes. 
Transfer liquid to new eppendorf and repeat step 5 centrifuge 
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Phenol: Chloroform and EtOH precipitate the DNA from the liquid 
Re-hydrate the pellet in 10tl TE 
Qiaex Gel Extraction Method 
(Qiaex Gel Extraction kit 150, cat. 20021. Suited to smaller molecular weight DNA) 
Cut out desired DNA band from agarose gel. 
Add 3 x gel volume of buffer QX1 
Leave at 50 °C for 10 mm. until gel is dissolved. Mix well. 
Add 10 tl Qiax II (vortex first), leave 10 min at 50 °C, shaking every 2 minutes 
Centrifuge for 30 seconds and remove supernatant 
Add 0.5 ml QXI and resuspend pellet 
Centrifuge for 30 seconds and remove supernatant 
Repeat steps 6-7 
Add 0.5m1 wash buffer (with EtOH added) and resuspend pellet 
Centrifuge 30 seconds and remove supernatant 
Repeat steps 9-10 
Remove all supernatant, dry pellet at room temperature for 10 - 15 minutes 
Add 10 il TE, vortex & mix, Leave at room temperature for 5 minutes 
Centrifuge 30 seconds, transfer supernatant to fresh eppendorf as contains DNA 
Repeat steps 13-14 
2.1.8 Polymerase Chain Reaction for genotyping mouse tail digests 
Tail Digestion 
Tails Proteinase K digested overnight (200mg/mi) in 0.3 M NaAc, 10 mM Tris.HC1 
pH 7.9, 1 mM EDTA and 1% w/v SDS at 37 °C, then briefly vortexed and frozen. 
Tail PCR for genotyping 
Thaw tail digests 
Vortex briefly to mix sample. 
Centrifuge at 1300 rpm for 10 minutes at 4 °C, 15 minutes for frozen digests. 
Transfer 20 j.tl of supernatant into labelled eppendorfs (optional step). 
Make up PCR mix, don't add taq polymerase until ready to add to samples. 
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Add 1 drop mineral oil/PCR tube, pipette 1 jtl tail DNA/tube underneath oil. 
Denature samples on PCR machine (15 min at 95 °C, then cooled to 65 °C). 
Add 50/25 pi PCR reaction mix with taq polymerase to DNA under oil. 
Run BLG PCR programme (30 sec at 92 °C, 5 min at 65 °C, cycled 30 x). 
15 .tl samples of the PCR reaction are run on a 2% agarose gel at 100 V. 
Standard mix for BLG/HPRT primed tails for 50 t1 reactions: 
mixltube: 5 tl 10 x Mg reaction buffer 
8 p1 1.25mM dNTPs (dATP, dGTP, dTTP and dCTP in equal ratio) 
5 jtl DMSOa  (dimethyl sulphoxide C2H60S) 
0.5 p1 10 mM BLG 5' + 3' primers 
0.5 p.! 10 mM HPRT 5' + Y primers 
0.15 p.1 Taq DNA polymerase enzyme 
31 j.il H20 (distilled and autoclaved) 
* 25 p.1 reactions work equally well 
Alternative Method for PCR 
• Make up ready reaction mix, aliquot 25 p.1 per tube, add oil and 1 p.1 tail digest 
• Run straight on BLG programme without denaturing step 
200 X reaction mix: 
10xMg reaction buffer 500 p.1 
1.25mMdNTPs 800 p1 
DMSOa 500 p.1 
10mM BLG 5'+ 3' primers 50 p1 
10mM HPRT 5'+ Y primers 50 p.1 
H20 (distilled & autoclaved) 3 100 p.1 
(a = Sigma) 
Ready Reaction mix: 
Taq DNA polymerase enzyme 3 p.1/1000 p.1 reaction mix 
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2.1.9 X-Gal staining of ears for identification of PGK IRES 3Geo mice 
Rinse ears in 1XPBS, each ear in a well on a 48 or 24 well plate on ice. 
Fix 5 minutes in 2% Formaldehyde: 0.2% Glutaraldehyde in PBS in fridge 
Rinse three times in PBS with 2 mM MgCl 
Add stain solution, cover plate and leave overnight in a box at 37 °C. 
Examine under microscope, blue ears are easily identifiable. Can change staining 
solution for PBS to make detection easier. Most results can be seen by eye. 
Fix Solution: 	2.5 ml 37-40% Formaldehyde 
0.4 ml 25 % Glutaraldehyde 
PBS to 50 ml total volume 
Stain Solution: 	1 mg/ml X-Gal dissolved in DMSO 
5 mM Fe3+/Fe2+ (K3Fe(CN)6 + K4Fe(CN) 63H20) 
2 MM  MgC126H20 
Make up in 1 X PBS 
Mix and filter before use 
X-Gal = 5-bromo-4-chloro-3-indolyl-b-D-galactosidase, from Melford Laboratories. 
2.1.10 Mass screening of bacteria for successful ligations (colony lifts) 
Prepare duplicate sets of plated bacterial colonies, use sterile toothpicks to plate 
out colonies in a pattern that can be used to orientate the plate 
Cool plates in coldroom for a minimum of 30 minutes before transfer 
Label each filter in pencil (0.45 ptm Nytran filter D-37582 Dassel from 
Schleicher & Schuell, 82 mm) 
Place filters pencil side up on plates and leave 1 minute, use a pin to stab 
orientation holes through the filter into the agar plate 
Remove filter and place on 3MM double layer of whatman paper soaked in 
denaturing solution (0.5 M NaOH, 1.5 M NaCl) for 5 minutes, plaque side up 
Transfer filter to 2 X 3MM whatman paper soaked in neutralisation solution (0.5 
M TrisHCl pH 7-8, 1.5 M NaCl) for 5 minutes 
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Transfer to a 2 X SSC (tri sodium citrate) bath, submerge and agitate until 
bacterial debris is washed off filter 
Dry filter plaque side up on 3MM paper, then crosslink at 1200 J 
Wet filter in 2 X SSC and place plaque side up in hybridisation tube, add 20 ml 
of hybridisation buffer and prehybridise at 65 °C for 20 - 30 minutes before 
adding probe (see 2.2.5). Hybridise overnight. 
Rinse with wash buffer, add 20 ml of wash buffer and return to oven for 20 
minutes. Repeat twice 
Wrap filters in cling film, put in cassette, add film and leave overnight in —70 °C 
freezer. 
Hybridisation buffer (Church-Gilbert buffer): 
250 ml Phosphate buffer (1 M = 70.9 g Na 2HPO4, 4 ml 
85% orthophosphoric acid in 1 L) 
35 g SDS 
5 g BSA (fraction V) 
1 ml 0.5 M EDTA 
make up to 500 ml with distilled water, heat until ingredients are in solution 
Wash buffer (1L): 	40 ml Phosphate buffer 
2ml0.5MEDTA 
10 g SDS 
958 ml distilled water 
2.2 Cell Culture work 
Sterile techniques observed at all times. Fume hoods are category 1 containment 
level. Cell culture designated labcoat and non-powdered gloves worn. 70% Ethanol 
used as general disinfectant, Microzid used to clean fume hoods. 
2.2.1 HC-11 Cells, routine maintenance 
HC-1 1 cells are immortalised mammary epithelial cells, described in detail by 
Burdon and colleagues (1994). 
RPMI complete medium (for HC - 11 cells) 
RPMI 1640 mediuma 	 500 ml 
FCS b  (foetal calf serum) 	 50 ml 
LGlutaminec (50 j.xg!ml) 	 5.6 ml 
Penicillin/Streptomycin a  (10 000 U/ml) 	5.6 ml 
EGF a  (epidermal growth factor, 10 ng/ml) 500 tl 
Insulin d  (5 .tg!m1) 	 500 .tl 
Filter sterilise additions to medium before addition. Store in fridge. 
(a = Sigma, b = Globepharm, c = Life Tech., d = Gibco BRL) 
Recovery of Frozen Cells 
Remove cell vial from liquid nitrogen, place in hot water to thaw quickly. 
Transfer cells to 15m1 falcon with 5m1 medium, centrifuge 5 min at 1000 rpm 
Remove supernatant, resuspend cell pellet in 5m1 RPMI complete medium 







. Rinse with PBS if there is much cell death before adding fresh medium. 
• Check cells daily and change medium every two days or more often, a lighter 
medium colour indicated need for change. 
• Seed at lower densities with larger medium volumes if keeping cells 
unattended over weekend. 
Trypsinisation of cells: 
Wash cells with PBS 
Add lml TEG (trypsin-EGTA solution) prewarmed to 37 °C to a T25 (2m1 for a 
T75) and return to incubator for 10 minutes. 
Slap bottle to dislodge cells, then add 3-5 ml medium. This stops reaction. 
Transfer liquid to a falcon and centrifuge for 5 minutes at 1000 rpm 
Remove supernatant, resuspend cells in 0.5 ml, make up volume to 10 ml and 
transfer to T75 (or split into smaller flasks as V4 or desired cell seeding density) 
Gently agitate new flask to ensure even distribution and return to incubator 
TEG: 3.15 g/L NaCl, 0.06 g/L Na2HPO4, 0.108 g/L KH 2PO4 , 0.166 g/L KCL, 0.45 
g/L D-glucose, 1.35 g/L Tris, 0.45 mi/L 1% Phenol Red, 50 ml/L 10 x 2.5% trypsin 
(ICN FLOW), 0.2 g/L EGTA, 0.05 g/L PVA. Filter before use, store at —20 T. 
Freezing Cells 
Trypsinise cells, centrifuge and resuspend in 3 ml RPMI complete medium 
Add 3 ml of freezing mix gently to the cells, and dispense as lml aliquots into 
pre-chilled labelled cryogenic screwtop tubes 
Place in styrofoam box that has been pre-chilled in normal freezer and put in —70 
°C freezer for a few days before transferral to liquid nitrogen 
Freeze Mix 	10 ml 
RPMI complete 	6 ml 
DMSO 	 2 ml 
FCS (filter first) 	2 ml 
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2.2.2 Transfecting HC-11 cells using Calcium Phosphate method 
Need: 
RPMI complete medium 
DMEM complete medium: Dulbecco's Modified Eagle's Medium' 
10% FCSb 
LG1utaminec (5.6 ml in 500 mls) 
2M CaC12 solution 
2 X Hepes Buffered Saline (HBS): 50 mM Hepese, pH 7.1 
280 mMNaC1 
1.5 mMNa2HPO4 
HEPES = N-2-Hydroxyethylpiperazine-N'-2-ethane suiphonic acid (C 8H 18N204 S) 
(a = Sigma, b = Globepharm, c = Life Tech., e = Merc) 
Day —1 
• Seed 5 X 105  cells in T75 flask, usual medium and culturing conditions apply. 
Day 0 (transfection day) 
Change medium at 9 am, use 15 ml DMEM complete medium, incubate for 3 hrs 
to ensure peak growth rate. 
Defrost CaCl 2 , 2 X HBS, DNA solutions at room temperature 
Start preparing transfection mixes from 11 am, 0.5 ml 2 X HBS per transfection 
Mix plasmid DNAs with CaC1 2, make up to 0.5 ml with H20dda. 0.5 ml contains 3-
5 jig pSVNeo, 20 jig plasmid DNA, 62 j.tl CaC12 (final concentration 250 mM) 
Add the DNA-CaC1 2 solution drop-wise to the 2 X HBS. 
Leave to rest at room temperature for 30 mm. 
Add the 1 ml transfection solution dropwise to the cells in the T75 flasks and 
gently shake the medium to mix, return to incubator and leave 5 hours. 
Wash cells with DMEM complete medium, add 10 ml RPMI complete medium, 
leave to incubate overnight. 
Day +1 
. Leave cells in RPMI complete medium without selection 
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Day +2 
Change medium to 10 ml RPMI complete with 200 .ig/ml of G418 (G eneticinc) 
Day +3-+14 
• Continue selection, change medium every two days. Check for resistant colonies 
Day+15-+ 17 
• Collect and pool the colonies from each flask, divide between 2 T25 flasks. 
• Culture in RPMI complete medium without G418 for 2 days after they have 
reached confluence. 
Day +18 - + 19 : Induction of expression 
• Culture the cells with RPMI low serum for 2 days. 
Day +20-+24 
• Apply induction medium and culture cells for 4 days. Culture non-induced 
control cells in parallel, usual culture conditions for both. 
Day +25 
• Induction of expression complete 
• Harvest cells and stain for expression 
Induction Medium 
RPMI 1640 medium' 	100 ml 
FCSb 3 ml (final conc. 3%) 
L-Glutamine' 1.1 ml (final conc. 50 .ig/ml) 
Pen/Strep' 1.1 ml (final conc. 10 000 U/ml of each) 
Dexamethasone a 100 tl (final conc. 4 p.M) 
Insulin  100 j.il (final conc. 5 j.tg/ml) 
Prolactina 200 tl (final conc. 5 .ig/ml) 
Low Serum Medium 
RPMI 1640 medium' 100 ml 
FCSb 	 1 ml (1% final conc.) 
PenlStrepa 	 1.1 ml (final conc. 10 0000U/ml of each) 
Insulin' 	 100 j.tl (final conc. 5 p.g/ml) 
(a = Sigma, b = Globepharm, c = Life Tech., d = Gibco BRL) 
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2.2.3 X-Gal Staining of cells for LacZ expression 
Wash cells 1 xwith 1 XPBS 
Overlay with 10 ml fixative (volumes for T75), leave at 4 °C for 10 minutes. 
Wash cells 3 x with 1 X PBS 
Overlay with staining solution (10 ml for T75), incubate overnight at 37 °C with 
flask tightly closed. 
Remove staining solution and overlay with 1 X PBS. 
Visualise cells and staining under microscope 
Photograph cells 
Fixative: 
2% Formaldehyde (40 % stock = 5m1 in 100 ml) 
0.2% Gluteraldehyde (25% stock = 0.8 ml in 100 ml) 
Make up to desired volume with 1 X PBS 
Staining solution for 3-Gal: 
lmg/ml X-Galactose 	(20 mg/ml stock = 5 ml in 100 ml) 
5mM K3Fe(CN6) 	(0.5M stock = 1 ml in 100 ml) 
5mM K4Fe(CN6)3H20 (0.5M stock = 1 ml in 100 ml) 
2mM MgC126H2O 	(1M stock = 200 j.il in 100 ml) 
2.2.4 ES cells, Routine Maintenance 
• ES cells divide every 18 —24 hours and should have their medium changed every 
day. Normal feeding is 5 —7 ml per T25, 16-20 ml per T75, 60 ml per T180. 
• Cells passaged every 2-3 days, V4 flask used for seeding. 1/6 118th  for weekend 
survival, add extra medium (T25 = 10 ml, T75 = 25 ml, T180 = 100 ml). 
• Cells are grown at 37 °C in 5% CO2 
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Medium 
BHK —21 Medium' (Glasgow MEM) 	500 ml bottle 
Foetal Calf Serum 	 28 ml 
New Born Calf Serumb 	 28 ml 
L- Glutaminec 	 5.6 ml 
Non Essential Amino Acids' 	 5.6 ml 
Sodium Pyruvatec 	 5.6 ml 
- mercaptoethanola 	 1.1 ml 
ESGRO (LIF = leukaemia inhibitory factor) 0.3 ml 
Filter sterilise through 0.22 im filter + 0.8 jim prefilter before adding to medium. 
(a = Sigma, b = Globepharm, c = Life Tech., f= Chemicon) 
Passaging cells 
Cells should be passaged at 85 - 90 % confluency and survive better if medium is 
changed 2-3 hours prior to trypsinisation. 
Change medium on cells, gelatinise new flask (5 ml 0.1% gelatin for T25, needs 
20 minutes to set) 
After 3 hours wash cells with 1 X PBS and then add trypsin solution (TEG) 
• Need 1 ml for a T25 
• 1.Sml for aT75 
• 2mlforaTl80 
Leave trypsin on for one minute (can put in incubator), smack flask and check 
under the microscope that the cells are dislodged without clumping. 
Add medium to inactivate trypsin: 5 ml for a T25 
8ml for aT7S 
16 ml for T180 
Pipette the cell suspension using glass narrow holed pipettes, this ensures single 
cell suspension. Centrifuge in falcon tubes at 900 - 1000 rpm for 5 minutes. 
Remove almost all supernatant, flick tube to resuspend cells, add fresh medium 
and use glass pipette to create single cell suspension. Transfer to fresh flask. 
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Resuscitating cells 
Remove vial of cells from LN 2 tank and thaw rapidly in warm water. 
Resuspend in 5 ml of complete ES medium; centrifuge 5 minutes at 1000 rpm. 
Aspirate most of medium and resuspend pellet in remnant. Add 5 ml fresh 
medium and create single cell suspension using glass pipette. 
Transfer to gelatinised T25 and incubate as normal 
Freezing cells 
Change medium 3 hours in advance, freeze only 80% + confluent cells. 
Make up or thaw out 2 X Freezing mix: lOml: 6 ml Complete Medium 
2 ml FCS 
2 ml DMSO 
(Filter before use) 
Label cryotubes and place in styrofoam box in freezer to cool down 
Trypsinise and resuspend in 1 or 2 ml (T251T75) complete medium. 
Slowly add imi (T25) or 2 ml (T75) 2 X FM (kept on ice) dropwise, mix once 
before quickly dispensing into cryotubes (I ml per tube) using glass pipettes. 
Place box of tubes in - 70 °C freezer, leave 24 hours before transferring to LN 2 
Freezing down cells in 24 well plates 
Make up 1 X Freezing mix: 	10 ml: 8 ml Complete Medium 
1 mIFCS 
1 ml DMSO 
(Filter before use and chill) 
Change medium 3 hours prior to freezing 
Remove 24 well plate from incubator and put on ice 
Aspirate medium 
Add 300 tl 1 X FM to each well gently down the side 
Put on lid and tape round it with paraflim, securing with autoclave tape. 
Place in - 20 °C freezer until all wells are frozen (approx 30 minutes) 
Plate is placed in precooled padded bag, sealed, labelled and placed in - 80 °C 
freezer. Should keep for 4 weeks. 
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Resuscitating cells in 24 well plates 
Warm medium to 37 °C 
Remove plate from - 70 °C, add 1 ml warm medium down side of wells, leave a 
few minutes at 37 °C for cells to defrost, aspirate carefully from side of well. 
Add fresh 2 ml of medium and incubate for rest of day 
Change medium again late in afternoon 
Change medium again the following day 
An alternative method is to suck up all medium, centrifuge and replate cells. 
2.2.5 ES cell targeting work 
ES cells: RI p14  (129 Ola) 
Targeting Construct: HBZ (approx. 21 Kb) 
. 4.3 Kb BLG promoter from pBJ39 (Sal JIRV) 
4.6 Kb LacZ w. Poly A signal (Clontech pGal-Basic) 
• M44.8 (A. Smith HPRT targeting vector): 
9Kb gHPRT from exon 6 (with some of intron 5) 
3 Kb pBS backbone 
Reporter inserted into unique exon 6 site (as Sal I fragment) with targeting construct 
linearised using Xho I. 
Reaction Conditions: 
• 2 lots of 200 p.g linearised vector in 200 tl HBS (from 
4mg!ml stock that has been Qiagen purified) 
• 2 lots of 2x 107 cells in 600 tl HBS 
• BioRad Gene Pulser set at: 800 V, 3 jtF, T=0. 1 
Culture of Cells Prior to Electroporations: 
• RI (p13) vial of ES cells defrosted and cultured for 14 days 
prior to electroporations. Cells are now p14. 
• Split 7 times prior to electroporations, cells cultured in 
T180 flasks from day 3 post-resuscitation. 
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Electroporation & Selection of Targeted Cells: 
Day 0 
DNA spun, EtOH washed and resuspended in 2 aliquots of 200 pd 1xHBS 
RI cells trypsinised and spun down as normal, the pellet resuspended in 
15 ml 1xHBS using a glass pipette to ensure a single cell suspension 
The cells were counted using a graticule. The squares of the grid were 
used to count the cells. The number of cells/ml is the number of cells 
counted in a grid x10 4 . 
2 batches of 2x107 cells were prepared in 600 j.xl 1xFIBS each, and mixed 
with the 200tl aliquot of DNA. 
The DNA/ES Cell suspension was pipetted into a 0.4cm electrode cuvette 
(BioRad cat. no: 115 —2088) ensuring that no bubbles formed. 
The BioRad Gene pulser is set at 800V and left to warm up. 
3 jj.F 
T=0.1 
The cuvette is placed into the chamber and pushed into place until the 
electrodes surround it. 
• Both charge buttons are then pushed simultaneously until a beep is 
heard and the "charging" icon has vanished from the screen 
• A check is made to ensure that the electroporation parameters 
have not been altered before the cuvette is removed and left to 
stand for 10 minutes 
Each of the two electroporations were resuspended in 100 mis medium. 
The resuspended cells were plated out on circular dishes (10 mls/dish = 20) 
Cells need to be cultured for 6 days before selection can proceed 
(endogenous HPRT to be degraded completely prior to selection). 
Day 6 (1 of selection) 
• Selection with 6TG (2-amino-mercaptopurine, from Sigma) started (1.67 
j.tg/ml) filtered in normal medium, change every two days. 
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Day 16 (10 of selection) 
• Colony Picking: 48 colonies picked, half of each to 2 x 24 well plates 
• The appearance of colonies and the time to pick them will vary between 
experiments, depending on cell growht, selection strength and means. 
48 eppendorfs and 48 wells were labelled, each well filled with 1 -2m1 
selection medium. 
A P200 set at 120 was used. Holding the plunger down and using the tip to 
dislodge the pellet, the colony was lifted off the plate and placed in the 
labelled eppendorf. 
The pellet was carefully pipetted and approximately half the suspension was 
transferred to the relevant well. 
The 24 well plates were placed in the incubator to expand the colonies, the 
cells in the eppendorfs were spun down and resuspended in 1xPCR buffer 
(Mg+) with Proteinase K added and incubated for 2 hours at 65 °C: 
2 ml: 	lOx PCR buffer (Mg+) 	200 tl 
Proteinase K (20 mg/ml) 	2 tl 
H20dda 	 1.798 ml 
The Proteinase K was inactivated by incubation at 90 °C for 15 minutes. 
15 - 20 tl of the lysate was used for a routine PCR assay screening for the 
BLG promoter. The active components of the reaction mix were increased by 
2/5 (2.1.7) as total volume was increased to 50 pJ with 20 jtl lysate. 
• Fixed and stained the leftover plates of unpicked colonies (methanol fixed, 
stained with 10 % Giemsa): 
Wash with 1xPBS 
Add fresh PBS and left at room temperature for 10 —15 minutes 
Remove PBS, overlay with Methanol, leave 10-15 mm. at room 
temperature. 
Remove Methanol, add 10% Giemsa, leave 10 mm. at room 
temperature 
Pour off Giemsa stain and rinse very gently with tapwater. 
Leave to air dry, colonies visible as purple spots. 
2.2.6 Screening of cells for making chimaeric mice 
DNA Extraction for Southern Blotting 
Genomic DNA prepared by digesting the cells overnight with proteinase K cell 
lysis solution on a shaker, then isopropanol precipitating the DNA (Laird et al 
'91). The precipitated DNA was washed in 70% EtOH and left to air-dry for a 
few minutes before rehydration in 0.5 ml TE. 
The resulting DNA was of such high molecular weight that it had to be 
physically sheared using a needle (26G Y2, 0.45 x 13) and further diluted 
before digestion for Southern Analysis could take place. 
Digests performed overnight using high concentration enzyme with top up first 
thing and the digest proceeding for further two or three hours before being run on 
a 0.8 % agarose gel. 
Blotting 
Digest gDNA in as small a volume as possible and ensure thoroughly digested. 
Ran finished digests on 0.8 % agarose gel, either during day at 80 - bOy or 0/N 
at 20 V. Gel should be no more than 7mm thick. 
Stain gel with ethidium bromide after run finished and photograph. 
Depurinate gel before setting up transfer: 0.25M HC1 on shaker until blue loading 
dye has turned yellow 
Rinse with distilled water 
Setup blot: 
. 0.4 M NaOH is used as transfer buffer and Zetaprobe or Hybond 
N+ is membrane used for transfer 
. Buffer is poured into metal tray and a cleaned glass sequencing 
plate is placed over it. 
• 4 sheets of 3MM whatman paper is cut to the approximate width 
of the gel (a little larger) and the full length of the paper. These are 
soaked in the buffer and left with the ends folded under the glass 
plate to form a wick. 
• Use a glass pipette to roll the paper flat 
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. Place gel face down on the wetted paper (leaves a smooth surface 
for the transfer). Cover gel completely with cling film, including 
sides. Ensure that there is plenty of buffer on top of gel. 
. Place pre-wetted (water or transfer buffer) membrane cut to fit on 
gel starting from the middle. Do not remove once in place. Avoid 
air bubbles, roll with glass pipette for smooth finish. 
• Soak 2 3MM whatman paper cut to fit the gel exactly and place on 
top of transfer membrane. Place 2 dry whatman on top 
. Make stack of approx 5 cm using green towels, ensuring that they 
are evenly stacked and that bottom rows cover the blot evenly. 
• Place tray on top of stack and weigh with 250 ml bottle on top. 
• Blot 0/N or minimum 5 hours (if target size is over 20 % or gel 
concentration exceeds 1%: always blot 01N) 
Dismantle blot: 
• Dismantle blotting apparatus, carefully remove membrane and 
rinse in2XSSC 
• Dry membrane between two sheets of Whatman at 65 °C for an 
hour (do not UV crosslink using these membranes) At this point 
the membrane may be stored dry between whatman paper in a 
plastic bag at room temperature. Drying is not required for 
Hybond N+, it can be transferred straight to prehybridiation. 
• Prehybridise in 20 ml of hybridisation solution for 5 - 30 minutes 
before adding probe so that membrane is evenly coated. Ensure no 
bubbles form between the membrane and the glass walls of the 
hybridisation tube, and that there are no creases in the membrane. 
Probe blot: 
• Place membrane in 20 ml of prewarmed hybridisation solution (65 
°C) in hybridisation tubes in oven. 
Hyb Solution: 
0.25 M Na2HPO4 , pH7.2 (25 ml of 1 M stock in 100 ml) 
7% SDS (35 ml 20 % stock in 100 ml) 
1mM EDTA (0.1 ml of 1M stock in 100 ml) 
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• Inject probe into tube and leave to hybridise 0/N with rotation 
• Wash twice for 20 minutes (65 °C) with wash solution A: 40 mM 
Na2HPO4 , 5% SDS (40 ml 1M in 1L, 25 ml 20% in 1L). 
• Wash twice for 20 minutes (65 °C) with wash solution B: 40 mM 
Na2HPO4, 1% SDS (40 ml 1M iniL, 5 ml 20 % in 1L). 
• Optional high stringency wash for 20 minutes (65 °C): 20 mM 
Na2HPO4 0.5% SDS (20 ml 1M in 1L, 2.5 ml 20% in 1L) 
• Cover in double layer of cling film and place down to image. Do 
not allow to dry, especially if want to strip and reprobe blot. 
Making Probe 
Boil 25 ng of probe DNA in total volume of 11 j.xl for 2 minutes. Probe length is 
suggested to be between 200 - 1000 bp 
Centrifuge down briefly, ice for 1 minute 
Add: 	4 il High Prime 
5 jtl (50 jiCi) a 32P dCTP 
Leave at room temperature for 10 minutes 
Stop reaction with 5 jil 2M NaOH and leave for a few minutes. This has the 
additional effect of denaturing the probe for you. 
Increase volume to 100 jil or more with hybridisation buffer or NaOH. 
Inject into hybridisation tubes via cap hole and run down glass wall not occupied 
by blot membrane. 
2.2.7 Karyotyping Cells 
Preparation of mitotic spreads 
Use all of T25 50% confluent flask 
Feed cells 1 - 1.5 hrs before trypsinisation, adding 10jil/5ji1 medium of Colcemid 
(KaryoMax Colcemid stock at 10 jig/ml from GIBCO BRL) 
Trypsinise as per usual and centrifuge as normal etc 
Resuspend in lml hypotonic solution, dropwise mixing by shaking at room 
temperature. 
Add excess of hypotonic solution to 5 ml and invert once to mix 
Leave at room temperature for 10 minutes, centrifuge for 5 min at 1000rpm 
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Aspirate. 
Flick tube to disrupt cells and add freshly prepared ice-cold fixative 1 ml 
dropwise as for step 4. If a pellet settles, give it a gently flick to resuspend. 
Add another 5 mIs iced fixative, invert, leave at room temperature for 5 minutes 
Centrifuge 500 rpm for 5 minutes 
Repeat steps 7 - 10 twice 
Resuspend final pellet in 1 ml of fixative (can now be kept at - 20 °C if not used 
on day, but fixative will have to be changed immediately before use). 
Slides are kept under MeOH in fridge. Wipe dry and label with pencil. 
Drop droplets of the solution on to the slides from as high as possible. 
Dry and check for decent spreads under microscope. 
Stain slides in 10% Giemsa stain for 10 min at room temperature 
Count chromosomes using microscope. 
Hypotonic Solution: 
0.56% w/v NaCitrate (KC1) 
Fixative: 
18 ml Me011: 6m1 Glacial Acetic Acid 
2.2.8 Blastocyst Injections 
Day 1 
Resuscitate 1 vial of ES cells (into T25 flask) 
Day  
AM 
Feed ES cells, flask should be 75-80% confluent 
Make up ES medium with HEPES (200 tl 1M HEPES per 10 ml medium) Need 
at least 1-2 ml per mouse, plus 5 - 10 ml for ES cells and injection procedure. 
Make up droplets ready for collected embryos on a small round plate and cover 
with oil (embryo oil saturated with CO2) Place in incubator. 
Make spare collection needles for blastocyst collection 
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5. Start flushing embryos from 10.30 
. Kill by neck dislocation, cut abdominal skin and expose abdominal 
cavity. Open cavity and gently push aside guts etc. Ovary is found just by 
the kidney, uterus is usually a yellowish-white tubing thing. Trace 
downwards until reach T-junction where the other uterine tract is found. 
• Cut across ovary and then downwards towards junction and cut just above 
the join place on a paper towel with the fat downwards and the ovary 
side facing the wall. Repeat for second ovary. 
• Lift ovary side of tract with forceps, trim fat sticking to tissue as well as 
blood vessels. Place on paper towel with ovary facing towards you. 
• Fill 5 ml syringe with HEPES buffered ES medium and ensure that there 
are no airbubbles. Attach brown needle (26 G '/2, 0.45 x 13). 
• Pick up oviduct and stretch uterus, insert needle carefully at top by uterus 
and hold in place with forceps. Flush out embryos using 0.2-0.5 ml 
medium into sterile bottle. Repeat for second oviduct. 
• Once bottle filled, cap and keep warm until can transfer to incubator. 
• Blastocysts sorted under microscope in hood and transferred by mouth 
pipetting to the collection droplets under oil 
PM 
Blastocysts injected with ES cells from 13.00, so T25 is trypsinised at 12.30 and 
spun down as normal. Y2 of cells used for injections, resuspended in 4m1 total 
HEPES buffered ES medium. 15-20 ES cells per blastocyst injected. 
Injected blastocysts transferred to recipient female, 12 + transfers per female 
preferable, expect about 50% not to implant. 
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2.3 PROTEIN PROTOCOLS 
2.3.1 Preparation of milk samples for protein analysis 
Thaw milk samples on ice. 
Vortex samples briefly to mix milk. 
Rinse Hamilton syringe with sterile water before taking a 30/50 il milk sample. 
Rinse the syringe with water 4-5 times between each sample. 
Dilute the samples 1/5 in sterile water (30/150 = 120 .il)(50/250 = 200 tl). 
Vortex and centrifuge briefly (let machine gain full speed, then switch it off). 
Remove defatted milk (140/200 j..tl), disrupt mycelles without disturbing the fat. 
Pipette the defatted milk into a new eppendorf. 
Dilute 115 with loading buffer (50 j.il DF milk and 200 jil LB) 
Boil samples for 4 minutes (pin a hole in the tubes, or they will explode). 
Measure sample volume and adjust for any evaporation with loading buffer. 
Dilute a sample of 1/25 stock with loading buffer to make a 1/250 dilution. 
Load 40/50 j.ii sample using Hamilton syringe (rinse between samples). Load 
empty wells with loading buffer to ensure a smooth and uniform run. 
Milk Reducing/Sample Buffer 16 ml 
0.5M Tris.HCI pH 6.8 2 ml 
10% v/v Glycerol 1.6 ml/2.09 g 
10%w/vSDS 3.2m1 
5% v/v pmercaptoethanola 0.8 ml 
0.1% w/v Bromophenol Blue  2 ml 
H20(distilled, autoclaved) 6.4 ml 
(a = Sigma, g = BDH) 
2.3.2 Pouring, running and staining protein gels 
Pour resolving gel the afternoon before use, cover with water and cling film to 
avoid evaporation. The gel should come up to a level of 1-2 cm below the comb. 
Remove water, place combs at an angle before pouring stacking gel (prevents air 
bubbles forming underneath the teeth). Leave to polymerise for 30-45 minutes. 
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Make running buffer 
Remove combs, rinse wells with distilled water with final rinse of running buffer. 
Set up protein rig, fill upper chamber with buffer to check for leakage (wipe 
surface with buffer to ensure good seal between chamber and gel plate). 
Load wells using Hamilton Syringe before placing into buffer-filled lower 
chamber. Top up upper chamber buffer if necessary. 
Run stacking gel at 30 mA (V max = 500, Wmax = 30), approx. 1 hour. 
Run resolving gel at 60 - 70 mA. This holds for 2 gel. Adjust downwards one gel, 
upwards for 4. Run will take approx. 2.5 hours. 
Stop run 15 minutes after dye has run off bottom. Remove from tank, cool. 
Open plate and remove stacking gel using spacers. Wet gloves in running buffer 
and lift gel from plate and place in plastic box. 
Add fix/stain, place in 50 °C oven for rest of day (enhances stain penetration), 
place on shaker at room temperature overnight (ensures even stain uptake). 
Remove stain/fix from gels and add destain until just covering gel. Return to 
shaker and change destain solution every hour until suitably destained. 
Use destain without acetic acid for final destain (make up volume with water). 
Place finished gel on a cleaned glass plate and cover with cling film. Remove 
cling film for image capture. Store at 4 °C. 
Alternatively, make gel during day and run overnight at 25mA. The resolving gel 
should set in 4 hours; the separating gel in 30-45 minutes. Leave gel in oven all day, 
then shake overnight. This method was preferred as it gave tighter, cleaner gels. 
Resolving gels (makes two 20 cm gels) 17.5% gel 20% gel 
Acryl.Bisacryl! (37.5:1) 34.965m1 39.960 ml 
H20 (distilled, autoclaved) 9.135 ml 4.140 ml 
1.5M TrisHCl pH 8.8 15 ml 15 ml 
w/v SIDS 600 j.tl 600 	l 
APS (ammonim persulphate) 300 .il 300 .tl 
TEMEDa 30 il 30 il 
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Stacking gels 10 ml for 2 gels 
30% Acryl.Bisacryl." (37.5:1) 1.3 ml 
H20 (distilled, autoclaved) 6.1 ml 
0.5M TrisHCl pH 6.8 2.5 ml 
10%w/vSDS 100 p 
10%APS 50j.xl 
TEMEDa 10 jtl 
TEMED = N,N,N',N'-tetramethyl ethylene diamine. C 6H 16N2 
Protein Running Buffer 	5 L lx buffer 	1 L lOx buffer 
25mMTris 	 15g 	 30g 
0.2 M Glycine 	 72 g 	 144 g 
0.4mMSDS 	 5g 	 lOg 
H20 distilled 	 5 L 	 1 L 
Make 5L lx buffer on day of use, lOx stock can be kept for at least 2 weeks. 
Protein fix/stain: 
50% MeOH 
7.5% Acetic Acid (glacial) 
2% w/v TCA (trichloro acetic acid) 
0.04% Coomassie brilliant blueg (G-250) 
H20 distilled 
Destain 	 1L 
23%MeOH 	 230 ml 
7% Glacial Acetic Acid 	70 ml 
H20 distilled 	 700 ml 








3.3.3 Image Capture and Quantification 
Capture image of gel using lighbox (not UV) and camera attached to computer 
running Molecular Analyst version 1.1 (BioRad). Indicate that image is captured 
using white light setting. 
Process using Molecular Analyst programme with settings indicating that gel is 
coomassie stained. 
All BLG and -casein bands are boxed in manually, using local background type 
as the setting. 
The three BLG standards are identified and used to generate a standard curve 
upon which the volume report is based (i.e. protein concentration of all boxed 
samples on gel). 
The volume report provides the raw data for the BLG samples. 
The BLG samples are adjusted for loading differences using the -casein bands 
of the transgenic samples standardised to the b-casein of the non-transgenic 
control sample: Adjusted BLG = raw BLG x (transgenic f3-casein/control 13-
casein) 
The adjusted BLG is the value used to calculate the actual transgenic protein 
concentration in the milk samples: 
(Adjusted BLG/volume loaded) x 250 (dilution factor) 
This formula gives the protein concentration in tg/pJ = mg/ml. 
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2.4 FISH 
Ensure that all instruments required are baked overnight at 180 °C, and that solutions 
are made up in advance and DEPC (diethyl pyrocarbonate, C6H 1005 , Sigma) treated. 
2.4.1 Fixation and wax embedding of liver and mammary tissue 
Day 1 
Make 4% Paraformaldehyde in DEPC 1 X PBS (25 ml/tissue) (takes 2 hrs) 
Pour into 25 ml sterile tubes and keep on ice. 
Label 4 cryotubes/mouse (2 for mammary tissue, 2 for liver). 
Check mice are ready for milking and sacrifice: 
• Pups removed 3 hours prior to oxytocin injection that induces lactation. 
10 minutes after administration of oxytocin a general anaesthetic is given. 
• Trained staff milk the mice, leaving one gland untouched for fixation. 
• Mice are killed humanely by neck dislocation immediately prior to 
dissection once they have been milked. 
• Unmilked gland is dissected and cut in half before placing into 
paraformaldehyde solution. One lobe of liver is fixed (cut into strips to 
aid fixation). Remaining tissue is frozen in liquid nitrogen for RNA/DNA. 
Tissue in paraformaldehyde fixed overnight at 4 °C on shaker. 
Day 2 
Wash fixed tissues, using shaker for all steps 
• 1XPBS 	30 min at4 °C 
• 30 % EtOH 	15 min at room temperature 
• 70 % EtOH 	30 min at room temperature 
• 70 % EtOH 	30 min at room temperature 
Tissues can be kept in final 70% EtOH wash at 4 °C and wax embedded later. 
Prepare tissues for histological treatment and wax embedding 
• Label histology cages with tissue data in pencil 
• Remove tissue samples and place in prelabelled cages. 
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. Place cages in histology basket, run RNA programme (takes 16 hours) 
o 70 % EtOH 10 min room temperature 
o 70 % EtOH 1 hr 30 min room temperature 
o 	64 OP (alcohol over proof) 1 hr 30 min 35 °C 
o 640P lhr30min 35 °C 
o 	740P lhr30min 35 °C 
o 74 OP lhr30min 35 °C 
o 	74 OP/xylene 1 hr 30 min 35 °C 
o 	xylene 1 hr 30 min 35 °C 
o 	xylene 1 hr 30 min 40 °C 
o 	xylene 1 hr 30 min 45 °C 
o WAX lhr30min 53 °C 
o WAX lhr30min 60 °C 
2.4.2 Sectioning of Wax Embedded Tissues 
TESPA treatment of slides 
• Oven bake slides at 180 °C overnight (or minimum of 4 hours). 
• Place in baked glass racks (can be baked with slides in them). 
• Treatment A: 	10% HC1:75% EtOH 	10 seconds 
DEPC water 	 10 seconds 
100 % acetone 	10 seconds 
AIRDRY 
• Treatment B: 	2% TESPA in acetone 10 seconds 
100% acetone 	10 seconds 
100 % acetone 	10 seconds 
AIRDRY 
Can be stored for up to 4 weeks with dessicant. Otherwise, redo step B. 
All solutions should be made fresh on day used. 
TESPA = 3-aninopropyltriethoxysilane, from Sigma. 
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Sectioning of tissues 
Keep parafin blocks chilled on ice throughout 
• Trim off any excess wax 
• Wipe waterbath and all instruments with 100 % EtOH, fill waterbath with 
DEPC treated H 20 and heat to 42 —45 °C. 
• Mount block on microtome with label pointing towards you, section 10 
micron sections until you hit the tissue (angle set at 10). 
• Once tissue is reached, remove block, clean excess wax from microtome 
blade and wipe again with EtOH. 
• Change microtome thickness to 5 microns. 
• Cut a smooth ribbon of about 8 sections, catching end with forceps and 
extending. Use brush to remove strip from blade and place on a clean 
slide (NOT TESPA treated!). 
• Squirt 30% EtOH under ribbon to smooth out creases. 
• Dip slide vertically into waterbath and let section float off. 
• Allow wax to melt (1 mm), use tweezers to separate individual sections. 
• Dip TESPA coated slides vertically into water and catch section. 
• Leave slides until water evaporates, label and bake overnight at 60 °C. 
• Store at 4 °C. 
2.4.3 Prehybridisation 
All dishes baked and washed with 100% EtOH before use. PFA (paraformaldehyde), 
Proteinase K and TEAITCA with acetic anhydride prepared fresh each time 
NB! Protocol has to be modified if want to use for genomic FISH (2.4.6) 
 100% Xylene 20 mm 
 100% Xylene 20 mm 
 100% Xylene 5 min on shaker 
 100%EtOH 2mm 
 100%EtOH 2mm 
 90 % EtOH 2 mm 
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70 % EtOH 2 mm 
50%EtOH 2mm 
30 % EtOH 2 mm 
10.1XPBS 2mm 
11. 4%PFA 10 min  
12.1XPBS 2mm 
13.1XPBS 2mm 
14. Prot K solution 	 7min 30 seconds 
15.1XPBS 	 1mm 
16.4%PFA 	 2mm 
DEPC 1-120dis till ed 	 10 seconds 
0.1 M TEA or TCA (steps 18-20) 	30 seconds 
0.1 M TCA + acetic anhydride (625 tl) 5 mm 
0.1 M TCA + acetic anhydride (625 iJ) 5 mm 
21.1XPBS 2mm 
 0.85 % NaCl 2 mm 
 30 % EtOH 2 mm 
24.50 %EtOH 2mm 
25.70%EtOH 2mm 
 90 % EtOH 2 mm 
 100 % EtOH 5 mm 
28.100%EtOH 5mm 
29. 100 % EtOH 5 mm 
Air dry slides. Can be stored dessicated for several months before use. 
2.4.4 Hybridisations for mRNA expression 
• The probes used were cocktails made up of 5 30'mer oligos (sense or antisense) 
labelled 5' & 3' with Fluorescein, Digoxigenin or Cy3 (5' only). The oligos were 
synthesised by MWG. 
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• The oligo mix was made from stocks, taking 2 jtg of each and combining in 1 ml 
of water. This mix was aliquoted into 200 p1 batches and stored at - 20 °C to 
avoid contamination. 20 tl of the cocktail was used in lml buffer solution to give 
a final concentration of 40 nglml. 
• Hybridisations were performed at 37 °C. 
Protocol for mRNA FISH 
Prehyb with buffer alone is not necessary 
Heat sections with probe overlaid (approx 100 p1 per section) for 6 minutes at 90 
°C on a heating block (keep out of light). 
Cool for one minute on ice 
Cover with parafilm cut to size instead of usual glass coverslips 
Place in a damp chamber and hybridise at 37 °C overnight 
Wash sections in covered coplin jars: 
2XSSCat37 °C 10 min  
2 X SSC at 37 °C 30 mm 
0.1 X SSC at room temperature 10 mm 
0.1 X SSC at room temperature 30 mm 
Dry slides with soft tissue, avoid tissue 
Fix tissue using Vectashield Mounting medium (Vector Laboratories) with 
antifading agent (no DAPI), attach methanol-cleaned coverslip, fix to slide using 
colourless nail varnish. 
Visualise and capture image using FISH microscope 
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Hybridisation solution 
(modified from protocol in "Boehringer Mannhein non radioactive in situ 
hybridisation application manual, 2nd  edition 1996, p.  130) 
1 Oml 
40 % Formamide 4 ml (100% stock) 
2 X SSC (tri sodium citrate) 1 ml (20x stock) 
1X Denhardt's solution 0.2 ml (50x stock) 
10 % Dextran Sulphate 2 ml (50 % stock) 
50 mM Phosphate Buffer 0.5 ml (1M stock) 
50 mM DTT (dithiothreitol, Melford Labs.) 0.5 ml (1M stock) 
0.250 mg/ml tRNA 0.25 (10 mg/ml stock) 
0.5 mg/ml denatured salmon sperm DNA 0.5 ml (10 mg/ml stock) 
H20 DEPC 1.05 ml 
Denhardt's Solution: 	0.5 g Ficoll 400 (Pharmacia) 
0.5 g Polyvinylpyrrolidone 
0.5 g BSA, fraction V 
50 ml DEPC distilled autoclaved H 20 
Do not autoclave or DEPC treat once made as this will destroy the proteins. 
2.4.5 Nuclear FISH for intronic sequence detection. 
Secondary detection by anti- DIG/Fluorescein with suitable fluorescent label 
Hybridise overnight as for mRNA FISH 
Wash slides as for mRNA FISH 
Overlay with incubation buffer without antibody to block for 10115 minutes 
Add incubation buffer with antibody (1/125 or 1/250 dilution anti DiG, 1/100 
dilution of anti-fluorescein), incubate at room temperature for 30 - 45 minutes. 
Rinse sections 3 X 5 minutes in wash buffer. 
Mount using Vector Mounting medium for fluorescence with DAPI counterstain 
to identify intact nuclei. 
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Incubation Buffer 
100 mM Tris-HC1 pH 7.4 
150 m NaCl 
1% Blocking Reagent (serum, same as antibody source) 
Wash Buffer 
100 mM Tris-HCI pH 7.4 
150 m NaC1 
2.4.6 Nuclear FISH for genomic sequence detection 
As the genomic target is less abundant than transcribed RNA, the signal has to be 
considerably amplified (6 - 9 times). The genomic DNA is also much less accessible 
than the RNA, probably due to the chromosomal proteins. The prehybridisation 
protocol therefore has to be modified for the probe to gain access to the target. 
1. Follow normal prehybridisation protocol up to and including step 21 then: 
1 X PBS at 37 °C for 2 minutes 
0.1% w/v Pepsin in 0.2M HC1 37 °C for 15 minutes (may need to vary 
depending on tissue, have used between 10 and 20 mm.) 
1 X PBS at room temperature for 1 minute 
4% PFA at 4 °C for 2 minutes 
H20 10 seconds 
Repeat steps 18-21 and carry on with rest of protocol as normal 
2. Hybridise and amplify signal as for intronic FISH with antibodies to Fluorescein 
(Rat anti-FITC conjugated to FITC, Serotec). The signal is amplified 6-9 times to 
get a good image. 
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2.4.7 Antibodies & sera used 
Antibodies: 
Against Hapten Host Fragment Source 
DiG Rhodamine Sheep Fab Boehringer 1207 750 
DiG Fluorescein Sheep Fab Boehringer 1207 741 
Biotin Fluorescein Goat Fab Vector Labs SP-3040 
Biotin Cy3 Goat Fab Rockland 700-104-098 
Fluorescein Fluorescein Rat 1gM Serotec MCA 1332 F 
Rhodamine none Rabbit IgG Molecular Probes A-6397 
Rabbit IgG Cy3 Goat IgG H & L Rockland 611-104-122 
Sera: 
Rat 	Serotec C 138 B 
Goat 	Diagnostics Scotland T 028 
Sheep 	Diagnostics Scotland T 031 
2.4.8 Probes used 
BLG: Exonic and intronic probes based on sequences in GenBank X12817, 
genomic/promoter probes based on sequences in X68105 
EXON PROBES: 
 Position 1621 - 1250 
 Position 1681 - 1710 
 Position 2591 - 2620 
 Position 3851 - 3880 
 Position 4581 — 46 10 
INTRON PROBES: 
 Position 1801 - 1830 
 Position 1861 - 1890 
 Position 1981 — 20 10 
 Position 2041 - 2070 
 Position 2161 —2190 
GENOMIC/PROMOTER PROBES: 
 Position 3545-2574 
 Position 2656-2685 
 Position 2769-2798 
 Position 2957-2986 







13-casein: Exonic and intronic probes based on sequences in GenBank X13484 
EXON PROBES: 
 Position 9291 —9320 
 Position 9411 - 9440 
 Position 9471 - 9500 
 Position 9531 - 9560 
 Position 9621 - 9650 
INTRON PROBES: 
 Position 5041 —5070 
 Position 5141 —5170 
 Position 5201 - 5230 
 Position 6311 - 6340 
 Position 6381 —6410 
WAP: Intronic probes based on sequences from U38816 
INTRON PROBES: 
 Position 2651 —2680 
 Position 3121-3150 
 Position 3591 - 3620 
 Position 4031 - 4060 
 Position 4621 - 4650 
 Position 4931 - 4960 
LacZ: Exonic probe based on sequences from GenBank U13 184 
EXON PROBES: 
 Position 861 - 890 
 Position 921 —950 
 Position 1381 - 1410 
 Position 1441 - 1470 
 Position 1501 - 1530 
 Position 1621 - 1650 
 Position 1681 - 1710 
 Position 1851 - 1880 
 Position 1951 - 1980 
Position 2071 —2100 
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Chapter 3 
Analysis of Backcrossed BLG/7 Variegating Mice 
3.1 Introduction 
Most examples of variegation are caused by mutations (van Deutekom et al 1996, 
Spiegel 1997, Gottlieb et al 2001), translocations (Muller 1930, Milot et al 1996) or 
transgene insertions into unfavourable positions in the genome (Dobie et al 1996, 
Henikoff 1996). The latter two examples are known as position effect variegation 
(PEV). Drosophila has dominated the research into PEV, a small genome and fast 
generation time facilitating analysis of many well-characterized and distinct strains. 
The work has uncovered many modifiers of PEV (Henikoff 1990, Singh 1994). 
Advances have enabled studies in other organisms (most notably plants, yeast, fungi 
and rodents), and homologues of modifiers of PEV already identified in Drosophila 
have been found (Singh et al 1991, Cowell & Austin 1997). Some of these 
homologues are interchangeable between species and can exert a modifying effect on 
variegating genes in place of the endogenous modifier gene (Stankunas et al 1998, 
Aagaard et a! 1999, Festenstein et a! 1999). 
The relative abundance of modifier proteins can influence transgene expression 
(Festenstein et a! 1999, McMorrow et a! 2000). Modifiers can vary between strains, 
both qualitatively and quantitatively, resulting in strain-specific modification of 
expression (Schweizer et a! '98). Transgenic mouse line BLG/7 was created on a 
mixed Fl CBA:C57BL/6 background (Dobie et a! 1996). BLG/7 mice express the 
ovine -lactoglobulin transgene during lactation. Although correctly expressed both 
temporally and spatially, transgene expression levels differ between siblings, due to 
variegated expression at the cellular level in the mammary gland (Dobie et a! 1996). 
The integration of the transgene as a concatemer of approximately 25 intact copies 
close to centromeric heterochromatin suggested that the observed variegation could 
be related mechanistically to PEV. Alternatively, the observed variegation could be 
caused by the presence of a mixed set of modifier genes from the two different 
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genetic sources that make up the Fl background of the line. As a C57BL/6 
background has been demonstrated to influence transgene expression levels for more 
than one transgene (Koetsier et al 1996, Schweizer et a! 1998, Sutherland et a! 
2000), strain-specific modification of expression resulting in variegated BLG/7 
expression was a strong possibility. 
Ideally, strain specific effects on transgene expression should be investigated in a 
congenic background. Backcrossing was therefore initiated into the two respective 
strains (see appendix C3 for mating regimes). At the 3rd  generation, there was little 
evidence for any strain—specific effects affecting gene expression (Dobie et a! 1996), 
which suggested that no dominant single modifier locus was responsible for the 
variegated expression. There was, nonetheless, a small trend towards a lower mean 
expression level of the transgene for the CBA backcross population, suggesting the 
possible existence of minor modifier loci. This trend was also weakly apparent for 
the C57BL/6 backcross population. Although the observed trend was not statistically 
significant for either backcross population, it did not rule minor modifier loci as a 
causative agent of variegation, so backcrossing was continued for a further 10 
generations. The 13th  generation backcross mice are considered functionally 
congenic (99.4%) (M. A. Suckow, P. Danneman & C. Brayton, "The Laboratory 
Mouse", CRC Press). 
3.2 AIM 
The aim of this investigation was to establish conclusively whether previous work on 
3rd generation BLG/7 (Dobie et a! 1996), which concluded that variegation was a 
product of the transgene itself at its site of integration, held true in the 13 th generation 
backcross mice. 
3.3 Experimental Approach 
We wished to evaluate the effect of backcrossing into a congenic background on 
BLG/7 transgenic protein expression levels in the milk of lactating females. 
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A backcrossing regime to inbred CBA and C5713L16 colonies was therefore set up 
for BLG/7. The line was also maintained on the original Fl background in parallel 
with the backcrosses, enabling sampling of this group to establish if any changes in 
expression levels occurred after multiple passages through the germline. BLG protein 
content in the milk samples was determined by quantitative SDS gel electrophoresis 
as described earlier (2.3). 
There are several reasons why we sampled our mice at the 13th  generation. 
Generation time was a major factor. 13 rounds of backcrossing take 6Y2 years, 
assuming a generation turnaround of 6 months. Additionally, maintenance becomes 
increasingly difficult with a limited number of inbred transgenic mice. The 
equivalent BLG/7 F 1 outbred mice were also sampled so that the expression levels of 
all three groups could be compared to each other and to the original samples from the 
3rd generation of transgenic mice, both backcrossed and Fl genotypes. At the 13th 
generation of inbreeding, the mice are considered congenic (99.4%). Apart from 
material close to the transgene integration site (up to 0.6% of genome), all loci 
(99.4% of genome) should contain genetic material solely derived from a single 
inbred background. Any strain-linked loci that may be responsible for the observed 
variegated expression should therefore be evident at this stage. The two strains in this 
case are CBA and C57BL/6. 
3.4 Results 
3.4.1 Strategy and critique of backcrossed BLG/7 milk sample analysis 
Sample generation 
Expression levels of BLG peak at mid-lactation, which in mice is the 11th  day of 
lactation (Whitelaw et al 1992). The day of birth is counted as day 0. The majority 
of milk samples were taken at this time point, although a few were taken at either day 
10 or day 12. 
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An intensive mating regime was set up to generate 13th  generation backcross females 
from both backgrounds and an equivalent number of control outbred BLG/7 Fl 
females. The control females served a dual purpose. The main function of the control 
females was as an outbred comparison to the two inbred backgrounds. The second 
function was as a means to test for any changes in BLG expression connected to 
generation time, when compared to the expression levels of the original outbred mice 
(Simons et al 1987, Whitelaw et a! 1992, Dobie et a! 1996). All three lines have been 
maintained in parallel through male germline transmission. An equal number of 
generations separate the lines and the founder mice, which were generated by 
microinjection (Simons et a! 1987). 
Milk samples at the I I  Ih day of lactation were collected from 21 C5713L/6 and 18 
CBA BLG/7 females. A control group of 19 Fl outbred BLG/7 females were also 
sacrificed for milk at the same lactational stage. The females were all between 3 and 
4 months old, enabling us to discount any age-related factors (1.5.1) when analysing 
the protein content in their milk. Although the age and lactational stages were the 
same for all females, milk collection spanned several months due to the reluctance of 
the backcross mice to breed. Backcross mice gave rise to much poorer milk yields 
than their Fl counterparts. About 115th  of the females did not release any milk from 
their teats, even after chemical induction of milk release using oxytocin. This 
necessitated the setting up of more breeding couples in order to generate enough 
lactating females to ensure that sufficient milk samples were provided for the 
successful conclusion of the experiment. Since collection was spread over a 
considerable time, milk samples were frozen fresh. As soon as all the samples had 
been collected, they were processed together. This treatment of the samples was 
designed so that any variability in expression could not be attributed to differences in 
the buffers and solutions, which could arise if they were processed separately. 
Sample processing 
All sample processing is described in the materials & methods section (2.3). The 
BLG standards were from the same source, as were all chemicals used in the protein 
gels, buffers, fixes and stains. The BLG standards were purified from sheep milk and 
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quantified using the micro—Kjeldahl technique (Aschaffenburg & Drewry 1957) prior 
to the commencement of the project. 
Quantification of protein concentration was done in triplicate sets for each sample, 
using pixel intensity comparisons to the three BLG standards run on every protein 
gel. Analysis of the gels used the Multi Analyst Programme version 1.1 (BioRad). 
Three dilutions of BLG standard provided an accurate standard curve, with all BLG 
bands boxed in manually. Loading differences were corrected for using 13-casein as 
an internal control standardised to the non-transgenic sample present on every gel. 
The same non-transgenic control sample was run for each line. The arithmetic mean 
of the three measurements was used in determination of BLG expression levels for 
each individual sample. 
The backcross milk samples were compared to each other and to the outbred results. 
The expression profiles of all three groups were compared to earlier published data 
for this line (Simons et al 1987, Whitelaw et al 1992, Dobie et al 1996). 
All gels run contained three BLG standards, one non-transgenic control milk sample 
and nine transgenic milk samples. A total of 9 C5713L/6 BLGI7 protein gels, 6 CBA 
BLGI7 gels and 9 outbred protein gels were run. A gel from each backcross group is 
reproduced in Figure 3.1. Figure 4.1 contains an example of the outbred protein gels 
(hemizygotes). Although the protein gels were Coomassie stained, greyscale 
depictions were preferred, as the protein bands are more clearly defined. All analysis 
of the images was done with the gels defined as coomassie stained by the software 
package (2.3.3). 
3.4.2 Backcross milk samples display down-regulation of all milk proteins 
The first observation of differences between the backcross and Fl outbred milk 
samples occurred before any quantification of BLG expression levels took place. 
Trial gels were run to determine the ideal sample loading volume, non-transgenic 
control and BLG concentrations for the standard curve (the BLG standards had to fall 
within the expression range of the samples and below the saturation point of the 
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Figure 3.1 	SIDS PAGE of milk protein samples for CBA & C57BL16 
13th  generation 
backcross mice C = non-transgenic control milk, BLG = 3-lactoglobulin 
standard. Transgenic samples were loaded 50 tl of 1/250 dilution. 
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Figure 3.2 	SDS PAGE of milk protein samples for all 3 genotypes. 
A) is 13th  generation CBA backcross samples, B) is 13"'generation 
backcross C57BL/6 and C) is outbred samples. C = non-transgenic control 
milk, B = 3-lactoglobulin standard: 2 j.g for A) + B), 3 .tg for C). A) + B) 
transgenic samples were 50 ul of 1/250 dilution, C) had 40 Lil loading 
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image capture system). An immediately noticeable characteristic of the protein gels 
was that the inbred milk sample proteins were consistently less abundant than in 
equivalent Fl outbred samples (Figure 3.2). This down-regulation was not limited to 
BLG, but appeared to include all the endogenous milk proteins. Comparative protein 
band intensities were only achieved when 50 tl of a 1/250 dilution were loaded for 
the backcross milks, as opposed to 40 j.i1 for the rest. This gives a rough estimate of 
115th reduction in overall protein expression in the backcrossed samples. 
3.4.3 Variegation occurs irrespective of genetic background, with mean 
expression levels remaining stable in an outbred background 
The second observation made by visual examination of the protein gels from all three 
backgrounds was that BLG expression varied between individuals within each group 
(Figure 3.1, 3.2 & 4.1). Within a genotype, the endogenous milk proteins did not 
appear to vary. Both backcross genotypes exhibited high levels of variegation for 
BLG expression. It could be suggested this provides conclusive proof that the 
observed variegation is an inherent property of the transgene at the integration site, 
independent of genetic background. The continued variegation of BLG expression 
within the Fl outbred mice also indicates that passage number through the germline 
does not affect the variegating properties of the transgene. 
Raw data of both BLG and 3-casein concentrations were collected in triplicate sets 
(Appendix Al) and BLG protein levels quantified (2.3.3). This gave three separate 
BLG concentration measurements for each milk sample in mg/ml (Table 3.1). The 
arithmetic mean of the three measurements was used for the calculation of individual 
expression levels. A representation of the BLG protein yields for all three groups of 
mice is shown in Table 3.2 and Figure 3.3 (a-c). 
The data generated for BLG expression levels (Table 3.2) was subjected to statistical 
analysis. Mean expression, standard deviation and coefficient of variation was 
compared between the three groups, and comparisons were additionally made to 
previously published data (Dobie et a! 1996) for the 3   generation backcrosses 













CBA 713 3.49 3.50 
3.4 
3.62 
CBA 714 4.79 4.73 
4.82 
4.59 
CBA715 4.05 4.17 
4.25 
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CBA7I 11 3.07 2.88 
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Table 3.1 	A) BLG measurements for 
13th  generation BLG/7 CBA backcrosses 
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BLG BLG BLG BLG 
measured average measured average 
mg/ml mg/ml mg/ml mg/ml 
C57 711 6.24 6.22 C57 7111 6.23 6.23 
6.26 6.13 
6.16 6.33 
C57 712 4.10 4.13 C57 7112 5.71 5.88 
4.14 5.97 
4.16 5.98 




C57 7114 0.12 1.06 
C57714 4.12 4.14 1.14 
4.22 1.93 
4.09 
C57 7115 6.08 6.27 
C57 715 3.76 3.78 6.29 
4.00 6.44 
3.59 
C57 7116 5.06 5.18 
C57 716 7.47 7.43 5.40 
7.37 5.09 
7.45 
C57 7117 5.61 5.83 
C57 717 4.72 4.77 5.98 
4.69 5.91 
4.89 
C57 7118 6.45 6.57 
C57 718 5.23 5.29 6.64 
5.28 6.61 
5.36 
C57 17 19 9.80 9.45 
C57 719 5.88 5.71 9.96 
5.31 8.59 
5.74 
5.89 C57 17 20 5.49 5.51 
5.67 
C57 7110 4.48 4.54 5.38 
4.63 
4.50 C57 17 21 9.79 9.61 
9.84 
9.21 
Table 3.1 B) BLG measurements for 13 generation BLG/7 C57BL16 backcrosse 
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Average 	Mean STD CV Average Mean STD CV 
BLG mg/ml mg/ml BLG mg/ml mg/ml 
CBA 711 3.28 	4.31 	1.18 27.30 C57 711 6.22 5.80 	1.92 33.07 
CBA 712 2.67 C57 712 4.13 
CBA 713 3.50 C57 713 5.88 
CBA 714 4.73 C57 714 4.14 
CBA 715 4.17 C57 715 3.78 
CBA 716 3.76 C57 716 7.43 
CBA 717 6.63 C57 717 4.77 
CBA 718 2.68 C57 718 5.29 
CBA 719 5.38 C57 719 5.71 
CBA 7110 6.37 C57 7110 4.54 
CBA 7111 2.88 C57 7111 6.23 
CBA 7112 4.55 C57 7112 5.88 
CBA 7113 3.91 C57 7113 8.34 
CBA 7114 5.29 C57 7114 1.06 
CBA 7115 4.70 C57 7115 6.27 
CBA 7116 5.13 C57 7116 5.18 
CBA 7117 4.56 C57 7117 5.83 
CBA 7118 3.30 C57 7118 6.57 
C57 17 19 9.45 
C57 17 20 5.51 
C57 17 21 9.61 
Table 3.2 Average BLG expression with mean, SD & CV for 13th generation BLG/7 
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Figure 3.3 	Bar charts representing individual BLG milk protein yields in mg/ml 
A = CBA backcross samples, B = C57BU6 backcross, C = outbred samples 
Each bar corresponds to the mean BLG expression of the individual numbered below (i.e, in 
chart A individual 1 = CBA 1 etc) 
C) 
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mice and my Fl CBA:C57BL/6 outbred BLG expression values. The mean 
expression value of 8.2 mg/ml compares well with the two previously published 
results for BLG/7 F! mice of 7.4 mg/ml +1- 1 (McClenaghan et al 1995) and 9.5 
mg/ml +1- 4.9 (Dobie et al 1996). Comparisons of the coefficient of variegation for 
my Fl BLG/7 outbred CBA:C57BL/6 mice (42%) and both 3' generation backcross 
(45% + 54%) (Table 3.3) and Fl (52%) data (Dobie et at 1996) also fail to unearth 
any significant differences. 
MICE MEAN SD CV 
(standard deviation) (coefficient of variation) 
CBA 4.2 mg/ml 1.03 24.5% 
13th gen. backcross 
C57BL/6 5.8 mg/ml 1.92 33.2% 
13th gen. backcross  
Outbred Fl 8.2 mg/ml 3.46 42% 
CBA:C57BL/6  
CBA 6.3 mg/ml 2.8 45% 
3rd gen. backcross* 
C57BL/6 9.7 mg/ml 5.3 54% 
3rd gen. backcross* 
* = from Dobie et al 1996 & K.W. Dobie PhD Thesis 1996. 
Table 3.3 	Backross, outbred and 3d  generation milk protein results 
Transgene expression levels are therefore maintained in the parental population. The 
result confirms that variegation is successfully maintained over many generations 
without any progressive silencing through repeated rounds of germline transmission. 
This indicates strongly that both the cause and mechanism responsible for 
variegation at this locus remain unchanged. 
3.4.4 Endogenous proteins show evidence of inbreeding depression, which 
selectively represses the BLG transgene 
Initial observations of protein gel staining intensities suggested that endogenous milk 
protein production was reduced in the backcross populations (3.4.2). The reduction 
in BLG expression levels and variance around the mean (Table 3.3) for the backcross 
samples was therefore expected. As the outbred BLG/7 population did not vary from 
results gained in earlier experiments (3.4.3), samples from all three populations were 
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sent out for micro-Kjeldahl analysis in order to determine total protein content and 
enable comparisons between the populations. The technique works by measuring the 
total nitrogen content of a sample, from which an estimation of the total protein 
content can be made. 
Micro-Kjeldahl analysis requires a minimum of 100 tl per sample for analysis, with 
all sample measurements duplicated. Poor milk yields from the backcross mice 
resulted in milk samples that averaged less than 100 pJ from each mouse, with 30 tl 
of this used in the initial sample preparation. It was therefore necessary to pool the 
samples for each group. Duplicate samples from each of the two pools (CBA and 
C57BL/6 13" generation BLG/7) and individual outbred F1 BLG/7 samples were 
sent to the Hannah Institute, where the analysis of total protein content was 
performed by Dr Eleanor Noble. The mean BLG expression level is already known 
for each pool and the individual outbred Fl BLG/7 samples (Tables 3.2 & 3.3), so 
endogenous protein content estimation was easily calculated by subtracting the 
known BLG content from individual results (Table 3.4). 
Total Protein - BLG Endogenous BLG protein 
expression protein expression 
CBA 85 mg/ml 81 mg/ml 85% 53% 
13th gen. 
backcross  
C57BU6 87 mg/ml 81 mg/ml 85% 71% 
13 th  gen. 
backcross  
Outbred Fl 103 mg/ml 95 mg/ml 100% 100% 
CBA:C57BL/6  
Table 3.4 	Micro-Kjeldahl analysis results 
Compared to the Fl outbred results, both backcross populations had their 
endogenous milk protein levels reduced by 15% (Table 3.4). This ties in neatly with 
my estimate of 115th  reduction based on visual examination and loading adjustments 
(3.4.2). I have attributed the down-regulation of endogenous milk protein production 
to the effects of inbreeding depression as both genotypes exhibited identical levels of 
depression. The depressed expression of endogenous milk proteins may extend to all 
endogenous protein expression, and could be a major contributory factor responsible 
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for the loss of fecundity in the backcross populations. Others have reported loss of 
both fecundity and viability with increased levels of inbreeding in other systems 
(Morjan et al 1999). 
Next, the reduction in BLG content in the backcross populations was compared with 
the outbred F 1 BLG/7 mice. Unexpectedly, the reduction in BLG expression exceeds 
15% in both backcross populations (Table 3.4). This result suggests that the factors 
contributing to inbreeding depression may selectively suppress the transgene. 
3.4.5 Strain-specific modification of expression is superimposed on inbreeding 
depression effects, with 13th  generation backcross populations differing 
from each other and outbred BLG/7 populations 
The reduction in BLG expression in the backcross mice does not only exceed the 
15% reduction of endogenous gene expression, but the level of additional reduction 
varies considerably between the two genetic backgrounds (Table 3.4). The C5713L/6 
13th generation backcrossed BLG/7 mice exhibit a 29% reduction in BLG expression 
levels, whereas the CBA background exhibits a staggering 47% reduction in mean 
expression. This clearly demonstrates that there are strain-specific differences 
between the two backgrounds that can exert an effect on transgene expression. 
The backcross mice results differ significantly (p<0.01), both from outbred BLG 
expression values and from the outbred variance (see Figure 3.4). Mean expression 
values and coefficient of variance values are lowered for both backcross groups 
compared to the Fl outbred mice (Table 3.3). This means that the 13th  generation 
backcross populations also differ significantly from the 3rd  generation backcrosses. A 
mild trend towards a reduction in mean expression and variegation apparent in the 3' 
generation of CBA backcrossed BLG/7 mice is substantially enhanced in the 13th 
generation CBA BLG/7 backcross mice. Although no such trend towards lowered 
expression and variance was observed in the 3f  generation of C5713L/6 backcrossed 
BLG/7 mice, 13th  generation backcross mice provide ample evidence that down-
regulation of expression and variance also takes place in this background. More 
surprisingly, the backcross mice also differ significantly in mean expression and 
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Figure 3.4 	Scatterplot showing individual BLG milk protein content and mean 
BLG expression for all 3 genotypes 
variance from each other. Mean C57BL/6 BLG expression levels are significantly 
higher than the levels observed in CBA mice (p<O.Ol).  The variance of BLG protein 
levels in the C5713L/6 population is also significantly greater than in the CBA 
population (p<0.05). Therefore, although BLG/7 still variegates after extensive 
backcrossing into the CBA and C5713L/6 genetic backgrounds, significant 
differences in expression levels between these two populations have been uncovered. 
Fluorescent in situ hybridisation for BLG and -casein expression (2.4.4) was 
performed on mammary tissue from backcrossed C5713L16 BLG/7 mice. The results 
demonstrate clearly that the observed variable expression of BLG within the 
backcross population is due to variegation, with only a proportion of the mammary 
epithelial cells expressing BLG whilst all of them express 13-casein (Figure 3.5). This 
had already been demonstrated previously for the parental population (Dobie et al 
1996), but the result confirmed that the mechanism through which the variegation 
operates had not changed. 
3.4.6 Inbreeding- and strain-dependent down-regulation of BLG/7 expression 
is not heritable 
The probable multilocus effects of inbreeding and background could reasonably be 
attributed to subtle changes and differences in protein concentrations and 
composition. How these multilocus effects act on the transgene locus is unknown, 
though it is highly possible that some of them modify the locus epigenetically. Direct 
investigation into the nature of epigenetic modification at the locus would be very 
difficult, as the locus itself is highly methylated even in the active state (Stephen 
Kwan & C.B.A. Whitelaw, personal communication). The variegated nature of gene 
expression in the mammary tissue would also confuse any results, as dissection of 
expressing cells from non-expressing cells is extremely technically demanding, and 
outside available resources. One practical avenue of investigation was open, the 
possibility that the epigenetic modifications may be inherited through the germline. 
Inbreeding depression, progressive silencing or a combination of the two could be 
causing the reduction in transgene expression in the backcrossed populations. To 
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Figure 3.5 	Fluorescent in situ hybridisations of backcrossed mammary tissue 
Probes used were 5 30'mer oligo cocktails of BLG (Red, Cy3 labelled) and 3-casein 
(Green, Fluorescein labelled) sequences. There were control sense probes (A) and 
antisense probes for transcription (B & C). Tissue from 18th  generation backcross. 
A) Sense probing of transgenic tissue, both probes. Signal is due to 
autofluorescence in the blue light range B) Antisense probing of non-transgenic 
tissue, both probes used. Only 3-casein is expressed (green signal). C) Antisense 
probing of transgenic backcrossed C57BU6 tissue, both probes used (3-casein is 
expressed in all epithelial cells, where BLG is also expressed the signal is orange 
due to mixing of red and green probe signals. Bright yellow fluorescence is caused 
by autofluorescence of wax residues, easily distinguished from mRNA signals 
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C5713L/6 BLG/7 males mated to purebred CBA females were examined for BLG/7 
expression. Restoration of expression to reference F1 animal levels would confirm 
inbreeding depression, whilst persistent depression would support progressive 
silencing with inheritance of epigenetic modification at the transgene locus. The 
reciprocal cross between CBA BLG/7 and C57BL6 was not performed because the 
CBA backcrossed line had been discontinued for logistic reasons. 
The C5713L/6 BLG/7 males mated to purebred CBA females were 16th and 17th 
generation backcross. The progeny are of comparable genetic composition (50% 
CBA, 50% C57BL/6) to reference outbred Fl BLG/7 animals, and to differentiate 
between the two populations will be referred to as outcrossed Fl BLG/7. Outcrossed 
F! BLG/7 females were mated to non-transgenic stock Fl males. Milk samples were 
collected on day 11 of lactation, and 40 p.1 of 1/250 diluted samples were run on the 
protein gels. The endogenous proteins were compared to, and loading adjustments 
were made using the same non-transgenic control sample that was used for the 
original Fl outbred samples (Figure 3.6). BLG concentrations were assessed as 
previously (see Table 3.5 & Figure 3.7). Mean expression, standard deviation and cv 
were calculated as before (see Table 3.6). The Fl outcrossed BLG/7 results were 
compared to the Fl outbred BLG/7 data collected previously (Table 3.7). Complete 
reversion to original BLG mean expression levels was observed for the Fl 
outcrossed BLG/7 mice. It was evident from the level of staining on the protein gels 
that expression had reverted to Fl levels for both endogenous proteins and BLG. 
Variegation of BLG expression was nonetheless very much evident in these mice. 
MICE MEAN SD CV 
CBA 
13th gen. backcross 




13  th  gen. backcross 
5.8 mg/ml 1.92 33.2% 
Outbred Fl 8.2 mg/ml 3.46 42% CBA:C57BL/6 
Outcrossed 8.23 mg/ml 1.79 21.8% 
50:50 CBA:C57BL/6 
Table 3.7 	Backcross, outbred & outcross milk protein results 
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BLG 
C Outcross samples 	 Outcross samples119 
Albumin 
a-case in 	 — 
13-casein -* -- - 	 -- - -- 
25.1 kDa 





Figure 3.6 	SIDS PAGE of milk protein samples for outcrossed mice 
C = non-transgenic control milk, BLG = J3-lactoglobulin standard. Transgenic 
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Figure 3.7 	Bar chart representation of individual outcrossed BLG milk protein 
yields in mg/ml 
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[BLG] Average [BLG] Average 
BLG 
mg/ml Mg/ml mg/ml BLG mg/ml 
MP 1.3 10.31 10.28 MP 3.2 10.82 10.72 
10.13 11.04 
10.42 10.30 
MP 1.5 6.11 6.20 MP 3.3 6.60 6.31 
6.23 6.07 
6.26 6.28 
MP 1.6 9.92 9.95 MP 5.3 7.43 7.30 
9.99 7.40 
9.96 7.08 
MP 1.7 5.73 5.85 MP 6.3 10.77 10.60 
5.94 10.42 
5.88 10.61 
MP 1.11 7.90 7.99 
7.88 
8.18 MP 6.4 9.05 8.68 
8.66 
MP 1.12 8.74 8.82 8.32 
9.55 
8.17 MP 6.5 6.70 6.62 
6.28 
MP 1.14 7.06 7.22 6.90 
7.82 
6.78 MP 6.6 11.24 10.98 
10.80 
MP 1.15 7.09 7.44 10.89 
8.10 
7.14 
MP 6.7 6.83 6.66 
6.38 
6.77 
Table 3.5 	BLG measurements for outcrossed BLG/7 mice (=MP) 
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Average 	Mean 	STD 	CV 
BLG mg/ml 	mg/ml 
MP 1.3 10.28 8.23 	1.79 	21.79 
MP 1.5 6.20 
MP 1.6 9.95 
MP 1.7 5.85 
MP 1.11 7.99 
MP I.12 8.82 
MP 1.14 7.22 
MP 1.15 7.44 
MP 3.2 10.72 
MP 3.3 6.31 
MP 5.3 7.30 
MP 6.3 10.60 
MP 6.4 8.68 
MP 6.5 6.62 
MP 6.6 10.98 
MP 6.7 6.66 
Table 3.6 	Average BLG expression with mean, SD & CV 
for outcrossed BLG/7 mice 
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3.5 Discussion 
The study of long-term transmission of transgenes in mice supports current beliefs 
that once stably integrated and proven to transmit intact, a transgene will remain 
stable (Aigner et a! 1999). Unfortunately, most papers do not thoroughly examine the 
stability of their constructs once a line has been confirmed to express the transgene 
product. One article that does address transgene stability, examines the same 
transgene construct (a—i antitrypsin) in both sheep and mice (Carver et a! 1993). 
Sheep transmitted and expressed the construct stably, possibly aided by the use of an 
ovine promoter. Mice displayed variegated expression, unstable transmission or 
genotypic background effects in 3/4  of all lines. A different example is given by a 
paper reporting stable production of IGF- 1 in transgenic rabbits (Zinovieva et al 
1998). Closer examination of the data presented in the article reveals large 
differences in individual protein yields, with evidence for decreased expression with 
increasing generations. The discrepancy between the conclusions of the paper and 
the data presented is surprising, but may be due to a general reluctance to accept that 
within-line variegation can exist in mammals. That a variegated phenotype can be 
maintained through several rounds of cell division is demonstrated in plants, where 
regeneration from a variegated sector of a tobacco leaf containing a transgenic Sulfur 
gene gave rise to variegated plants (Fitzmaurice et a! 1999). This suggests that 
variegated expression can be heritable, with the instability heritably stable. 
Transgenic mouse line BLG/7 has previously been shown to exhibit variegated 
transgene expression analogous to position effect variegation in Drosophila (Dobie 
et a! 1996). As different mouse genetic backgrounds can exert widely different 
effects on transgene expression (McGowan et a! 1989,   Allen et a! 1990, Elliot et al 
1995, Schweizer et a! 1998), the generation of BLG/7 on an Fl CBA:C57BL/6 
background could be the source of the variegated expression. It can be argued that 
the mixture of the two different sets of modifier proteins could affect the transgene 
expression potential, leading to variegated expression. However, analysis of 3rd 
generation backcrosses provided no evidence for any major strain-specific modifier 
of variegation affecting the transgene array at this locus in either of the two 
backgrounds, although there was a small but statistically non-significant trend 
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towards a decrease in expression (Dobie et al 1996). The evidence was therefore 
suggestive of stable maintenance of variegation, but could not conclusively rule out 
the influence of strain-specific modifiers. 
A C57BL/6 background is documented to affect transgene expression, though the 
reports are conflicting. Two papers report downregulation of transgene expression 
with concurrent increased methylation at the transgene locus (Koetsier et a! 1996, 
Schweizer et a! 1998). A third paper reports upregulation of transgene exression with 
decreased methylation at the locus (Sutherland et a! 2000). In none were backcrosses 
continued for more than 4 generations, and strain-specific modifications usually 
presented themselves within two generations. The different effects on gene 
expression exerted in the same background are difficult to explain, though I will 
attempt to forward my own hypothesis. Several different factors may be contributing 
towards determination of expression. Firstly, local factors that are intrinsic to the 
insertion site could affect expression potential. Secondly, residual background effects 
and epigenetic inheritance, varying with the backgrounds the lines were created on 
may also exert an effect on expression. Thirdly, passage through the germline could 
also affect transgene loci differently; depending on a combination of insertion site, 
integration profile and gamete sex. Combine the above with strain-specific 
differences in modifier protein content and composition, and the outcome will 
depend on the balance of activating and silencing factors. The trend in the 3' 
generation BLG/7 backcross mice suggests that in this instance, C57BL/6 may exert 
a repressive effect on the transgene locus. The backcrosses into both genetic 
backgrounds were therefore continued, and sampled at the 13th  generation for the 
presence of minor modifier loci that may be contributing towards the observed 
variegated expression profile of the Fl and 3rd  generation backcross BLG/7 
populations. 
The aim of this investigation was therefore to establish whether the level of 
variegation was maintained through the generations in both backcross and Fl outbred 
backgrounds, and if there was evidence that minor modifier loci could be responsible 
for the phenotype. Analysis of milk samples demonstrated that Outbred Fl 13th 
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generation BLG/7 mice maintain the same transgenic expression profile as the 
founder population. 13th  generation backcross BLG/7 populations differ both from 
each other and outbred populations, indicating the presence of background-specific 
modifier loci affecting BLG expression. In addition, inbreeding depression 
downregulates all milk protein expression in the backcross populations, with a 
selective depressive effect on BLG/7. These background- and inbreeding specific 
effects are not transmitted through the germline when outcrossed to generate an Fl 
mixed genetic background. The conclusion of all this is that BLG/7 still variegates 
after successive rounds of germline transmission in both a congenic and mixed 
genetic background. 
3.5.1 Variegation is an inherent property of BLG/7 
The BLG/7 locus displays variable expression in both 13th  generation CBA and 
C57BL/6 backcross populations (3.4.2 & 5). This suggests that the mixed 
background upon which the transgenic line was generated is not responsible for the 
variegation phenotype, as separation of the different genotypic modifiers by 
backcrossing has failed to generate a stable expression pattern. Variegation is also 
observed in Fl outbred BLG/7 mice maintained in parallel with the backcross 
populations (3.4.2), suggesting that the cause of variegation is maintained through 
successive germline transmissions. Maintenance of expression levels and cv values 
in the Fl outbred BLG/7 mice that are comparable to earlier generations of BLG/7 
mixed background mice indicate that passage through the germline does not affect 
the extent of variegation and expression potential of the transgene (3.4.3). The above 
observations prove that BLG/7 variegation is an inherent property of the transgene at 
the site of integration. What is observed for BLG/7 is therefore a position effect. 
Previous studies of the BLG/7 line has identified that the transgene has integrated as 
a multicopy array close to centromeric heterochromatin of chromosome 15 (Dobie et 
al 1996). This integration site is highly suggestive of a position effect akin to 
Drosophila PEV acting on the transgene locus of BLG/7. If this is the case, the locus 
should be open to modification of expression through changes in concentrations of 
heterochromatic proteins and other modifiers of PEV. 
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3.5.2 BLG/7 expression is open to modification through inbreeding depression 
Although BLG/7 expression continued to variegate on both backcross genetic 
backgrounds, there were significant differences in expression levels and variance 
when compared to the Fl outbred BLG/7 data (3.4.5, Table 3.3). Therefore, BLG/7 
expression is open to quantitative modification. 
Inbreeding depression represses endogenous protein production 
Both 13th  generation backcross populations exhibited reduced BLG expression levels 
and a decreased variance around the mean when compared to the outcross Fl BLG/7 
mice. Visual observations of the protein gels suggested that endogenous milk protein 
expression was reduced in the backcross mice (3.4.2). Micro-Kjeldahl analysis 
confirmed this observation (3.4.4), the results demonstrating that expression was 
only 85% of the outbred level. 
The reduction of endogenous protein expression is almost certainly the manifestation 
of inbreeding depression effects, as both backcross populations exhibit the same 
level of depression. Protein expression was only examined in the milk, but there is no 
reason not to assume that the results observed are representative for all tissues. A 
frequent manifestation of inbreeding depression is the reduction of viability and 
breeding fitness, the result of the accumulation of duplicate copies of deleterious 
gene alleles. Both backcross genotypes exhibit reduced levels of breeding success 
and poor milk yields. 
Selective reduction of BLG/7 
Since the endogenous protein production was reduced by 15%, the extent of BLG 
repression in both backcross populations was compared to the outbred F1 BLG/7 
population. The outbred mean of 8.2 mg/ml was set at 100%. Surprisingly, backcross 
BLG expression levels were depressed by more than 15% (3.4.4). The C57BL/6 
BLG/7 mean expression was reduced by 29%, and CBA levels by 47%. This is, to 
my knowledge, the first reported case of selective "discrimination" of a transgene in 
an inbred environment. 
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The results provide clear evidence that whilst inbreeding depression down-regulates 
all milk protein expression; there is an additional negative bias towards the 
transgene. There is also a genotype-specific component involved (3.4.5), as 
demonstrated by the different levels of depression exhibited by the backcross 
populations, addressed in the next section. 
Genotype-specific modifier action may account for the reduction in BLG/7 
expression in both backcross populations, with different levels of down-regulation in 
each background. Alternatively, genotype-specific modifiers may only act on the 
transgene in the CBA background. The additional 14% reduction in the C5713L/6 
backcross population, in excess of the 15% inbreeding-specific reduction, could be 
the manifestation of an additional selective disadvantage for the transgene in an 
inbred backcground. This explanation is credible, as the 3rd  generation C5713L/6 
backcross results do not support decreased transgene expression, whereas a reduction 
(albeit statistically non-significant) in mean expression was seen in the CBA 3rd 
generation backcross (Dobie et al 1996). 
BLG/7 may be at a positional disadvantage 
The additional negative bias towards the BLG/7 locus afforded by inbreeding 
depression effects may be a direct result of its genomic position. The positioning of 
the transgene array close to centromeric heterochromatin could impose a twofold 
disadvantage on the construct. Firstly, the location may render it more susceptible to 
changes in chromatin protein composition (Festenstein et al 1999, McMorrow et al 
2000). The multicopy nature of the transgene integration product could exacerbate 
the effects afforded by close proximity to heterochromatin. (Dorer & Henikoff 1994, 
Matzke & Matzke 1995, Hsieh & Fire 2000). Inbreeding may reduce the availability 
of factors that contribute towards keeping the locus in an open conformation. A 
reduction in such locus activating complexes would increase the probability of the 
locus becoming silenced, decreasing the mean expression level. The levels of 
available transcription complexes may be reduced in an inbred background. This 
could influence activation levels as transcription factors are capable of initiating 
changes in higher order chromatin structure during the early stages of gene activation 
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(Lundgren et al 2000, Ahmad & Henikoff 2001). An increase in repressive factors, 
such as heterochromatic proteins, could also account for the decrease in BLG 
expression (Festenstein et al 1999, McMorrow et a! 2000). 
Secondly, the transgene integration site could render it at a positional disadvantage 
within the nucleus. The chromosomal position occupied by the transgene may 
sequester it to a different nuclear compartment to that occupied by the endogenous 
milk genes. Recent papers highlight the importance of nuclear localisation for gene 
expression potential (Francastel et al 2000, Brown et a! 2001). Circumstantial 
evidence suggests silencing factors are non-uniformly distributed throughout the 
nucleus (Wallrath 2000), and may also hold true for activating factors. There is even 
evidence that subcellular localisation can influence gene expression in prokaryotic 
organisms (Kim & Wang 1999). Integration close to centromeric heterochromatin 
may localise the transgene array away from nuclear compartments where 
endogenous milk protein gene transcription takes place, making it harder for the 
BLG/7 transgene to compete for limited resources needed for transcription (should 
inbreeding lead to a reduction in production of parts of the translational and 
transcriptional machinery). A combination of nuclear position and regulatory region 
composition may thus render the transgene selectively disadvantaged. 
Whatever the cause, the selective reduction of BLG/7 expression due to inbreeding 
depression presumably reflects a recruiting disadvantage for the -lactoglobulin 
sequences when compared to the endogenous milk genes. An extreme consequence 
of inbreeding depression could be complete transcriptional silencing of a gene 
(Matzke et a! 1993). Although this was not observed in either background at the 13th 
generation of backcrossing, it is still theoretically possible that this could occur in 
later generations if the depressive effects are increased. Should the repressive effect 
on transgene expression of an inbred background be common, then current 
backcrossing strategies designed to alleviate unstable transgene expression may 
exacerbate the problem instead of curing it. 
112 
3.5.3 Evidence for genotype-specific modification of BLG/7 
Genetic background may play a part in influencing expression levels. Dominant 
strain specific modifiers are documented (McGowan et a! 1989, Elliot et a! 1995), 
with over-expression of a single heterochromatic protein component capable of 
modifying the extent of transgene variegation in mice (Festenstein et a! 1999). 
Genetic background can influence methylation and expression of a variegating 
transgene (Koetsier et a! 1996). 4th  generation backcross mice continued to variegate, 
with increased levels of methylation and silencing associated with a C57BL/6 
background. This background was also associated with de novo methylation of a 
hepatitis B virus surface antigen (HBsAg) transgene (Schweizer et a! 1998). HBsAg 
expression levels differed depending on the strain, backcrossing enhancing the 
effects. Segregation of strain-specific factors meant that crosses produced offspring 
exhibiting both up- and downregulation of expression, due to the cooperative effects 
of different combinations of modifier proteins. Intriguingly, background effects were 
only observed when the transgene was transmitted through the male germline. 
The 13th  generation backcross populations differ in both mean expression levels and 
spread of expression from 3rd  generation backcross mice, outbred mixed genotype 
mice and from each other (Table 3.3). These results suggest that whilst strain-
specific modifiers are not primarily responsible for BLG/7 variegation, modifiers 
capable of down regulating without silencing the transgene exist. The modifiers will 
vary between strains, with the extent of modification and thus silencing varying 
between the two genotypes. 
Inbreeding depression effects can account for 15% of the reduction in expression in 
both backgrounds. An additional 14% of the reduction may be assigned to a putative 
selective depressive effect exerted by inbreeding depression-specific factors on the 
transgene. All of the reduction in BLG/7 expression in the C5713L/6 background 
could therefore be solely due to the effects of inbreeding, although it cannot be 
discounted that a part or all of this reduction may be caused by genotype-specific 
modifier action. In the CBA background, a reduction in BLG/7 expression of 18% 
remains unaccounted for from the total reduction level observed (47%). Background- 
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specific modification of expression is the only remaining explanation for the 
additional decrease in mean BLG/7 expression level in the CBA 13 1h  generation 
backcross compared the C5713L/6 background. 
Multiple recessive modifier loci must be responsible for BLG/7 background-
specific reduction in expression 
There are numerous reports of strain-specific modification of transgene expression 
levels (Allen et a! 1990, Schwizer et a! 1998, Mayeaux-Portas et a! 2000). None 
examine backcrosses beyond the fourth generation, with the strain-specific 
modifications generally evident by the 2' or 3rd  generation. Clear segregation 
patterns emerge that are indicative of a single modifier locus. This is supported by 
the demonstration that over-expression of a single protein can exert a modifying 
effect on the expression of a variegating transgene (Festenstein et al 1999, 
McMorrow et a! 2000). 
The BLG/7 transgene locus exhibits no significant changes in expression in the 3rd 
generation of backcrossing to the CBA and C5713L16 genetic backgrounds. This led 
to the conclusion that no single major modifier locus was present that affected 
BLG/7 expression (Dobie et a! 1996). The reduction in the 13th  generation 
backcrosses of both mean expression and variability, not wholly explained by the 
effects of inbreeding depression, suggests that strain-specific modification can take 
place (3.4.5). As no clear evidence for strain-specific modification was evident in the 
3rd generation, this suggests that multiple recessive loci exist. Together, these loci 
can exert an effect on BLG/7 expression, at least in the CBA background. Each of 
these loci would have a subtle but cumulative effect on expression as genotypic 
background purity increases. The different levels of expression and variability 
between the backcross genotypes indicate that the composition and/or concentration 
of modifiers differ between the two backgrounds. Whether the cumulative effects 
would enable silencing of the locus in later generations remains to be seen. If the 
modifications generated by the modifier loci can be transmitted through the 
germline, there is increased probability that some individuals will exhibit complete 
silencing of BLG/7 expression in future generations. 
114 
All the results so far provide evidence that both inbreeding- and strain—specific 
factors can have a quantitative effect on BLG/7 expression. What is equally evident 
is that none of these factors can affect the underlying mechanism responsible for the 
variegation phenomenon. In other words, inbreeding— and strain—specific factors 
appear to exert a quantitative but not a qualitative effect on BLG/7 transgene 
expression. 
3.5.4 Epigenetic modifications not inherited 
There are several papers reporting progressive silencing of genes through successive 
germline transmissions (Kilby et a! 1992, Lardon et a! 1999), continued 
manifestation of a phenotype after removal of the transgene (Davies et a! 1997, 
Jensen et a! 1999) or incomplete erasure of epigenetic modifications in the germline 
(Morgan et a! 1999). Although the early separation between somatic and germ cell 
lineages in animals renders epigenetic inheritance of non-imprinted loci a rarity, 
there are some examples. Epigenetic inheritance of modifications due to strain-
specific and inbreeding factors was therefore investigated by outcrossing 
backcrossed BLG/7 to the opposite inbred strain in order to generate 1St  generation 
50:50 CBA:C57BL/6 BLG/7 mice, the genetic counterparts to our outbred Fl BLG/7 
mice. 
The complete reversion to outbred BLG/7 mean expression levels indicates that 
inbreeding- and/or genotype-specific modifiers do not convey a heritable epigenetic 
modification at the BLG/7 locus, at least not in a mixed genetic background through 
male germline transmission (3.4.6). This is mirrored in a paper examining the effects 
of inbreeding and outcrossing in ladybeetles (Morjan et a! 1999). Maintenance of 
variegated BLG/7 expression provides additional confirmation that this is an inherent 
property of the transene at the site of integration irrespective of genetic background. 
Despite displaying expression levels within the range seen for the outbred Fl BLG/7 
mice, the coefficient of variance was considerably reduced in outcrossed BLG/7. 
Outbred F 1 BLG/7 mice have a cv of 42%, whilst the outcrossed F 1 BLG/7 mice 
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only exhibit a cv of 22%. This was unexpected. As the C57BL/6 BLG/7 generation 
13 backcross mice have a cv of 33.2%, the outcross results remain especially 
puzzling. A possible explanation lies in the genotypic composition of the outcrossed 
versus outbred Fl mice: 
The Fl outbred BLG/7 population is maintained on a mixed genetic background 
generated through F2 x F1 matings, where any given pair of homologus loci can 
contain three combinations of genetic-background alleles (hemizygous, or 
homozygous for either CBA or C57 alleles). The greater genetic variability generates 
greater variance in expression levels between individuals in the group. The 
outcrossed mice are genotypically 50% CBA and 50% C57BL/6, being first 
generation outcrosses from a C57BL/6 background to a CBA background. Each 
duplicated chromosomal locus can only have a single combination of alleles, one 
each from the CBA and C57BL16 backgrounds. This reduction of genetic variability 
would explain the reduction in the coefficient of variation. The higher variability of 
the backcross parental population may be explained by the effects of inbreeding 
depression- and background-specific modification. The two sets of modifiers may 
interact, possibly with random segregation within and between individuals, 
generating more diversity in a stochastic fashion than the backcrossed genotype 
might initially suggest possible. The homogeneity of allele combinations in the 
outcrossed Fl BLG/7 mice greatly reduces their scope for variability, and hence the 
reduction in the cv value. Mean BLG levels revert to outbred Fl BLG/7 levels due to 
a combination of heterosis and absence of inherited epigenetic modification, but the 
range of expression levels is reduced due to the homogeneity of modifier loci in this 
background. Figure 3.8 depicts all four genotypic backgrounds with expression 
levels and range. I fully expect that the outcrossed F 1 BLG/7 mice will revert to a cv 
level in line with outbred F1 BLG/7 mice after a few generations of maintenance on 
the Fl background. 
The reversion to parental expression levels and maintenance of variegated expression 
supports the conclusion that there is no progressive silencing of the transgene 
through repeated rounds of germline transmission, at least in a mixed genetic 
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BLG expression ranges for all 
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Scatterplot showing individual BLG milk protein content and mean 
BLG expression for all 4 genotypes 
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background. Inheritance of epigenetic modifications or modifier proteins responsible 
for inbreeding- and background-specific depression of expression can also be 
discounted by the results of this experiment. This result also excludes germline 
mutation as a possible cause of reduced expression in the inbred background. 
3.5.5 Variegation is maintained through the generations 
BLG/7 expression variegates in all genetic backgrounds examined and at all 
generational stages investigated. The depressed BLG/7 expression in the backcrossed 
mice is de-repressed upon outcrossing, even after 16/17 generations of backcrossing, 
and reverts to the expected outbred BLG/7 levels. Expression does not fall with 
increasing age of an animal, as has been demonstrated for other transgenic mice 
(Cohn et al 1991, Robertson et al 1996, Sutherland et al 1997). In my study, the 
BLG/7 mice are sampled in their prime. Serial lactations indicate that BLG protein 
expression does not differ significantly between individual lactations (Dobie et a! 
1996), suggesting that the observed variegation is not age-related. BLG/7 transgene 
expression is lactation specific, whereas other studies use transgenes containing 
constitutively active promoters, at least for their cell type (Cohn et a! 1992, 
Robertson et a! 1996, Sutherland et a! 1997). The limited window of expression 
differentiates our mice from the others, and may render our transgene immune to 
time or age-related repression effects. 
These results indicate that there are no generational or age-related effects on BLG/7 
expression, and that the transgene locus is not subject to any restrictions imposed by 
a genome policing system. 
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Chapter 4 
The effects of homozygosity on the expression patterns of 
the highly variegating transgene in BLG/7 mice 
4.1 Introduction 
Position effect variegation (PEV) studies in mammals have investigated copy 
number effects by generating multicopy transgene array inserts that induce 
variegation, and then reducing the copy number at the site in order to study the 
effects of a reduction in array size. The first paper outlining such an experiment 
reported that reducing copy number abolished PEV and led to even expression in all 
cells (Garrick et a! 1998). The second paper, published three years later, reports the 
exact opposite result (Ramirez et a! 2001). Reduction in copy number did not abolish 
variegation. The level of variegation remained largely unchanged, with the 
occasional quantitative reduction in expression from cells that expressed the 
transgene. 
A separate issue was addressed by Belyaeva and co-workers (1993) and Lloyd and 
co-workers (1997), where the behaviour of two different variegating constructs in the 
same system was investigated (both groups used Drosophila). The two variegating 
genes may or may not be subject to common silencing mechanisms, so combining 
both in the same system could give rise to two results. If there is competition for a 
limiting factor, then the established silencing patterns for one or both genes will be 
disrupted. The absence of either limiting steps or an overlap of silencing pathways 
would ensure that both genes variegate as normal independently of each other. Both 
outcomes were observed (Belyaeva et a! 1993, Lloyd et al 1997), so it is probable 
that there are limiting factors and mechanistic pathway overlaps operating in the 
various reported incidences of PEV. 
The ability of unlinked variegating loci to affect each other's expression may be 
connected to certain phenomena so far only reported in non-mammalian species. A 
series of studies have suggested that the expression state of one allele can 
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occasionally affect the expression of the other allelic locus. This has been reported in 
Drosophila (Henikoff & Dreesen 1989, Golic & Golic 1996, Henikoff 1997), fungi 
(Woloshuk et al 1995) and plants (Meyer et al 1993, Matzke & Matzke 1995) for 
both endogenous genes and transgenic loci. Pairing of the two loci is a requirement 
of all the phenomena. In Drosophila and fungi, the phenomenon is termed 
transvection, with the interaction able to either activate or inactivate gene expression. 
Both outcomes can be associated with a single gene, an example being the pointed 
gene of Drosophila (Scholz et a! 1993). A transgenic example of transvection in 
Drosophila is provided in the case of the white gene (Martin-Morris et al 1997). In 
plants, a similar phenomenon of pairing dependent inactivation of gene expression is 
termed "paramutation" (Winkler 1930, Matzke & Matzke 1995). This may be the 
mechanism responsible for the complete silencing of a repeated chalcone synthesis 
transgene in Arabidopsis in the homozygous state, whilst hemizygous plants display 
variegated expression (Davies et al 1997). 
Transvection and paramutation both describe phenomena that influence the 
transcriptional status of both paired alleles, and may share mechanistic pathways. 
The mechanisms underlying trans effects are not known, but may include the transfer 
of heterochromatic proteins and/or histone deacetylases between the loci (Henikoff 
& Dreesen 1989, Ronserray et a! 1998). 
As discussed earlier, the BLG/7 transgene is integrated close to peri-centromeric 
heterochromatin and is predisposed to silencing. Position effect variegation is 
suggested as the underlying cause of the variegated expression of the transgene, with 
variable spread of heterochromatin into the transgene integration locus from the 
centromere the proposed mechanism (Dobie et al 1996). It is entirely possible that 
the peri-centromenc location causes the physical recruitment of the transgene locus 
into heterochromatin, with inactivation the result of an environment lacking in 
activating factors rather than physical heterochromatinisation of the locus itself, as 
reported in Drosophila (Sabl & Henikoff 1996). To my knowledge, no investigations 
have been made into the effects of a homozygous environment on a variegating 
transgene in mammals. 
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4.2 AIM 
The aim of this investigation was to test whether the highly variegating transgene 
locus of BLG/7 would behave independently when in the homozygous state. 
4 	Experimental Approach 
We wished to evaluate the possibility that expression of the highly variegating 
BLG/7 transgene might be influenced by the presence of an identical variegating 
locus on the homologous chromosome. 
As a first approach, we sought to generate BLG/7 homozygous animals and 
determine the expression levels of BLG protein in the milk. As will be discussed 
below, the protein expression results initiated an extension of the investigation to 
include an in situ hybridisation analysis of both homozygous and hemizygous 
transgenic mammary gland tissue. 
BLG/7 has been maintained on a mixed Fl CBA:C57BL/6 background (generated 
through F2 x Fl matings) as both a hemizygous and homozygous colony (see 
appendix Cl for maintenance mating regime). A mating regime was set up to 
generate 20 females from each colony for milk and tissue sampling. Samples were 
collected on the 1 11h  day of lactation (peak of BLG protein production, Whitelaw et 
a! 1992), from 19 hemizygous and 19 homozygous BLG/7 females. 
Levels of BLG protein were determined by quantitative SDS gel electrophoresis as 
described earlier (2.3), whilst fluorescent in situ hybridisation (2.4) using probes 
against BLG and -casein mRNA was used to evaluate the proportion of alveoli 
producing BLG mRNA. The results of the investigation into protein and mRNA 
expression led to the examination of nuclear transcription from the BLG/7 loci and 
localisation of the integrated transgene locus with respect to the primary transcripts. I 
believe this may be the first successful attempt at performing chromosomal FISH 
using wax embedded tissue sections. The available protocols describing 
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chromosomal FISH are all based on chromosomal spreads, or single cell layers using 
cultured or blood derived cells. 
4.4 Results 
4.4.1 Strategy and critique of hemi- and homozygous BLG/7 analysis 
Estimation of transgenic protein concentration in milk samples 
Quantification of protein concentration was done in triplicate sets for each sample, 
using light pixel intensity comparisons to the standard curve generated by the 
staining intensities of the three BLG standards run on each protein gel. Analysis of 
the gels used the Multi Analyst Programme version 1.1 (BioRad). Loading 
differences were corrected for using -casein as an internal control standardised to 
the non-transgenic sample present on every gel. The same non-transgenic control 
sample was run for both hemi- and homozygous samples. The arithmetic mean of the 
three measurements was used in determination of BLG expression levels for each 
individual sample. 
18 protein gels were run in total, 9 each for the hemi- and homozygous samples. A 
gel from each group is reproduced in figure 4.1. Although the protein gels were 
Coomassie stained, greyscale depictions were preferred, as the protein bands appear 
cleaner and more clearly defined. All analysis of the images was done with the gels 
defined as Coomassie stained by the software package (2.3.3). 
Fluorescent in situ hybridisation (FISH) 
Serial sections of 5j.im thickness were taken from each individual wax embedded 
mammary sample. Inexperience in the use of the microtome and water bath meant 
that initial tissue wastage was high. 
Although radioactive in situ hybridisation techniques were available for qualitiative 
investigation into 3-lactoglobu1in expression in our mammary tissue, a fluorescent 
alternative was deemed desirable both from the point of view of increased safety and 
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Figure 4.1 	SDS PAGE of milk protein samples for Hemi- and Homozygous BLG/7 
C = non-transgenic control milk, BLG = 3-lactoglobulin standard. Transgenic 
samples were loaded 40 ul of 1/250 dilution. 
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improved resolution at the cellular level. The development of such a technique would 
also enable simultaneous probing for expression patterns of several different mRNA 
transcripts. 
The FISH protocol for wax-embedded tissue sections took six months to develop and 
is a hybrid of several different published experimental protocols (see 2.4.3 - 4). RNA 
probes did not provide a sufficiently strong signal, and were exchanged for a cocktail 
of five 30'mer DNA oligos based on the published BLG and —casein (control) 
coding sequences (2.4.8). Oligo sequences were separated by a minimum 30 bases to 
avoid steric interference between the fluorescent haptens attached at the 5' and 3' 
ends. SINE and LINE elements were excluded from the probes, as were obvious 
repetitive sequences. MWG synthesised the oligos and attached the haptens (Cy3 to 
BLG probes, Fluorescein to 3—casein controls). Oligos were ordered in both sense 
and antisense orientations, enabling probe specificity to be checked. 
Prehybridisation follows standard protocols, with an extended xylene dewaxing step 
(2.4.3). Heating the sections with hybridisation buffer overlaid serves the dual 
purpose of easing probe access into the tissue and dispersing any residual wax. The 
freezing step ensures that the wax solidifies into easily identifiable globules (see 
yellow-white spots in in situ figures, e.g. Figure 4.2). Control hybridisations using 
both sense and anti-sense oligo cocktails for BLG and -casein probes alone or in 
combination were performed on transgenic and non-transgenic tissue (Figure 4.2, a-
e). The tissues auto-fluoresces weakly in all light ranges due to residual wax, with 
the strongest fluorescence in the blue light range. This is not a problem as the probes 
are labelled with either Cy3 (red, BLG probes) or Fluorescein (green, -casein 
probes). Sense probes do not generate a signal, and BLG antisense probes only 
hybridise in transgenic mammary tissue, confirming probe specificity (Figure 4.2). 
When both sets of probes are used together, the BLG signal appears orange, due to 
the mixing of two fluorescent signals as all mammary epithelial cells express - 








FISH for BLG mPNA in Hem izyocious tissues 
Sense control BLG (Cy3, red) & 
casein (Fluorescein, ( l r i , green) probes 
against DAPI (blue) background 
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C) Antisense Cy3 (red) BLG probe 
against DAPI (blue) background 
using BLG/7 transgenic tissue 
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casein & Cy3 (red) BLG probes using Fluorescein (green) 3-casein  probes 
non-transgenic control tissue 	using BLG17 transgenic tissue (red + 
green = orange signal) 
Figure 4.2 	mRNA FISH (BLG & 3-casein) in lactating mammary tissue 
10 X magnification. Scale: 1 cm = 80 pm 
Control hybridisations using sense (A) and antisense (B-D) probes for 13-casein (A,B & 
D, green signal = Fluorescein) and BLG (A, C & D, red signal = Cy3) mRNA 
expression in transgenic (A, C&D) and non-transgenic (B) tissue Bright fluorescence 
is caused by autofluorescence of wax residues, easily distinguished from mRNA 
signals. Whole tissue autofluoresces in blue light range (DAPI). 
Double FISH using cocktails of oligos against both BLG and -casein exonic 
sequences were performed in duplicate sets for each individual tissue sample. Ten or 
more views from each section were digitally captured and the proportion of 
expressing alveoli in each view was estimated manually. Each alveolus was scored as 
to whether it was 100% ON, 100% OFF, 3/4  ON, V2 ON, ¼ ON, 118th  ON or 1/ 16" ON 
(see below for representative examples). The assignation of individual expression 
status is to a certain extent subjective, and the error margin must reflect this. By 
repeating the hybridisations, I have tried to minimise the level of human error. Where 
the two counts have differed significantly, a third round of hybridisations were 
performed in order to ascertain a more detailed picture of the relative expression 
profile. 
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Limitations of the FISH analysis 
The main two limitations identified for this approach are human error and sampling 
size. The cause of human error lies in the manual assignation of relative expression 
levels for each alveolus, a subjective decision, and the repetitiveness of the task. This 
has been compensated for by the repeated rounds of analysis. 
The effects of sampling require further explanation. Ideally, each mammary tissue 
should be subjected to serial sectioning, with samples covering the entire gland 
quantified for expressing alveoli. The timescale involved, and the number of samples 
in need of processing (38), rendered such a detailed investigation impossible. 
Instead, enough 5.tm sections were cut to ensure that a minimum of five slides, each 
containing 2-3 sections, were available from each tissue sample. As my skill in using 
a microtome increased, less tissue was needed to generate the same number of slides. 
Earlier tissue samples cut (hemizygous) thus cover more of the total mammary gland 
than the later samples (homozygous tissues). Hemizygous counts may therefore be, 
on an individual basis, slightly more representative of the total tissue than individual 
homozygous counts. As most expression levels are duplicated, the combined results 
should be representative of the general trend. The data presented verifies the validity 
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of this approach (Figure 4.10). I am therefore confident that the data generated by 
the technique provides an accurate insight into the relationship between transgenic 
milk protein content and proportion of expressing cells in both groups of mice. 
Primary transcript and genomic DNA FISH 
The success of the mRNA FISH prompted a similar approach to identify primary 
transcript generation from the BLG/7 loci. Probes were designed against intronic 
sequences, again using five 30'mer oligos. Digoxygenin (DiG) was used as a hapten 
in order to enable signal amplification, as it was considered improbable that 
sufficient primary transcript would be present to enable visualisation without a 
secondary amplification step. Hybridisation proceeded as for mRNA detection, with 
the addition of an antibody detection step. The antibody used was conjugated to 
either Fluorescein or Rhodamine (Red) (the antibody can be purchased with either 
hapten). Visualisation was at 100x magnification. Nuclei were DAPI counterstained 
to enable identification and provide a contrasting background to the transcript signal. 
Probes against 3-casein intronic sequences labelled first with biotin, then fluorescein, 
failed to generate a signal. Initially interpreted as a failure of the antibody to biotin, 
the subsequent failure of the fluorescein labelled probe in conjunction with 
antibodies to fluorescein prompted the conclusion that the intronic 3-casein sequence 
data may be inaccurate. A second set of intronic probes, against mouse whey acidic 
protein (WAP), was ordered. Although not as abundant as the caseins, this protein 
can still be seen as the smallest protein at the bottom of the milk gel, just below the 
BLG band in the transgenic samples (Figure 4.1). Sufficient intronic sequence data 
was not available for any of the more abundant milk proteins. 
Probe generation for chromosomal FISH was identical to the other oligo designs. Ten 
30'mer oligos against the BLG promoter region were made. A fluorescein hapten 
was attached 5' and 3', with amplification via a fluorescein antibody conjugated to 
fluorescein (2.4.6). The pre-hybridiation protocol was modified to include a pepsin 
digestion step (2.4.6), which was essential to ensure probe access to genomic DNA. 
Pepsin may exert its effect through digesting chromosome-specific proteins or 
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protein bonds. All chromosomal FISH protocols that include a digestion step use 
pepsin, which is why it was included in this protocol. The chromosomal FISH 
protocol took two months to perfect. Concerns that the additional digestion step 
might eradicate the primary RNA transcript were allayed by excellent test FISH 
results using intronic BLG probes. The primary transcript signal was, if anything, 
stronger than before. Double FISH for intronic RNA and genomic DNA also worked 
well. Primary transcripts were detected using the DiG antibody conjugated to 
rhodamine, whilst fluorescein was used to amplify the chromosomal signal. 
4.4.2 BLG protein levels suggest that the two homologous loci do not variegate 
independently 
Raw data was collected for each protein gel, with both BLG and -casein levels 
measured (Appendix A2). Three separate measurements of BLG concentration were 
generated for each sample (Table 4.1). The arithmetic mean of these measurements 
was used to calculate individual expression levels, with the results shown in Table 
4.2 and Figure 4.3. The BLG expression levels for both populations were subjected 
to statistical analysis, with mean expression, standard deviation and coefficient of 
variation values calculated and compared (Table 4.3). 
The most noticeable result was the absence of an increased upper limit of BLG 
expression in the homozygous mice compared to their hemizygous counterparts. This 
upper limit is most obvious when the data is represented in the form of a scatterplot 
(Figure 4.4). Neither population exceeded a transgenic protein expression level of 20 
mg/ml. The highest hemizygote expression was 18mgIml, the highest homozygote 
expression 19 mg/ml. This ceiling of BLG/7 protein expression does not represent a 
physiological restraint as another line of transgenic mice containing a variegating 13 -
lactoglobulin transgene (BLG/45) essentially doubles transgene output in the 
homozygous state, achieving an average expression of 32 mg/ml (McClenaghan et al 
1995). This result shows that the mammary gland is capable of higher levels of BLG 
production than the maximum achieved by the BLG/7 line. The absence of a 
doubling of expression in BLG/7 homozygote mice must therefore be caused by 
some other reason than a pure physiological constraint. The homozygous mice do 
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BLG measured BLG average 
mg/ml mg/ml 
HI 13.76 14.09 
14.33 
14.19 
H2 8.97 8.82 
8.50 
8.99 
H3 8.04 8.16 
8.21 
8.22 
H4 19.13 18.35 
18.13 
17.80 
H5 5.49 6.08 
6.43 
6.32 
H6 11.43 11.38 
11.24 
11.45 
H7 5.36 5.25 
5.23 
5.16 
H8 7.96 7.70 
7.44 
7.70 
H9 7.85 7.98 
8.08 
8.02 
HIO 5.46 5.59 
5.68 
5.63 
BLG measured BLO average 
mg/ml mg/ml 
HIl 8.08 7.99 
7.67 
8.23 
H12 5.82 5.62 
5.11 
5.92 
H13 6.44 6.35 
6.26 
6.34 
H14 4.37 4.43 
4.17 
4.74 
H15 11.14 10.45 
10.95 
9.25 
H16 7.92 7.61 
7.36 
7.56 
H17 9.83 9.16 
8.74 
8.91 
H19 4.61 4.19 
3.58 
4.37 
H20 7.78 7.54 
7.47 
7.37 
Table 4.1 	A) BLG measurements for hemizygous BLG/7 mice 
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BLG measured BLG average BLG measured BLG average 
mg/ml mg/ml mg/ml mg/ml 
HHI 13.12 13.81 HHII 18.10 18.20 
13.63 18.66 
14.67 17.82 
HH2 12.82 13.97 HH12 8.72 8.94 
14.21 8.69 
14.87 9.41 
HH3 9.25 9.22 HH13 11.07 11.12 
9.43 11.00 
8.98 11.29 
HH4 9.75 9.56 HH14 8.94 9.06 
9.56 9.05 
9.37 9.18 
HH5 9.76 9.74 HH15 11.61 11.74 
9.94 11.75 
9.52 11.86 
HH6 11.56 12.12 HH16 7.56 7.68 
12.30 7.44 
12.50 8.04 
HH7 7.66 7.64 HH17 18.47 18.81 
7.78 18.85 
7.48 19.10 
HH8 11.88 12.45 HH18 11.69 11.54 
12.78 11.89 
12.71 11.04 
HH9 9.29 9.30 HH19 12.43 12.42 
9.50 12.32 
9.12 12.51 
HH20 12.01 12.03 
11.79 
12.30 
Table 4.1 B) BLG measurements for homozygous BLG/7 mice 
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Average Mean STD CV 
BLG mg/ml mg/ml 
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Table 4.2 	Average BLG expression with mean, SD & CV for hemizygous (H) 














B) Homozygous BLG/7 















1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 1819 20 
Figure 4.3 	Hemi- & Homozygous milk expression 
Bar charts representing individual BLG milk protein yields in mg/mi. 
A = hemizygote samples, B = homozygote samples 
Each bar corresponds to the mean BLG expression of the individual 
numbered below it (i.e., in chart A individual 1 = Hi etc) 
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Hemi- & Homozygote Protein Expression Levels 
20 
S 
I 	 I 18 
IN 
14 I 	 I 
12 I • 
I 
10 
$ 	 I 





Hemizygotes 	 Homozygotes 
0 
BLG mg/ml 
Figure 4.4 	Scatterpiot showing individual BLG milk protein content for both 
genotypes 
Each dot represents one individual sample in the given population. It is clear 
from this representation that whilst the individuals from both populations with 
the lowest level of BLG expression have very different amounts of protein in 
their milk, the highest expressors in both populations display similar BLG 
milk protein content. 
nonetheless exhibit a near doubling of minimum expression levels compared to the 
hemizygous mice (Figure 4.4). 
Hemizygous protein yields exhibited a minimum level of just under 4 mg/ml, whilst 
the homozygous minimum was 7.5 mg/ml. Mean expression levels were therefore 
increased in homozygotes (11.5 mg/ml) compared to hemizygotes (8.2 mg/ml), 
whilst the coefficient of variegation was naturally reduced in the homozygote 
population (26.7% vs. 42%) (Table 4.3). 
MICE MEAN 
SD CV 
(standard deviation) (coefficient of variation) 
Hemizygous 
BLG/7 




(outbred Fl 11.54 3.08 26.71 
CBA:C57BL/6)  
Table 4.3 	Backross, outbred and 3d  generation milk protein results 
4.4.3 The spatial pattern of BLG expression revealed by mRNA FISH cannot 
discriminate between hemizygous and homozygous samples 
Initial examination of the mRNA FISH images prior to analysis provided clear 
evidence that even within a single section there are high levels of variegation, with 
views exhibiting strikingly different proportions of expressing alveoli. This was 
evident for both high (Figures 4.5 & 4.6) and low (Figures 4.7 & 4.8) expressing 
individuals of both hemizygous and homozygous origin. The alveoli rarely appeared 
to have every cell expressing the transgene, even in high expressors, mirroring 
previously published images for hemizygous BLG/7 mice using radioactive probes 
(Dobie et al 1996). When examining hemi- and homozygous individuals with equal 
protein expression levels, it did appear that they also shared roughly the same 
proportion of expressing alveoli with a similar pattern of expression evident (Figure 
4.9). 
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4 views from the crne section of high ex p ressing hemizyqote 
LO 
	
D 	 wax 
Figure 4.5 	Double mRNA FISH (BLG & 3-casein) from high BLG/7 
hemizygote expressor (HI = 14 mg/ml) Scale: 1 cm = 80 g.un 
4 different views (A - D) from the same section of lactating mammary tissue shown, 
magnified 10 X. Probe concentration used was 40 ng/ml. Probes used were BLG (Cy3 
red signal) & 13-casein (Fluorescein = green signal). All epithelial cell express 3-
casein (green), some also express BLG (red + green = orange). Note that alveoli can 
comprise of cells expressing both genes (i), 3-casein (ii) or a combination of the two 
(iii). Bright yellow fluorescence is caused by autofluorescence of wax residues, easily 
distinguished from mRNA signals. 
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Figure 4.6 	Double mRNA FISH (BLG & 3-casein) from high BLG/7 
homozygote expressor (HHI7 = 18.8 mg/mI) Scale: 1 cm = 80 p.m 
4 different views from the same section of lactating mammary tissue shown (A - D), 
magnified 10 X. Probe concentration was 40 ng/mI. Probes used were BLG (Cy3 = 
red signal) & 13-casein (Fluorescein = green signal) All epithelial cell express -casein 
(green), some also express BLG (red + green = orange). Note that alveoli can 
comprise of cells expressing both genes (i), 3-casein (Ii) or a combination of the two 
(ill). Bright yellow fluorescence is caused by autofluorescence of wax residues, easily 
distinguished from mRNA signals. 
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4 views from the same section of low expressing hem izygote 
FQ  B 
D 	wax 
Figure 4.7 	Double mRNA FISH (BLG & 3-casein) from lower BLG/7 
hemizygote expressor (H13 = 6.3 mg/ml) Scale: 1 cm = 80 jim 
4 different views (A - D) from the same section of lactating mammary tissue shown, 
magnified 10 X. Probe concentration was 40 ng/ml. Probes used were BLG (Cy3 = 
red signal) & -casein (Fluorescein = green signal) All epithelial cell express 3-casein 
(green), some also express BLG (red + green = orange). Note that alveoli can 
comprise of cells expressing both genes (I), -casein (ii) or a combination of the two 
(iii). Bright yellow fluorescence is caused by autofluorescence of wax residues, easily 
distinguished from mRNA signals. 
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Figure 4.8 	Double mRNA FISH (BLG & 3-casein) from low BLGI7 
homozygote expressor (HHI6 = 7.7 mg/ml) Scale: 1 cm = 80 lLm 
4 different views (A - D) from the same section of lactating mammary tissue shown, 
magnified 10 X. Probe concentration used was 40 ng/ml. Probes used were BLG (Cy3 
= red signal) & 3-casein (Fluorescein = green signal) Au epithelial cell express 3-
casein (green), some also express BLG (red + green = orange). Note that alveoli can 
comprise of cells expressing both genes (i), -casein (ii) or a combination of the two 
(iii). Bright yellow fluorescence is caused by autofluorescence of wax residues, easily 
distinguished from mRNA signals. 
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3 views from similar hemi- and homzyqous expressors 
B 	 E 
C 	 F 
Figure 4.9 	Double mRNA FISH (BLO & f3-casein) of similar hemi- (A-C) and 
homozygous (D-F) expressors (1-12 = 8.8 mg/ml, HH9 = 9.3 mg/ml) 
Scale: 1 cm = 100 pm 
Three different views of the same section of hemizygote H2 (A-C) and homozygote 
HH9 (0-F) lactating mammary tissues shown, magnified 10 X. Antisense probes for 13-
casein (Fluorescein = green signal) and BLG (Cy3 = red signal) mRNA expression 
used at a concentration of 40 ng/ml. All epithelial cell express 13-casein (green), some 
also express BLG (red + green = orange). Note that alveoli can comprise of cells 
expressing both genes (i), 13-casein (ii) or a combination of the two (iii). Bright yellow 
fluorescence is caused by autofluorescence of wax residues, easily distinguished from 
mRNA signals. 
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The compiled results for each round of in situ counts are in Table 4.4, with detailed 
data in Table 4.5 (hemizygous results) and Table 4.6 (homozygous results) at the 
back of this chapter. These results are also represented graphically, with Figure 4.10 
(a - c) showing the results of rounds 1 & 2, 3 & 4, and the combined results with 
BLG protein expression plotted against the proportion of active alveoli. For both 
groups, the proportion of expressing cells increases with the concentration of 
transgenic protein expressed in the milk. Both sets of mice appear to require similar 
levels of expression, as determined by % of expressing cells, to generate equal levels 
of protein in the milk (Figure 4.10). In neither population did the proportion of 
expressing alveoli exceed 50%, the highest were scored at around 40%. There may 
be a small trend towards a higher proportion of expressing cells in the homozygous 
samples, but this is not significant when human and sampling error are taken into 
consideration. Homozygote samples are generally higher expressors than 
hemizygotes, with subsequent higher probability of overestimation of the number of 
active cells. The sampling differences due to microtome experience mentioned above 
(4.4. 1) will also contribute to a slight increase in the wobble factor. 
4.4.4 The homologous loci of homozygous BLG/7 mice are not independent 
The homozyogous BLG/7 population exhibits a doubling in the minimum expression 
but displays an equal maximum expression level when compared to the hemizgous 
population. The homozygous population has a larger proportion of higher expressing 
individuals, which explains the differences in mean expression and variance. The 
presence of two transgenic loci in the homozygous population doubles the 
probability that one of the loci will be active, presuming that the two loci act 
independently of each other, and can account for the near doubling in minimum 
transgenic protein expression compared to the hemizygous population. The identical 
expression ceiling in both populations, on the other hand, suggests that the two loci 
cannot be operating independently of each other. Three testable models were 
proposed to explain the observations above: 
1) 	Both homologous loci are active, but at half the activity of the 
individual hemizygous loci. Activation remains a random process. 
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2) 	Only one of the two loci is active, with activity on par with 
hemizygous cells. 
3) 	Both loci are active, but only in half the number of cells. Each locus 
has the same activity as its hemizygous counterpart. 
Models 1 + 2 can be differentiated from model 3 by counting the number of actively 
expressing cells in the mammary tissue and correlating it to the known protein level 
in the corresponding milk samples. 
RNA FISH performed on hemi- and homozygous mammary tissue proved that both 
populations display variegation at the cellular level (Figures 4.5 - 4.9). Correlation of 
number of expressing cells with protein content in milk established that both 
populations exhibit similar expression patterns (Figure 4.10). There is no strong trend 
towards a halving or doubling in the percentage of transgene mRNA expressing cells 
in the homozygous population compared to the hemizygote results, enabling the 
elimination of model 3. This established that homozygous expression was either 
from a single locus in all expressing cells, or that both loci were active but at half the 
normal activity. This equates to models 1 & 2 and confirms that some form of trans-
homology interaction is taking place in BLGI7 homozygous mice. To differentiate 
between the two models, primary transcript FISH was performed on homozygous 
BLG/7 mammary tissue. 
As neither hemizygotes nor homozygotes exhibited more than 40% actively 
expressing cells, the search for nuclear transcription foci was concentrated in the 
higher expressing samples. RNA FISH against intronic BLG sequences in both hemi-
and homozygous mammary tissue provided nuclei with evidence of transcription. In 
both cases, an elongated transcription focus was evident (Figure 4.11). This 
elongated focus suggests that in transcribing cells, transcription may occur from 
multiple copies of the gene within the single array site. The size of the transcription 










































FBLG1 Round I Round 2 Round 3 
14.1 mg/ml 33.40% 20.90% 28.90% 
8.8 mg/ml 17.60% 17.10% 14.20% 
8.2mg/mi 21% 11.60% 
18.4 mg/ml 40.20% 36.50% 32.50% 
6.1 mg/ml 17.50% 12.30% 
11.4 mg/ml 22.60% 20.60% 12.90% 
5.3 mg/ml 17.40% 19.70% 10.80% 
7.7 mg/ml 19.80% 22.30% 
8.0 mg/ml 22.30% 15.90% 15.60% 
5.6 mg/ml 13.00% 7% 
8.0 mg/ml 19.50% 29% 
5.6 mg/ml 14.60% 18.80% 
6.3 mg/ml 16.70% 18.90% 8.70% 
4.4 mg/ml 10.60% 15.30% 
10.4 mg/ml 26.10% 20.70% 15.30% 
4.0 mg/ml 12.50% 17.30% 6.90% 
9.2 mg/ml 19.80% 25.50% 
4.2 mg/ml 3.70% 6.70% 2.70% 





















13.8 mg/ml 32.49% 30.40% 31.40% 31.43% 
14 mg/ml 32.38% 35.40% 28.40% 32.06% 
9.2 mg/ml 18.32% 22.30% 17.80% 19.47% 
9.6 mg/ml 22.74% 19% 20.87% 
9.7 mg/ml 22.30% 23.60% 13.90% 19.93% 
12.1 	mg/ml 25.94% 34.90% 30.42% 
7.6 mg/ml 23.42% 33.40% 28.41% 
12.5 mg/ml 11.97% 29.60% 22.90% 21.49% 
9.3 mg/ml 34.27% 22% 19.10% 25.12% 
18.2 mg/ml 38.74% 26.60% 33.50% 32.95% 
8.9 mg/ml 21.91% 29% 25.66% 
11.1 mg/ml 31.58% 30.10% 30.84% 
9.1 mg/ml 26.83% 29.20% 18.80% 24.94% 
11.7 mg/ml 26.46% 33.50% 29.98% 
7.7 mg/ml 25.88% 22.80% 24.34% 
18.8 mg/ml 37.93% 20.60% 31.00% 29.84% 
11.5 mg/ml 23.88% 28.40% 22.60% 24.96% 
12.4 mg/ml 17.69% 27.90% 22.80% 
12 mg/ml 27.02% 26.60% 23.80% 25.81% 
Table 4.4 Summary of mRNA FISH counts for both hemi and homozygote BLG/7 mice 
Each round represents one section where the numbers of active cells are evaluated 
as the proportion of alveoli expressing the transgene versus the total number of alveoli in 
view. Three separate rounds of mRNA FISH were performed, and the average of the three 
counts have been used. 
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1" round of in situ expression level results 
BLG expression vs % cells "on" 
(H blue, HH red) 
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Figure 4.10 A Graphical representation of the data from table 4.4 
1st and 2 rounds of in situ count results. The percentage of active 
cells (as determined by the proportion of alveoli in a given section actively 
expressing BLG mRNA) is plotted against the level of BLG protein in the milk 

































Y = 0.4678x + 2.8657 
= 0.8098 
2 n round of in situ expression level results 
BLG expression vs%cells "on" (HH blue, H green) 
X 
y0.5111x+25l67 	X 	,t 
= 0 8733 
X 	y = 0.4402x + 3.2509 
R2 = 0.5977 
X 	 Note: The green square is a 
	
X 	
repeat of HH1 and is not 
X 	 included in the regression line. 
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% cells "on" 
Figure 4.10 B Graphical representation of the data from table 4.4 
3rd and 4th  rounds of in situ count results. The percentage of active 
cells (as determined by the proportion of alveoli in a given section actively 
expressing BLG mRNA) is plotted against the level of BLG protein in the milk 
of an individual. Each cross represents a single individual mouse. 
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Combined in situ expression level results 
Combined data BLG expression vs % cells "on" 
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Combined data BLG expression vs % cells "on" 
(H and HH combined) 
X 
X 
y = 0.32x + 2.48 
R = 0.45 
X 
xX* 	 X 





0 	 10 	 20 	 30 	 40 	 50 
% cells "on" 
Figure 4.10 C Graphical representation of the combined in situ count results 
from table 4.4. 
The percentage of active cells (as determined by the proportion of alveoli in a 
given section actively expressing BLG mRNA) is plotted against the level of 














difficult to be sure as the size did vary in all samples depending on the cut and 
orientation of the nucleus. No evidence could be found for a spatially separate 
second transcription focus in homozygous samples, even when using rhodamine 
conjugated DiG antibody whose signal is weaker than that provided by the 
fluorescein hapten (Figure 4.11). It is possible that both alleles are transcribing, with 
co-localisation rendering it impossible to dissociate the two transcripts, resulting in 
the observed single elongated transcription focus. One control would be to check the 
number of expressing foci from an endogenous milk protein gene, although 
ultimately the intronic transcription would have to be correlated to the nuclear 
localisation of the two genomic loci in homozygous tissue samples. 
WAP primary RNA FISH suggests that both allelic loci are active for 
endogenous milk protein genes 
WAP was chosen as the control gene for primary transcription in the nucleus. The 
primary probes used fluorescein haptens. Hybridisations were performed as usual, 
and a faint signal was discernible after 9 amplification rounds, using the fluorescein-
conjugated anti-fluorescein antibody. This signal could be captured by the digital 
camera after a further 3 rounds of amplification (Figure 4.12). Two small, but 
distinct foci can be seen for WAP intronic transcription. These foci are close to, but 
physically separate, from each other. WAP is not highly expressed on day 11 of 
lactation, so the minute stature of the expression foci was anticipated. An 
extrapolation of this result would be that all endogenous milk protein genes probably 
express from both loci. 
BLG/45 homozyogus individuals express from both genomic loci 
Whilst trying to generate a working probe for endogenous gene intronic signal, 
samples of mid-lactation mammary tissue from BLGI45 homozygous individuals 
were collected. These mice are from a transgenic line known to exhibit a doubling of 
BLG expression in the homozygous population (McClenaghan et al 1995). When the 
tissues were probed for primary transcription, a single large transcription focus was 
initially revealed (Figure 4.13). Using the antibody conjugated to the less brightly 
fluorescent rhodamine conjugate, the signal resolved into two discrete foci positioned 
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Homozygous mammary tissue probed for intronic BLG transcription (Green) showing several actively 
expressing nuclei. lntronic BLG signal (A) is from antibody to DiG (Fluorescein conjusgated = 
green),which was the hapten of the oligo cocktail used. Nuclei (B) are DAPI counterstained (= blue) 
Note that size and shape vary, which could be due to different orientations of the nuclei relative to the 
cut of the section. The transcription foci were generally quite elongated, but never resolved into two 
separate foci. Green fluorescence outside of blue nucleii (C)due to auto fluorescence of tissue itself 




Close-up of transcription focus from a homozygous high expressor. lntronic BLG signal (A) is from 
antibody to DiG (Fluorescein conjugated = green),which was the hapten of the oligo cocktail used. 
Nucleus (B) is DAPI counterstained (= blue). 
Figure 4.11 	Intronic RNA FISH for nuclear BLG/7 transcription in homozygous 
sample (HHI7) 
Homozygous high expressors exhibit only a single (green) transcription focus (A) 
in each nucleus (B) visualised through DAPI staining (blue). Arrows point to 
representative examples in the images. 
Intronic BLG probe is DiG conjugated (40 ng/ml cocktail of 5 30'mer oligos) and 
visualised using antibody to DiG conjugated to fluorescein (green). Nuclei are 
counterstained with DAPI (blue) present in mounting medium. Magnification is 100 





Intronic RNA FISH for WAP 
P 
A 
Intronic WAP transcription: two green (Fluorescein) foci (A) are visible in the nucleus (B), which is 
DAPI counterstained (blue). Green fluorescence outside blue nucleus due to autofluorescence of tissue 
itself and luminescence from outside the focal plane. 
Close-up of transcription focus from a homozygous high expressor. Green intronic WAP signal (A) is 
from antibody to Fluorescein (Fluorescein conjugated), which was the hapten of the oligo cocktail 
used.The signal shows up as two small but distinct transcription foci. Image capture was difficult due 
to the small size of transcript foci and relatively faint signal compared to the blue DAPI nuclear stain. 
Green fluorescence outside blue nucleus due to autofluorescence of tissue itself and luminescence 
from outside the focal plane. 
Figure 4.12 	Intronic RNA FISH for nuclear WAP transcription in homozygote 
BLG/7 mammary tissue 
Two small, but distinct transcription foci (A) are visible in each nucleus (B), 
evidence that transcription occurs from both genomic WAP loci. 
Intronic WAP probe is Fluorescein conjugated (40 ng/mI cocktail of 6 30'mer oligos) 
and visualised using antibody to Fluorescein conjugated to Fluorescein (green). 
Nuclei are counterstained with DAPI (blue) present in mounting medium. 
Magnification is 100 X. Average nucleus diameter 2 pm. 
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Intronic RNA FISH for BLG in BLG/45 Homozyciotes 
A 
B 
BLG/45 hornozygote mammary probed for intronic BLU expression (= green) using primary probes 
labelled with DiG, and Fluorescein-conjugated antibody to DiG as secondary probe. The signal (A) is 
very bright, with an elongated transcription focus visible that may or may not come from two genomic 
loci. Nuclei (B) are DAPI counterstained (= blue). Green fluorescence outside of nucleii due to 
autofluorescence of tissue and luminescence from outside the focal plane. 
B- 
C 
BLG/45 homozygote mammary probed as above, but ibis nine the secondary probe is conjugated to 
the less brightly fluorescing Rhodamine (= red) which clearly shows that the elongated transcription 
focus above is resolved into two distinct foci (C) in the DAPI (= blue) stained nucleii (B). 
Transcription is therefore taking place at both genomic loci in BLG/45. Green and red fluorescence 
outside of nucleii due to autofluorescence and luminescence from outside the focal plane. 
Figure 4.13 	Intronic RNA FISH for nuclear BLG transcription in homozygous 
BLG/45 sample using either Fluorescein (green, top image) or 
Rhodamine (red, bottom image) conjugated antibodies to DiG. 
Homozygous BLG/45 exhibit two transcription foci (C) in nucleus (B) when DiG 
antibody is conjugated to the less brightly fluorescing Rhodamine hapten (= red). 
This proves that BLG can be simultaneously transcribed from both homologous 
genomic loci. 
Intronic BLG probe is DIG conjugated (40 ng/ml cocktail of 5 30'mer oligos) and 
visualised using antibody to DIG conjugated to Fluorescein (green) or Rhodamine 
(red). Nuclei are counterstained with DAPI (blue) present in mounting medium. 
Magnification is 100 X. Average nucleus diameter 2 .Lm. 
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close together (Figure 4.13). Two foci also became apparent if hybridisations using 
the fluorescein-conjugated antibody were left a week for the signal intensity to die 
down. This confirmed that the BLG gene is capable of bi-allelic transcription. 
These results suggested that BLG/7 homozygous mice only transcribe from one of 
the two loci, but this could not be conclusively proven with the data available. RNA 
FISH protocols would have to be adapted to perform double FISH for both primary 
RNA transcription and genomic BLG/7 sequence localisation in order to identify the 
number of active alleles. 
Intronic RNA and chromosomal FISH reveal only one active locus 
It can be clearly seen in figure 4.14 that there are two distinct genomic loci, but only 
one transcription focus for BLG/7 homozygotes. The two genomic loci appear to be 
in two different focal planes, suggesting that they occupy separate nuclear locations. 
The single transcription focus co-localises with only one of the two genomic loci, 
proving that only one of the two loci is transcriptionally active in BLG/7 
homozygous mice. This is an example of allelic exclusion, through some form of 
trans-homology interaction, a phenomenon never before reported in transgenic 
mammals. 
4.4.5 Nuclear positioning of BLG/7 alleles in liver suggestive of early 
separation of loci 
Chromosomal FISH was also performed on liver sections taken from the 
homozygous BLG/7 mice (Figure 4.14 D). The nuclei appear to be much smaller, as 
is the chromosomal signal (12x amplification needed), but again there appear to be 
two distinct signals that may be localised in different nuclear compartments. This is 
suggestive of early compartmentalisation of the BLG/7 locus, taking place before the 
liver and mammary lineages part company. 
An additional observation derived from the difficulty encountered in capturing 
images of the genomic BLG/7 location in liver nuclei. The image was captured as a 
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Intronic & qenomic FISH for BLG in BLG/7 Homozygotes 





BLG/7 homozyogte (1-11-117) mammary probed for intronic BLG expression (A) and genorrnc BLG 
location (B). Intronic transcripts (red) visualised through secondary detection of DiG labelled primary 
probes through Rhodamine-conjugated antibody to DiG (A = red signal). Genomic location (green) 
visualised through multiple amplification of fluorescein conjugated primary probes and fluorescein 
conjugated antibodies to fluorescein (B = green signal). It is evident that there is separation between 
the intronic signal (A) and a genomic signal (B). Green/Yellow fluorescence outside of nuclei (black 




i) 	 ii) 	 iii) 
	
IV) 
BLG/7 homozygote (1-11-12) tissue probed as above, with images captured for both probes (1), genomic 
signal (ii), and intronic signal (iii). This series of images shows conclusively that transcription takes 
place at only one genomic locus in homozygote mammary tissue, which is covered by the red signal in 
the double image capture (see i vs ii). The second genomic locus does not associate with a 
transcription focus. iv) is a liver nucleus from the same animal probed for genomic BLG. The image 
clearly shows two small green foci that appear to be inhabiting quite separate parts of the nucleus, 
both co-localising with brigher areas of blue fiourescence (D) which may be the condensed chromatin 
that forms the nucleolar bodies. 
Figure 4.14 	Intronic RNA & genomic DNA BLG FISH in homozygous BLG/7 tissue 
samples 
Homozygous BLG/7 show two clearly separate genomic signals (green, Ii) and only 
one transcription focus (red) which co-localises with one of the two (green) genomic 
signals (i & ii). Arrows identify nuclear transcript signal (A = red) and genomic signal 
(B = green). In I) - iii), nuclei (C) are DAPI counterstained (= blue). 
lntronic BLG probe is DiG conjugated (40 ng/mI cocktail of 5 30'mer oligos) and 
visualised using antibody to DiG conjugated to Rhodamine (Red). Genomic BLG 
probe is fluorescein conjugated (40 ng/ml cocktail of 10 30/mer oligos) and 
visualised after amplification using antibodies to fluorescein conjugated to 
fluorescein (Green). Nuclei are counterstained with DAPI (Blue) present in mounting 
medium. Magnification is 100 X. Average nucleus diameter 2.tm. 
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two-colour image using the DAPI counterstain to identify the nuclei. DAPI binds 
nucleic acids (predominantly DNA, although some binding to RNA can occur) and 
fluoreseces in the blue light range. Although the genomic probes (fluorescein tagged) 
were clearly visible under the microscope, capturing the signal was a problem due to 
the greater signal intensity of the DAPI signal, especially in the areas of presumed 
condensed chromatin that comprise the cytological structures termed chromocenters 
(Singh & Huskisson 1998) or heterochromatin foci (Netzer et a! 2001). The BLG/7 
genomic loci have an apparent tendency to co-localize with these structures, the 
DAPI signal obliterating the weaker fluorescein signal. This nuclear localisation, 
together with their apparent physical separation in a tissue where neither is 
expressed, provides additional circumstantial evidence that BLG/7 expression may 
be regulated in part by its specific nuclear localisation. 
4.5 Discussion 
The general assumption has been that if a transgene is expressed in the hemizygous 
condition, then the homozygous individuals should exhibit a doubling in both 
transcription and translation; provided the cellular machinery can cope. The validity 
of this belief has been challenged by reported homology-dependent silencing of both 
transgenes and endogenous genes (tenLohuis et a! 1995, Vaucheret 1993, Henikoff 
1997, Selker 1999, Birchler et a! 2000). The majority of papers describe plant 
systems, with a few depicting similar phenomena in Drosophila (Dorer & Henikoff 
1994, Pal-Bhadra et a! 1997, Muller et a! 1999) and fungi (Selker 1999). For 
homozygous variegating transgenes, only one paper describes a detailed 
investigation (Davies et a! 1997). Arabidopsis containing additional copies of 
endogenous chalcone synthetase gene variegated when hemizygous, with expression 
from all loci silenced in the homozygous state. Outcrossing only partially alleviated 
the silencing, possibly due to incompleter erasure of methylation during meiosis. 
To my knowledge, no investigations have been made into the effects of a 
homozygous environment on a variegating transgene in mammals. Belyaeva and co-
workers (1993) and Lloyd and co-workers (1997) looked at the behaviour of two 
different variegating constructs in the same system (both used Drosophila) (4.1). The 
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results suggested that there probably are limiting factors and mechanistic pathway 
overlaps operating in the various occurrences of PEV. Homozygous BLG/7 mice 
contain the transgenic locus on both homologous chromosomes, and the two 
homologous loci are thus initially subjected to exactly the same external and internal 
influences. 
The aim of this investigation was to test whether the highly variegating transgene 
locus of BLG/7 would behave independently when in the homozygous state, helping 
to elucidate whether mammals possess any of the homology-based trans-sensing 
mechanisms described for other systems (Wu & Morris 1999). BLG protein 
expression in milk was quantified, and mRNA FISH using wax embedded sections of 
lactating mammary tissue was used to determine the proportion of alveoli actively 
transcribing the transgene. The results for hemi- and homozygous BLG/7 populations 
were compared, and indicated that the two homologous homozygous loci do not 
variegate independently. Subsequent FISH for nuclear transcription and 
chromosomal FISH proved that BLG/7 expression is mono-allelic. 
4.5.1 The hypothesis 
As our BLG/7 mice, along with the separate BLG/45 line of mice carrying a similar 
construct at a different integration site, were the first reported transgenic mammals 
with PEV (Dobie et al 1996), further characterisation of this line was undertaken by 
breeding homozygous individuals and investigating the effect of two homologous 
variegating loci on transgene expression. Four possible outcomes were hypothesised: 
Average BLG expression doubles in the homozygous population, indicating 
independent operation of each locus without limiting factors at either the 
transcriptional or the translational stages. 
Expression is upregulated but not doubled in the homozygous populations, 
indicating a limiting step present at the transcriptional or translational stages. 
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The homozygous population exhibits expression levels equal to the hemizygote 
population, indicating some form of homology—effect and/or a rate-limiting step. 
Expression is downregulated in the homozygous population, indicating that some 
form of homology-dependent silencing is activated (a phenomenon so far only 
reported in plants, Drosophila, fungi and yeast) 
Option 2 could be eliminated immediately, as a second variegating line of mice 
containing the 3-lactoglobulin transgene (BLG/45) can secrete up to 1.5 times more 
transgenic protein in their milk in their hemizygous state than the highest BLG/7 
hemizygous expressors (Dobie et al 1996). Homozygous BLG/45 mice secrete a 
mean value of 33 mg/ml BLG in their milk, close to twice the highest values 
measured for hemizygous BLG/7 individuals (McClenaghan et a! 1995, Dobie et al 
1996). The BLG/45 expression data thus indicate that the cellular machinery is 
capable of high protein throughput, and should therefore not pose a rate-limiting step 
for BLG/7 transgene expression. Nevertheless, the different integration locus of 
BLG/7 may impose a positional disadvantage in recruitment of transcription factors 
that may only become evident when two loci compete for a limited resource. Support 
for a possible positional disadvantage is provided by BLG/7 location to chromosome 
15, whilst endogenous casein genes reside on chromosome 5 and WAP on 
chromosome 11. In addition, Wilkie and colleagues (1999) suggest that 
chromosomal position may determine nuclear localisation of a gene. If this is true in 
mice as well as Drosophila, then it is likely that BLG/7 is not located near any of the 
endogenous milk protein genes in the nucleus. 
Two of the remaining three hypothetical outcomes are loosely based on an 
extrapolation of Balasov & Makunin's theory (1.7.7). Assuming that the 
homozygous loci act independently of each other, with heterochromatic proteins in 
limiting supply, I would expect twice or more than double the amount of expression 
when compared to the hemizygous population. This scenario equates to option 1. The 
logic behind this is that two loci double the likelihood that a given cell will contain a 
transcriptionally active transgene locus compared to single locus animals. If a 
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limiting heterochromatic factor is titrated out, there is increased chance that both loci 
will be operational in the same cell, more than doubling the output. This scenario 
assumes that the homologous loci operate independently of each other. An 
alternative scenario presents itself where the homologous loci pair and interact. If 
this occurs, with heterochromatin components in abundance, the CICs of both sites 
could cooperatively silence both alleles to a greater extent than expected for 
independent loci, giving rise to decreased expression levels when compared to the 
hemizygotes. This scenario equates to option 4. 
Having eliminated option 2 of the four hypothetical outcomes, and assigned options 
1 and 4 to the two scenarios outlined above, only hypothetical outcome 3 remains to 
be accounted for. This outcome was not considered to represent a likely event, as no 
evidence could be found in the literature to support it, until the publication of a 
recent transgenic plant paper. A transgenic line is described where homozygous 
plants exhibit expression levels identical to that of their hemizygous counterparts 
(Matzke et al 2001). Earlier investigations had been suggestive of such an event, but 
had failed to characterise the phenomenon in detail (Neuhuber et a! 1994). 
4.5.2 Transgenic BLG protein expression does not double in homozygous 
population compared to heniizygous results 
Both populations display variegated BLG protein expression in the milk (Figure 4.1 
& 4.3, tables 4.2 & 4.3). The near doubling in the minimum expression observed for 
the homozygous population compared to the hemizygous population is not 
unexpected. Assuming the two homologous loci operate independently of each other, 
the homozygote mice have twice the likelihood of at least one of the two sites 
becoming activated than the hemizygote mice have with only one transgenic locus. 
The observation of a maximum expression level of 20 mg/mi for both BLG/7 
populations is equivalent to hypothetical outcome 3 (4.5.1), where equal expression 
levels are exhibited by both hemi- and homozygous populations due to either 
homology effects or a rate-limiting step. As transgenic line BLG/45 demonstrates 
that expression from this gene can far exceed 20 mg/ml (4.5.1), it was considered 
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unlikely that the homozygous expression pattern could be attributed to any 
physiological constraint. This suggested that the absence of doubling of maximum 
BLG expression in the homozygous population must be due to a property of the 
transgene array at the site of integration, possibly due to a homology effect. 
Three possible explanations for the milk protein results were suggested: 
Each active homozygous cell displays only half the activity of an equivalent 
hemizygous cell. 
Each active homozygous cell displays twice the activity of the equivalent 
hemizygous cell, with the homozygous nature of the locus rendering it twice 
as susceptible to inactivation. 
Each active cell displays an equal level of activity irrespective of genetic 
composition. 
Scenario 1 is unlikely as it cannot account for the doubling of minimum BLG 
expression levels in the homozygous population. Scenarios 2 & 3 can both account 
for the observed protein expression patterns, and equate to hypothetical outcomes 3, 
and 1 & 2 respectively (4.5.1). The two scenarios can be differentiated by 
determination of the number of expressing cells required to give rise to a given level 
of protein expression in both populations. Scenario 2 would require that homozygous 
individuals display half the number of expressing cells than the equivalent 
hemizygous sample, whereas scenario 3 proposes that equal number of cells will be 
needed to generate the same protein level in the milk of both populations. To 
differentiate between these two scenarios, mRNA FISH was performed on wax 
embedded mammary tissue and the proportion of alveoli actively expressing the 
transgene were determined for each individual. 
The latter two scenarios both hinge on some form of homology effect taking place, 
either to silence transcription from one or both loci, or to reduce transcription pace. 
Although there are plenty of reports in the literature citing homology dependent gene 
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silencing (1.2 & 4.1), these examples are not representative of what is seen for 
BLG/7 mice. Transcription is not silenced, just maintained at hemizygous levels in 
both populations. Transvection in Drosophila involves pairing of homologues, with 
inactivation of both a frequent result (1.2.3). This is also the case for most examples 
of paramutation in plants, although sometimes expression persists at a lower level 
(1.2.3). These two phenomena involve the pairing of two dissimilar gene alleles, 
whereas BLG/7 homozygotes contain two identical loci. The involvement of either 
transfer of epigenetic marks or sequestration to a heterochromatic nuclear 
compartment in these documented phenomena (1.2), suggests possible mechanistic 
links to BLG/7 homozygote behaviour. The location of BLG/7 close to centromeric 
heterochromatin may facilitate pairing and exchange of heterochromatin between the 
two loci. Therefore, despite the differences in the outcomes of transvection and 
paramutation to BLG/7 homozygote expression patterns, it is possible that an 
analogous process is involved in BLG/7 expression control. 
4.5.3 Hemi- and homozygote BLG/7 mice exhibit similar cellular expression 
patterns 
Despite the manual evaluation of the number of expressing cells, the process 
remained accurate enough to distinguish between a halving in the number of 
expressing cells in homozygous samples compared to equivalent hemizygous 
expressors. The results show conclusively that there is no doubling or halving of the 
number of expressing cells when the two populations are compared (Tables 4.4-4.6). 
Homozygous BLG/7 expression is therefore either from both loci at half the normal 
activity, or from only one of the two loci. Some form of trans-homology interaction 
is thus likely to be taking place in these mice. 
The observation that different views from the same section, as well as views from a 
different section of the same tissue can vary drastically, underpins the variability of 
the expression patterns seen in BLG/7 mice. A variegated pattern of expression that 
varies throughout the mammary tissue adds an additional level of complexity to the 
assignation of correct estimation of the percentage of expressing cells that are 
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required to generate a given level of protein. This helps explain the "wobble" in the 
graphs of figure 4.10 (a-c). 
4.5.4 Probes for BLG/7 nuclear transcription reveals a single focus of 
transcription in homozygous samples, whereas both homozygous BLG/45 
mice and samples probed for WAP reveal two foci. 
RNA FISH against intronic sequences exhibited a single elongated focus of 
transcription in both hemi- and homozygous mammary tissue (Figure 4.11). The 
elongated nature of the transcription focus suggests that in active cells, transcription 
may be taking place from more than one of the gene copies along the transgene 
array. Although the single focus is suggestive of transcription from one locus, it 
could not be discounted that the homozygous loci could co-localise. 
Detection of nuclear transcription from endogenous whey acidic protein (WAP) 
revealed two small foci, close to but physically separate from each other (Figure 4. 
12). As WAP is not highly expressed relative to the caseins on day 11 of lactation, 
the minute stature of the transcription foci compared to BLG/7 was anticipated. An 
extrapolation of this result would be that endogenous milk protein expression 
probably takes place from both alleles. Although it is presumed that most genes 
exhibit bi-allelic expression in all tissues, there have to my knowledge not been any 
reports into concerted examination of multiple endogenous gene expression patterns 
at the nuclear level. 
Examination of homozygote samples from the line of transgenic BLG mice known to 
exhibit a doubling in expression levels from homozygote mice (McClenaghan et al 
1995) enabled resolution of what was initially seen as a single large transcription 
focus into two distinct foci (Figure 4.13). This confirmed that the BLG gene was 
capable of bi-allelic transcription. 
4.5.5 BLG/7 expression is monoallelic 
Double FISH for nuclear transcription and genomic DNA revealed a single focus of 
transcription that co-localised with only one of the two genomic signals (Figure 
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4.14). This proved that some form of trans-homology interaction occurs in BLG/7 
homozygous mice, which leads to allelic exclusion. In other words, in cells that are 
capable of actively expressing BLG, some mechanism operates to prevent expression 
from more than one of the two loci. This is the first reported trans-homology effect 
in transgenic mammals. 
The observation that the two genomic signals appear to occupy different nuclear 
locations (focusing so that both signals could be imaged together proved difficult, 
suggesting that they do not occupy the same focal plane) suggests that both active 
and silent states are irrevocably committed in the cell. I saw no evidence for 
switching of expression states between the alleles, as seen for globin genes (Wijgerde 
et a! 1995) where signals from two loci were sometimes retained in the same 
nucleus. It cannot be totally discounted that switching does not take place in my 
samples, the combination of low levels of cells expressing the transgene (40 % or 
less), with the low probability of capturing such a switch taking place, makes it 
possible that switching could be overlooked. The spatial separation of the two 
homologous loci in the nucleus does, however, argue against a model where 
expression switches from one locus to the other. It cannot, therefore, be discounted 
that expression from both loci may occur early in lactation, with one of the two loci 
inactivated in an analogous process to that determining either X-chromosome 
inactivation or post-transcriptional gene silencing (1.7.8, 1.2.1). 
Monoallelic expression from endogenous genes 
Monoallelic expression is already well documented for imprinted and X-linked genes 
(Tilghman 1999, Panning & Jaenisch 1998). There is also mounting evidence that 
other genes can display monoallelic expression (Chess 1998). IL-4 alleles in CD4+ T 
cells are independently regulated, and display both mono- and biallelic expression. 
This pattern of expression is "fixed" and clonally inherited, with the suggestion that 
IL-4 gene expression is random and established at a late stage of development (Bix 
& Locksley 1998). Another interleukin, IL-2 is also reported to exhibit monoallelic 
expression in some T-cells (Hollander eta! 1998, Rhoades et a! 2000), with other T-
cells exhibiting bialilelic expression (Rhoades et a! 2000). Randomised monoallelic 
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expression may also be the route used to generate functionally distinct olfactory 
neurons (Chess et a! 1994). These reports suggest that there are more endogenous 
genes than previously thought that may exhibit monoallelic expression, at least in 
certain cell types. The monoallelic expression seen in homozygous BLG/7 mice may 
therefore be the result of its integration site rather than the transgene array per Se. 
This is supported by BLG/45, where expression is from both loci (Figure 4.13). What 
none of the papers address is the actual mechanism by which one allele is 
functionally silenced, but not the homologue. Imprinting may hold a clue, at least as 
a plausible explanation for BLG/7 expression. 
Although there are no known imprinted regions on mouse chromosome 15, where 
BLG/7 is integrated close to centromeric heterochromatin (somewhere between 
cytological bands B2 - second half of A2), it is possible that some of the genes close 
to the integration site will be imprinted and thus influence BLG/7 expression. There 
are precedents for location in imprinted regions influencing gene expression 
(Tilghman 1999, Jeong et al 2000), and genes can be influenced by events that take 
place at a considerable distance. Deletions up to 1Mb away have been documented to 
affect expression of imprinted genes in Praeder-Willy syndrome (Tilghman 1999). 
There is also the possibility that the genes close to the transgene integration site are 
monoallelically expressed as part of a dosage compensation mechanism. This 
scenario appears increasingly plausible when one discovers that the integration site 
must be close to a cluster of hormone receptor genes that include Ghr, IL-7r, Lift, 
Npr 3, Osmr, Prl r, Ptgerep 2 & 4 (Jackson Lab Mouse Genetics Database). There is 
evidence for the involvement and synthesis of growth hormone receptor in 
differentiating and lactating mammary (Feldman et a! 1993, Glimm et al 1990). The 
involvement of the prolactin receptor in mammary function is well documented. It is 
not impossible that at least these two genes, whose involvement in mammary gland 
development and function is known, contribute to the regulation of these events 
through the mechanism of dosage compensation. BLG/7 may exhibit monoallelic 
expression due to close proximity to Ghr and Prlr, with shared temporal activation an 
accessory to the effect. As at least two interleukin genes are monoallelically 
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expressed, it is possible that control of the effects of the hormones is also exerted 
through receptor availability, therefore the IL-7r may also be monoallelically 
expressed. In this scenario, integration close to the IL-7r gene could also be 
responsible for the monoallelic expression pattern of BLG/7. 
The monoallelic expression of genes close to the BLG/7 integration site may exert an 
effect on BLG/7 by ensuring that one of the two loci is automatically silenced along 
with the endogenous gene locus chosen for inactivation. The homologous BLG/7 
locus could then be incorporated into a potentially active domain, but the final 
transcriptional status of the locus is controlled by factors not related to the control of 
expression of the monoallelically expressed endogenous gene. The potentially active 
locus is regulated by the mechanism responsible for the inherent variegating 
phenotype of BLG/7, which are independent of any other regulatory mechanisms in 
operation on nearby endogenous genes. 
An alternative variation on the theme above would be that there is a selective 
pressure to keep one of the loci active, due to the presence of a vital gene near the 
integration site. The cells where both loci are inactivated could be rescued by 
intercellular interactions with active cells. I find this improbable, as some 
homozygote tissues exhibit no more than 10-15% active cells. The active cells are 
usually located in discrete patches, with large areas of the mammary gland lacking 
any cells actively expressing BLG. I cannot envision that the remaining 85-90% of 
mammary epithelial cells can be rescued by the expression levels of the few active 
cells. 
Array structure as causative agent in trans-homology effect 
The multicopy nature of the BLG/7 insertion may initiate heterochromatin formation 
in cis, with the close proximity to centromeric heterochromatin increasing the 
probability that heterochromatin will form at the site. Each site may be independent 
of the other for formation of a repressive chromatin structure, but there may also be 
intermediate formation of heterochromatin at the site that does not constitute a 
repressive structure (due to the limited availability of repressive factors). Only if both 
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sites are activated, are the two homologous loci exposed to each other. This contact, 
in the form of pairing, ensures that the sub-critical amounts of heterochromatic 
formation at both loci also come into contact, and transfer of heterochromatin from 
one site to the other enables inactivation of one of them (Balasov & Makunin's 
model operating in trans, 1.7.7). 
The pairing of the two sites may be facilitated by the proximity to centromeric 
heterochromatin. It is believed that the heterochromatin plays a central role in the 
meiotic chromosomal pairing process (Renauld & Gasser 1997). The presence of 
repetitive sequences such as LINEs, SINEs, multiple pseudogenes and rRNA gene 
clusters may also contribute to this process. 
4.5.6 Nuclear positioning of BLG/7 alleles 
Homozygous BLG/7 tissues probed for genomic BLG/7 localisation exhibit two 
distinct signals that appear to be physically separate (Figure 4.14). This holds true for 
mammary tissue, where the active and silent loci occupy different nuclear locations. 
Prelimenary investigations in liver samples suggest that this physical separation of 
the loci also occurs in tissues where milk protein expression does not take place 
(Figure 4.14). 
These observations suggest that the decision with regards to the activational status of 
the transgene locus may occur early in development (before cells differentiate into 
liver and mammary lineage pathways), with nuclear localisation a possible key 
player in maintaining the decision. These are prelimenary observations and further 
investigations are needed using samples from other tissues, as well as trying to 
establish their relative positions in the nucleus with regards to key factors such as 
heterochromatic proteins and milk protein genes. 
4.5.7 Theoretical Model 
Irrespective of the details of how monoallelic expression is determined, BLG/7 
expression remains complex even when in the hemizygous state. Any theory as to 
when and how silencing of the transgene array is achieved has to be able to explain 
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both hemizygous and homozygous expression profiles. Both variegation and allelic 
exclusion have to be catered for, as well as the observation that there is expression 
from less than 50% of all cells, even in the highest expressing individuals. There is 
no clear way to reconcile these observations with current knowledge of gene 
expression control, I have therefore attempted to suggest a possible scenario. My 
model encompasses a three-step process, the first two steps common to both 
populations, with the third step exclusive to the homozygote condition (Figure 4.15). 
A detailed explanation of the theoretical model depicted in figure 4.15 
The first step takes place early in development, possibly coincidental with X-
inactivation determination. A random process permanently inactivates the BLG/7 
locus in approximately 50% of all the cells. There is no information in the literature 
that can cast a light on what such a process may be, although it could be linked to 
monoallelic expression of one or more of the endogenous genes close to the 
integration site. The remaining 50% contain a potentially active locus. In 
homozygous cells, inactivation of one locus also inactivates the homologous locus. 
This may be a trans-homology interaction step, and I envision a mechanism 
analogous to trans-inactivation of the brown locus in Drosophila. The multicopy 
nature of the transgene, coupled with the integration site close to centromeric 
heterochromatin, may render both sites susceptible if one of the pair is inactivated 
through ectopic modification. The modification and proximity to the centromere may 
drag both loci into a heterochromatic compartment in the nucleus, so that although 
only one of the sites may be physically silenced, the other copy, by its nuclear 
location, cannot become activated either. 
The second step occurs later in development. A random but stochastic process 
proceeds to determine whether the potentially active (potentiated) loci will remain 
active or silenced. Once this decision is made, the cell is committed and passes on 
the decision to all its progeny. This potentiation versus activation step has some 
experimental evidence to back it up (Bulger & Groudine 1999). In the hemizygous 
mice, this final event leads to the observed variegated expression pattern. 
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Theoretical Model Depicting Inactivation events for 
Hemi- (H) and Homozygous (HH) BLG/7 
HH 
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in only half 
of cells, but 
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Figure 4.15 	Theoretical Model explaining BLG/7 homozygote monoallelic 
expression. 
H = BLG/7 locus, X = inactivated BLG/7 locus, I = locus without BLG/7 insertion 
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In the homozygous mice, each potentiated cell has two potentially active loci. The 
random process of step 2 has four possible outcomes, as seen in figure 4.15. One of 
the possible outcomes is that both loci are activated, but the results from the FISH for 
both rnRNA and intronic transcription indicate that this does not take place. I have 
therefore included a putative 3 rd  step which is only operational when both alleles are 
activated in a single cell. This step, like one of the earlier steps, involves trans-
homology interactions, but in this case, the outcome is radically different. One allele 
is inactivated whilst the other remains active. Perhaps the open configuration of both 
paired loci contains only enough bound heterochromatic protein components 
between them to inactivate one locus. The locus with the highest concentration of 
heterochromatic proteins may, through increased density of bound heterochromatin, 
possess a higher affinity for the available heterochromatic complexes. A directional 
flow of heterochromatin ensues until the one locus has become entirely 
heterochromatinised, disrupting the pairing interaction. The disruption of pairing 
allows the sequestration of the inactivated locus to a heterochromatic region of the 
nucleus, spatially separate from the active locus. 
This model is the only one that I can think of which accounts for that no more than 
50% of cells are transcriptionally active in either population, the within line 
variegation, the identical maximum expression level for both hemi- and homozygotes 
and the doubling in the minimum expression levels. 
There is only one other report of a similar occurrence of transgenic allelic exclusion, 
and that is in transgenic plants (Matzke et a! 2001). Whereas I have FISH results to 
prove that only one of the two alleles in the homozygous mice remains active, the 
Matzke paper relies on the results of an outcrossing experiment. The outcrosses from 
the homozygous plants segregate 50:50 active and silenced progeny, which suggests 
that only one of the two loci is active in the parental population, and that this 
epigenetic modification is maintained through the germline. As the animal germline 
is segregated much earlier in development, there may not be any germline 
transmission of BLG.7 locus activation states, although the relevant outcrossing 
experiments should still be done to eliminate this (see chapter 6). 
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1st set ON 1/4 ON 1/2 ON 3/4 ON 1/8 ON 1/16 ON OFF SUM % ON 
HI 	a 27 5 7 13 2 2 11 233 33.4 
b 0 8 0 0 1 0 35 
c 7 11 5 9 0 6 17 
d 0 7 3 1 0 0 21 
e 3 8 2 6 0 0 16 
SUM 37 39 17 29 3 8 100 
% 15.9 16.7 7.3 12.4 1.3 3.4 42.9 
H2a0 0 0 0 0 0 17128 17.6 
b 1 13 5 4 0 0 7 
C 0 4 5 1 0 5 11 
d 0 4 5 0 0 0 14 
e  5 6 1 0 0 9 
f 0 0 0 0 0 0 11 
SUM 1 26 21 6 69 
% 0.8 20.3 16.4 4.7 0.0 0.0 53.9 
H3a4 6 2 3 0 0 8176 21.0 
b 0 14 0 2 0 0 20 
C 0 4 2 2 0 0 45 
d 2 12 5 13 0 0 6 
e 0 10 0 0 0 0 16 
SUM 6 46 9 20 0 0 95 
% 3.4 26.1 5.1 11.4 54.0 
H4 a 5 9 7 22 0 0 13 196 40.2 
b 0 14 5 5 0 0 16 
c3 5 4 8 0 0 1 
d  5 9 5 0 0 2 
e 1 22 6 14 0 0 15 
SUM 9 55 31 54 0 0 47 
% 4.6 28.1 15.8 27.6 0.0 0.0 24.0 
H5  1 9 8 3 0 0 29220 17.5 
b 0 25 5 3 0 0 10 
C 0 5 3 1 0 0 29 
d 0 10 6 1 0 0 19 
e 1 2 3 7 0 0 40 
SUM 2 51 25 15 0 0 127 
% 0.9 23.2 11.4 6.8 0.0 0.0 57.7 
H6a0 8 5 9 0 0 18167 22.6 
b 0 11 1 1 0 0 6 
C 0 12 1 5 0 0 16 
d 3 4 0 6 0 0 17 
e 0 6 3 5 0 0 30 
SUM 3 41 10 26 0 0 87 
% 1.8 24.6 6.0 15.6 0.0 0.0 52.1 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 1/9 
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1st set ON 1/4 ON 1/2 ON 3/40N 1/8 ON 1/16 ON OFF SUM % 
H7a0 4 4 7 6 19 19209 17.4 
b 0 2 1 1 3 3 14 
CO 13 5 4 4 8 21 
d 	1 17 4 4 0 0 18 
e  4 2 1 4 9 7 
SUM 1 40 16 17 17 39 79 
%0.5 19.1 7.7 8.1 8.1 18.7 37.8 
H8 	a  7 0 0 16224 19.8 
b  7 5 1 23 
c  17 6 3 17 
d3 31 5 5 19 
e  13 11 3 32 
SUM 3 75 27 12 107 
% 1.3 33.5 12.1 5.4 47.8 
H9 	a  7 5 6 21 211 22.3 
b2 16 3 5 26 
c  7 2 3 20 
d4 10 10 6 17 
e  17 0 1 22 
SUM 7 57 20 21 106 
% 3.3 27.0 9.5 10.0 50.2 
H10 a 0 11 0 0 10 144 13.0 
b  9 5 2 31 
CO 4 2 2 21 
d  6 0 0 23 
e  5 4 2 7 
SUM 0 35 11 6 92 
% 0.0 24.3 7.6 4.2 0.0 0.0 63.9 
HIl a 	0 14 2 2 0 0 12 222 19.5 
b 	1 10 5 10 0 0 16 
c  1 16 4 42 
d 0 16 7 0 0 0 34 
e 0 6 5 0 0 0 18 
SUM 2 47 35 16 0 0 122 
% 0.9 21.2 15.8 7.2 0.0 0.0 55.0 
H12a0 9 6 2 0 0 44240 146 
b 4 10 7 4 0 0 33 
c 0 8 6 0 0 0 30 
d 0 5 3 0 0 0 41 
e 	1 8 6 2 0 0 11 
SUM 5 40 28 8 0 0 159 
%2.1 16.7 11.7 3.3 0.0 0.0 66.3 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 2/9 
167 
1st set ON 1/4 ON 1/2 ON 3/4 ON 1/8 ON 1/16 ON OFF SUM % ON 
H1,3 a 	0 4 2 3 0 0 28 222 16.7 
b 0 14 0 0 0 0 23 
C 9 2 2 5 0 0 40 
d 2 11 6 2 0 0 33 
e 0 7 8 0 0 0 21 
SUM 11 38 18 10 0 0 145 
% 5.0 17.1 8.1 4.5 0.0 0.0 65.3 
H14 a 0 10 6 4 0 0 50 243 10.6 
b 0 13 3 0 0 0 43 
c 0 19 5 0 0 0 14 
d 0 4 0 0 0 0 40 
e 0 7 5 0 0 0 20 
SUM 0 53 19 4 167 
%0.0 21.8 7.8 1.6 68.7 
H15a0 4 5 0 0 0 6 166 26.1 
b 0 11 4 2 0 0 27 
C 0 5 5 5 0 0 12 
d 2 6 4 3 3 4 24 
e9 4 5 7 0 0 9 
SUM 11 30 23 17 3 4 78 
%6.6 18.1 13.9 10.2 1.8 2.4 47.0 
H16 12.5 
b 0 12 11 4 0 0 44 210 
CO 10 0 0 0 0 36 
d 0 12 1 0 0 0 32 
e  22 5 1 0 0 20 
SUM 0 56 17 5 0 0 132 
%0.0 26.7 8.1 2.4 0.0 0.0 62.9 
H17a0 0 0 0 30188 19.8 
b  16 8 0 16 
C  9 5 1 7 
d  8 7 3 24 
e3 20 10 4 17 
SUM 3 53 30 8 94 
%1.6 28.2 16.0 4.3 50 
H18a0 15 6 3 15223 22.4 
b  17 0 0 31 
c7 8 1 1 26 
dl 17 5 8 21 
e4 6 4 7 20 
SUM 12 63 16 19 113 
%5.4 28.3 7.2 8.5 50.7 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 3/9 
168 
1st set ON 1/4 ON 1/20N 3/40N 1/80N 1/160N OFF SUM % 
H19 a 0 5 0 0 3 6 26 219 	3.7 
b 5 0 2 3 3 32 
CO 0 0 0 0 0 43 
d 0 0 0 0 0 26 33 
e 0 0 0 7 6 19 
SUMO 10 0 2 13 41 153 
% 0 4.6 0.0 0.9 5.9 18.7 69.9 
H20 a 0 9 2 1 2 6 22 223 	11.0 
b 5 2 1 0 0 56 
C 0 3 1 0 4 2 35 
d 1 5 4 3 3 0 18 
e2 3 3 5 0 4 21 
SUM 3 25 12 10 9 12 152 
% 1.3 11.2 5.4 4.5 4.0 5.4 68.2 
2nd set ON 114 ON 1/2 ON 3140N OFF SUM % 
H2 	a 0 6 0 0 20 178 
b 0 7 0 0 19 17.1 
C 0 17 0 0 25 
d 0 14 1 2 15 
e 0 0 19 0 4 
f 0 12 10 0 7 
SUM 0 56 30 2 90 
% 0 31.5 16.9 1.1 50.6 
H4 	a 10 16 9 12 27 230 36.5 
b 0 12 3 2 13 
c 12 10 5 6 10 
d 2 11 2 2 23 
e 3 14 6 9 11 
SUM 27 63 25 31 84 
% 12.6 29.3 11.6 14.4 39.1 
H5 	a 0 5 1 0 29 165 12.3 
b 2 11 2 1 16 
c 0 14 1 0 20 
d 0 12 0 0 17 
e 0 20 0 0 14 
SUM 2 62 4 1 96 
% 1.2 37.6 2.4 0.6 58.2 
H6 	a 0 10 0 0 16 170 20.6 
b 0 27 5 4 0 
C 0 13 2 3 14 
ci 0 25 0 0 18 
e 0 21 3 1 8 
SUM 0 96 10 8 56 
% 0 56.5 5.9 4.7 32.9 
Table 4.5 BLG mRNA FISH counts for hemizygote BLG/7 population page 4/9 
169 
2nd set ON 1/4 ON 1/2 ON 3/4 ON OFF SUM % ON 
H7a1 17 3 3 22204 19.7 
b 0 14 1 1 16 
c 3 5 2 3 28 
d 	1 18 3 5 13 
e 0 23 2 2 18 
SUM 5 77 11 14 97 
%2.5 37.7 5.4 6.9 47.5 
H8 	a  17 4 3 24250 223 
b4 26 4 2 8 
c 0 22 7 3 19 
d 2 14 7 3 30 
e 	1 24 3 3 20 
SUM 7 103 25 14 101 
% 2.8 41.2 10 5.6 40.4 
H9 	b  10 2 1 16136 15.9 
C 0 20 3 2 8 
d 2 4 2 3 13 
e 0 7 0 0 15 
f 0 11 2 0 15 
SUM 2 52 9 6 67 
% 1.3 34.4 6.0 4.0 44.4 
HIla 	1 7 3 4 30 245 
b  13 4 2 24 29.0 
C 1 12 4 7 16 
d 7 5 5 11 4 
e 4 10 7 5 8 
f  6 2 2 32 
SUM 22 53 25 31 114 
% 9.0 21.6 10.2 12.7 46.5 
H12 	0 12 7 0 25 209 18.8 
b 0 15 1 1 17 
c 0 13 11 2 12 
d 0 20 0 1 21 
e 0 23 6 4 18 
SUM 0 83 25 8 93 
% 0.0 39.7 12.0 3.8 44.5 
H13 	0 17 5 2 33 220 18.9 
b 6 12 6 7 20 
C  12 1 4 36 
d  7 0 0 24 
e  10 3 5 10 
SUM 6 58 15 18 123 
%2.7 26.4 6.8 8.2 55.9 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 5/9 
170 
2nd set ON 1/40N 1/2 ON 3/40N OFF SUM % 
H14 	3 15 5 3 14 226 15.3 
b  8 0 5 39 
CO 7 1 0 23 
d 0 31 2 2 21 
e 0 17 1 0 29 
SUM 3 78 9 10 126 
% 1.3 34.5 4.0 4.4 55.8 
H15 	0 12 3 1 20 217 20.7 
b 0 31 5 2 6 
C  12 0 6 28 
d 5 18 3 2 35 
e 0 10 5 4 9 
SUM 5 83 16 15 98 
%2.3 38.2 7.4 6.9 45.2 
H16 a 0 13 2 0 24 220 17.3 
b 3 18 6 5 25 
c 3 16 4 2 28 
d 0 13 1 0 24 
e 0 11 2 2 18 
SUM 6 71 15 9 119 
%2.7 32.3 6.8 4.1 54.1 
H17 	0 31 4 1 13 221 25.5 
b 0 24 5 4 7 
c 3 15 4 9 12 
d 3 20 7 7 13 
e 0 8 0 0 31 
SUM 6 98 20 21 76 
% 2.7 44.3 9.0 9.5 34.4 
H18 	0 12 8 0 16 201 14.6 
b 0 7 0 0 39 
C 3 12 1 5 28 
d 0 12 5 1 25 
e 0 9 2 1 15 
SUM 3 52 16 7 123 
% 1.5 25.9 8.0 3.5 61.2 
H19a0 7 2 0 20141 6.7 
b  0 0 0 37 
CO 12 0 0 15 
d  0 0 0 18 
e  7 1 2 20 
f  0 0 0 15 
SUM 0 26 3 2 110 
% 0 18.4 2.1 1.4 78.0 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 6/9 
171 
2nd set ON 1/40N 1/2 ON 3/4 OFF SUM % 
H20 	0 9 0 0 9 147 15.5 
b 0 12 1 2 11 
c 0 7 1 1 18 
d 2 10 7 6 12 
e  0 0 0 24 
f  0 0 0 15 
SUM  38 9 9 89 
%1.4 25.9 6.1 6.1 60.5 
3rd set ON 1/40N 1/2 ON 3/4 ON 1/8 ON 1/16 ON OFF SUM % 
HI 3 a 0 4 2 1 2 2 25 292 	20.9 
3b 0 5 3 2 6 6 6 
3c 	1 5 2 4 7 4 10 
3d 	1 9 5 9 1 3 9 
3e 	1 7 4 5 2 5 16 
3 f 0 5 2 1 3 2 17 
3g 2 7 2 3 2 3 21 
3h 	2 6 3 6 1 4 8 
310 4 1 1 1 2 9 
SUM 7 52 24 32 25 31 121 
%2.4 17.8 8.2 11.0 8.6 10.6 41.4 
H23a0 2 0 0 0 5 19366 14.2 
3b 3 4 2 3 5 2 21 
3c 0 3 2 3 1 1 32 
3d 0 3 1 0 2 1 27 
3e 0 1 0 0 2 3 23 
3f 0 4 2 1 1 1 21 
3g 0 2 1 1 1 1 12 
3h 	1 12 0 1 2 2 13 
31 	1 6 4 0 6 3 15 
3j 	8 6 3 10 1 0 18 
3k 0 3 0 1 0 20 11 
SUM 13 46 15 20 21 39 212 
% 3.6 12.6 4.1 5.5 5.7 10.7 57.9 
H33a 0 2 1 0 1 8 18 291 	11.6 
3b 0 0 0 0 0 5 32 
3c 0 2 1 1 2 1 42 
3d 
3e 0 2 0 1 2 7 33 
3f 0 7 2 1 0 5 11 
3g 4 6 8 10 4 1 8 
3h 0 3 2 2 3 6 16 
31 	0 7 1 0 1 1 21 
SUM 4 29 15 15 13 34 181 
% 1.4 10.0 5.2 5.2 4.5 11.7 62.2 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 7/9 
172 
3rd set ON 1/40N 1/20N 3/40N 1/80N 1/160N OFF SUM % 
H43a9 8 3 9 0 0 6 338 32.5 
3b 1 12 2 2 2 2 8 
3c 1 9 1 3 6 4 12 
3d 4 9 2 6 2 3 10 
3e 4 6 4 5 2 4 16 
3f12 4 5 6 3 5 6 
3g 3 5 5 4 2 3 20 
3h 1 2 3 3 4 5 18 
31 6 8 6 5 6 3 8 
SUM 41 63 31 43 27 29 104 
%12.1 18.6 9.2 12.7 8.0 8.6 30.8 
H6 3a 0 1 0 0 0 2 51 213 12.9 
3b 0 3 3 2 6 1 15 
3c 0 4 1 2 0 20 10 
3d 0 3 2 4 0 1 8 
3e 0 6 0 1 0 17 7 
3f 3 5 2 6 1 5 21 
SUM 3 22 8 15 7 46 112 
% 1.4 10.3 3.8 7.0 3.3 21.6 52.6 
H7 3a 1 9 3 7 1 2 17 287 10.8 
3b 2 6 2 5 1 2 38 
3c 0 7 3 4 2 3 11 
3d 0 1 0 0 0 2 41 
3e 0 1 1 1 0 2 25 
3f 0 5 2 0 4 0 45 
3g 0 0 1 0 3 1 26 
SUM 3 29 12 17 11 12 203 
% 1.0 10.1 4.2 5.9 3.8 4.2 70.7 
H93a4 2 3 7 1 1 3931415.6 
3b 4 4 5 8 2 6 15 
3c 0 0 0 0 0 0 71 
3d 0 7 0 4 3 2 31 
3e 0 1 3 7 3 3 34 
3f 3 5 6 4 0 4 22 
SUM 11 19 17 30 9 16 212 
% 3.5 6.1 5.4 9.6 2.9 5.1 67.5 
H10 	3a 0 1 3 1 3 2 12 195 7.0 
3b 0 3 0 0 2 6 23 
3c 0 4 2 1 1 4 18 
3d 0 3 1 1 2 5 32 
3e 0 2 2 1 4 5 25 
3f 0 0 0 0 2 4 20 
SUM 0 13 8 4 14 26 130 
% 0.0 6.7 4.1 2.1 7.2 13.3 66.7 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 8/9 
173 
3rd & 4th set ON 1/4 ON 1/2 ON 3/4 ON 1/8 ON 1/16 ON OFF SUM % ON 
H13 3a 0 2 2 2 4 8 36 353 
3b 	1 9 6 3 2 2 49 
3c 0 0 0 0 0 0 61 
3d 	1 4 1 4 1 4 30 
3e 0 4 9 6 3 1 49 
3f0 4 0 0 1 5 39 
SUM 2 23 18 15 11 20 264 
% 0.6 6.5 5.1 4.2 3.1 5.7 74.8 
H15 3a 0 8 6 0 1 2 32 
_____ 
I 307 I 15.3 
3b 0 2 7 3 2 2 12 
3c 0 6 4 1 1 9 23 
3d 0 5 5 2 0 8 25 
3e 2 4 6 0 3 1 29 
3f 	1 1 8 8 4 5 21 
3q 0 6 6 1 4 4 27 
SUM 3 32 42 15 15 31 169 
%1.0 10.4 13.7 4.9 4.9 10.1 55.0 
H16 3a 0 0 0 0 0 2 36 
__ 
1255 I 6.9 
3b 0 3 2 1 2 3 42 
3c 0 4 2 0 4 7 23 
3d 0 8 8 2 3 4 42 
3e 0 4 2 1 3 4 43 
SUM 0 19 14 4 12 20 186 
%0.0 7.5 5.5 1.6 4.7 7.8 72.9 
H19 3a 0 6 2 0 1 1 17 
_____ 
1151 	I 2-7  
3b 0 1 0 0 1 1 21 
3c 0 1 1 0 1 2 31 
3d 0 0 0 0 0 0 30 
3e 0 0 0 0 0 0 34 
SUM 0 8 3 0 3 4 133 
% 0 5.3 2.0 0.0 2.0 2.6 88.1 
H20 3 a 0 0 0 0 0 0 35 
_____ 
327 5.7 
3b 0 3 3 1 2 7 24 
3c 0 4 4 2 1 3 37 
3d 0 7 0 0 1 1 34 
3e 0 6 0 0 1 2 32 
3f 0 4 3 1 6 2 20 
3u 0 5 0 0 2 5 32 
3h 0 1 0 0 2 1 33 
SUM 0 30 10 4 15 21 247 
%0.0 9.2 3.1 1.2 4.6 6.4 75.5 
HI 	4a 0 9 6 5 6 3 13 13341 
_____ 
21 
4b 	1 5 1 14 2 5 15 
4c 	1 2 3 2 1 1 33 
4 d 4 3 3 14 2 4 16 
4 e 3 2 7 14 3 1 7 
4f 	1 11 2 4 0 1 12 
4i 	0 4 1 4 1 2 20 
4h 2 4 9 10 2 3 15 
41 	0 4 1 4 2 0 4 
SUM 12 44 33 71 19 20 135 
%3.6 13.2 9.9 21.3 5.7 6.0 40.4 
Table 4.5 	BLG mRNA FISH counts for hemizygote BLG/7 population page 9/9 
174 
Istround ON 1/40N 1/20N 3/40N OFF SUM %ON 
HHI 	a 8 6 9 6 14 32.49 
b 5 33 15 8 18 
c 6 26 16 10 10 
d 0 10 4 3 24 
e 0 15 8 3 20  
SUM 19 90 52 30 86 277 
% 6.9 32.5 18.8 10.8 31.0 
HH2 a 4 20 9 10 8 32.38 
b 0 14 0 0 14 
c  9 4 2 8 
d 0 13 3 6 12 
e 5 18 10 7 7 
SUM 9 74 26 25 49 183 
% 4.9 40.4 14.2 13.7 26.8 
HH 3 a 0 23 4 7 30 18.32 
b 0 14 5 2 49 
C 1 13 2 5 46 
d 0 12 7 5 33 
e 6 15 4 9 26  
SUM 7 77 22 28 184 318 
% 2.2 24.2 6.9 8.8 57.9 
HH4 a 0 3 4 3 12 22.74 
b 0 17 5 12 36 
c 3 25 5 8 18 
d 3 7 2 1 41 
e 3 7 4 8 27  
SUM 9 59 20 32 134 254 
% 3.5 23.2 7.9 12.6 52.8 
HH 5 a 0 21 3 5 53 22.30 
b 0 24 5 4 50 
c 1 21 3 3 30 
d 16 18 6 21 31 
e 2 20 7 4 32  
SUM 19 104 24 37 196 380 
% 5.0 27.4 6.3 9.7 51.6 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 1/12 
175 
1st round ON 1/4 ON 1/2 ON 3/4 ON OFF SUM % 
HH6 a 0 15 5 0 28 25.94 
b 1 10 8 4 17 
c 7 9 5 8 31 
d 4 13 7 7 19 
e 1 22 10 9 25  
SUM 13 69 35 28 120 265 
% 4.9 26.0 13.2 10.6 45.3 
HH7 a 1 11 8 5 26 23.42 
b 3 13 6 7 14 
C 1 22 7 1 16 
d 0 6 2 0 23 
e 0 10 4 6 14  
SUM 5 62 27 19 93 I 	206 
% 2.4 30.1 13.1 9.2 45.1 
HH8a 0 2 2 2 7 11.97 
b 0 12 3 1 36 
C 0 17 6 5 33 
d 1 10 2 3 42 
e 0 10 0 0 44  
SUM 1 51 13 11 162 238 
% 0.4 21.4 5.5 4.6 68.1 
HH9 a 9 14 5 9 28 34.27 
b 
C 0 19 6 7 18 
d 12 19 10 10 28 
e4 7 2 3 3 
SUM 25 59 23 29 77 j 	213 	I 
% 11.7 27.7 10.8 13.6 36.2 
HHIO a 13 14 5 17 13 56.45 
b 21 3 3 12 8 
c 19 9 4 7 3 
d 26 7 6 5 12 
e 0 25 14 20 9 
SUM 79 58 32 61 45 275 
% 28.7 21.1 11.6 22.2 16.4 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 2/12 
176 
1st round ON 1/4 ON 1/2 ON 3/4 ON OFF SUM % ON 
HHII 	a 0 20 11 13 15 38.74 
b 15 33 10 11 3 
c 3 27 8 12 15 
d 1 25 3 10 16 
e 14 32 2 8 15  
SUM 33 137 34 54 64 322 
% 10.2 42.5 10.6 16.8 19.9 
HHI2 a 0 0 0 0 31 21.91 
b 0 10 0 0 20 
C 1 29 7 4 23 
d 13 25 5 2 19 
e 0 18 4 6 18  
SUM 14 82 16 12 111 235 
% 6.0 34.9 6.8 5.1 47.2 
HHI3 a 1 20 7 3 38 31.58 
b 9 9 8 10 2 
c 6 20 9 10 26 
d 0 13 8 9 35 
e 5 17 14 11 14  
SUM 21 79 46 43 115 304 
% 6.9 26.0 15.1 14.1 37.8 
HH 14 a 0 5 0 0 30 26.83 
b 0 13 4 9 9 
C 0 14 4 3 21 
d 6 12 9 9 15 
e 6 13 7 6 23  
SUM 12 57 24 27 98 218 
% 5.5 26.1 11.0 12.4 45.0 
HHI5 a 0 12 3 0 4 26.46 
b 3 7 1 10 2 
C 0 30 4 1 25 
d 1 22 5 5 15 
e 2 10 4 4 18  
SUM 6 81 17 20 64 188 
% 3.2 43.1 9.0 10.6 34.0 
Table 4.6 BLG mRNA FISH counts for homozygote BLG/7 population page 3/12 
177 
1st round ON 1/4 ON 1/2 ON 3140N OFF SUM % 
HH16 a 9 21 12 12 18 25.88 
b 0 10 1 1 53 
c 8 14 6 8 19 
d 0 21 3 4 18 
e 1 8 4 7 26  
SUM 18 74 26 32 134 284 
% 6.3 26.1 9.2 11.3 47.2 
HH 17 a 0 20 5 5 15 37.93 
b 0 10 7 3 15 
c 0 15 8 3 28 
d 14 34 5 22 1 
e 9 21 15 22 11 
SUM 23 100 40 55 70 288 
% 8.0 34.7 13.9 19.1 24.3 
HH 18 a 0 15 1 2 17 23.88 
b 0 18 2 0 25 
c 3 14 13 10 15 
d 0 12 4 3 12 
e 0 10 11 1 12 
SUM 3 69 31 16 81 200 
% 1.5 34.5 15.5 8.0 40.5 
HH 19 a 0 9 2 3 34 17.69 
b 2 17 2 11 36 
C 9 13 5 3 28 
d 6 10 3 9 14 
e 0 21 3 4 26  
SUM 17 70 15 30 138 270 	I 
% 1.1 25.6 11.5 5.9 30.0 
HH2O a 0 10 2 2 2 27.02 
b 0 12 4 3 7 
C 0 20 0 0 8 
d 4 12 2 6 13 
e  8 2 1 6 
SUM 4 62 10 12 36 124 
% 3.2 50.0 8.1 9.7 29.0 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 4/12 
178 
2nd round ON 1/4 ON 1/2 ON 3/4 ON OFF SUM % ON 
HHIa 1 30 6 4 20 30.4 
b 4 14 13 14 13 
C 0 20 4 3 7 
d 0 11 5 1 8 
3 8 7 1 1212091 
SUM 8 83 35 23 60 
% 3.8 39.7 16.7 11.0 28.7 
HH2e 3 10 7 7 4 35.4 
f 0 28 9 3 12 
g 1 10 7 2 8 
d 3 7 9 8 8 11461 
SUM 7 55 32 20 32 
% 4.8 37.7 21.9 13.7 21.9 
HH3a 1 19 8 2 8 223 
b 1 20 2 2 15 
c 0 15 3 2 34 
d 1 16 6 3 12  
f 3 24 5 4 2412301 
SUM 6 94 24 13 93 
% 2.6 40.9 10.4 5.7 40.4 
HH 4 a no OK pictures, redo 
HH5a 9 29 2 6 11 
b 0 6 0 0 32 
c 1 13 4 2 19 236 
d 0 20 4 6 13  
e 0 12 5 2 1412101 
SUM 10 80 15 16 89 
% 4.8 38.1 7.1 7.6 42.4 
HH6a 3 15 5 13 11 349 
b 3 13 6 7 14  
c 0 25 6 9 1212421 
SUM 6 53 17 29 37 
% 4.2 37.3 12.0 20.4 26.1 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 5/12 
179 
2nd round ON 114 ON 1/2 ON 3/4 ON OFF SUM % ON 
HH7a 3 12 2 7 6 33.4 
b 3 11 1 2 9 
C 0 9 3 11 3 
d 1 8 1 5 13 
e 3 13 3 3 3 
f 0 8 1 7 6 
g 0 19 4 4 1612001 
SUM 10 80 15 39 56 
% 5.0 40.0 7.5 19.5 28.0 
HH8a 3 15 5 2 26 29.6 
b 0 34 0 0 20 
C 0 23 4 0 6 
d 3 20 5 12 6 
e 9 9 4 6 5 12171 
SUM 15 101 18 20 63 
% 6.9 46.5 8.3 9.2 29.0 
HH9a 0 17 10 8 10 220 
b 0 22 1 2 26 
C 0 26 6 4 22 
d 0 18 4 0 3 
e 0 19 0 0 1312111 
SUM 0 102 21 14 74 
% 0.0 48.3 10.0 6.6 35.1 
HHIOa 3 20 9 4 0 49.0 
b 8 27 7 12 1 
C 11 21 8 3 0 
d 10 14 6 10 8 11821 
SUM 32 82 30 29 9 
% 17.6 45.1 16.5 15.9 4.9 
HHIIa 5 32 2 5 25 26.6 
b 4 32 5 8 10 
c 3 23 11 6 20 
d 1 29 1 1 18  
e 2 14 2 5 24 12881 
SUM 15 130 21 25 97 
% 5.2 45.1 7.3 8.7 33.7 
Table 4.6 BLG mRNA FISH counts for homozygote BLG/7 population page 6/12 
180 
2nd round ON 1/4 ON 1/2 ON 314 ON OFF SUM % ON 
HHI2a 0 22 7 5 26 29.4 
b 6 10 6 17 28 
c 2 25 10 11 10  
d 0 24 11 3 23 12461 
SUM 8 81 34 36 87 
% 3.3 32.9 13.8 14.6 35.4 
HHI3a 0 7 7 7 25 30.1 
b 0 20 10 3 17 
c 4 19 14 7 28 
d 13 25 3 9 10  
e 2 12 11 6 28 12871 
SUM 19 83 45 32 108 
% 6.6 28.9 15.7 11.1 37.6 
HHI4a 2 11 5 7 13 29.2 
b 1 26 4 8 20 
C 0 18 7 6 7 
d 0 36 9 1 10  
0 14 7 4 6 2221 
SUM 3 105 32 26 56 
% 1.4 47.3 14.4 11.7 25.2 
HHI5a 6 7 2 14 8 33.5 
b 0 21 1 0 14 
c 4 26 11 12 15 
d 5 8 9 9 20  
0 8 15 0 1712321 
SUM 15 70 38 35 74 
% 6.5 30.2 16.4 15.1 31.9 
HHI6a 0 19 6 1 16 22.8 
b 1 16 2 4 47 
C 0 20 8 0 25 
d 5 12 6 10 6 
e 0 15 2 4 6 12311 
SUM 6 82 24 19 100 
% 2.6 35.5 10.4 8.2 43.3 
Table 4.6 BLG mRNA FISH counts for homozygote BLG/7 population page 7/12 
181 
2nd round ON 1/4 ON 1/2 ON 3/4 ON OFF SUM % ON 
HHI7a 0 31 3 0 33 20.6 
b 0 20 6 2 14 
C 0 19 0 0 7 
d 4 11 3 1 15  
e 2 12 4 0 5 11921 
SUM 6 93 16 3 74 
% 3.1 48.4 8.3 1.6 38.5 
HHI8a 6 0 18 0 0 28.4 
b 3 2 2 3 6 
C 1 12 5 2 6 
d 0 0 0 0 30  
e 0 16 0 0 7 11191 
SUM 10 30 25 5 49 
% 8.4 25.2 21.0 4.2 41.2 
HHI9a 3 25 11 5 17 27.9 
b 4 20 5 11 20 
c 2 11 8 3 12 
d 0 17 9 4 16  
e 2 29 7 4 30 12751 
SUM 11 102 40 27 95 
% 4 37.1 14.5 9.8 34.5 
HH2Oa 0 7 2 6 7 26.6 
b 1 14 3 7 6 
C 0 11 3 8 17 
d 1 11 4 2 15  
e 0 21 0 0 9 11551 
SUM 2 64 12 23 54 
% 1.3 41.3 7.7 14.8 34.8 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 8/12 
182 
3rd round ON 1140N 1120N 3140N 1180N 11160N OFF SUM % 
HHI 	3a 0 4 7 2 4 0 9 F143] 31 .4 
3b 2 8 7 5 2 0 11 
3c 4 9 6 6 3 0 10 
3d 2 4 4 3 4 3 10 
3e 1 1 2 3 2 1 4 
SUM 9 26 26 19 15 4 44 
% 6.3 18.2 18.2 13.3 10.5 2.8 30.8 
HH2 3a 3 8 7 3 4 0 24 F359] 24.8 
3b 4 5 7 5 2 2 19 
3c 5 4 5 7 4 2 18 
3d 4 3 3 7 2 4 35 
3e 6 2 6 15 1 6 41 
3f 0 5 6 3 4 2 21 
3g 1 8 3 7 2 1 23 
SUM 23 35 37 47 19 17 181 
% 6.4 9.7 10.3 13.1 5.3 4.7 50.4 
HH3 3a 2 8 2 6 5 1 39 F613]  iL 
3b 0 6 4 1 2 4 41 
3c 5 8 5 8 3 10 30 
3d 4 2 4 6 5 3 35 
3e 2 3 7 3 2 5 29 
3f 5 8 2 7 4 3 31 
3g 4 7 4 6 1 3 33 
3h 0 7 8 6 4 4 47 
31 0 4 8 10 2 4 31 
3j 1 8 2 2 3 7 37 
SUM 23 61 46 55 31 44 353 
% 3.8 10.0 7.5 9.0 5.1 7.2 57.6 
HH4 3a 0 4 5 10 2 5 13 255 112 
3b 1 3 3 10 1 5 8 
3c 0 2 0 7 1 0 16 
3d 0 8 4 3 2 1 15 
3e 1 0 2 3 0 0 17 
3f 2 2 3 0 2 3 23 
3g 0 2 1 3 1 3 18 
3h 0 1 1 0 1 2 35 
SUM 4 22 19 36 10 19 145 
% 1.6 8.6 7.5 14.1 3.9 7.5 56.9 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 9/12 
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3rd round ON 1140N 1120N 3140N 1180N 1/16 ON OFF SUM % 
HH5 3a 0 6 3 0 1 5 41 244 I  13.9 
3b 0 12 6 7 0 5 17 
3c 1 7 2 5 3 4 29 
3d 0 5 8 0 2 2 24 
3e 0 6 2 3 2 3 33 
SUM 1 36 21 15 8 19 144 
% 0.4 14.8 8.6 6.1 3.3 7.8 59.0 
HH8 3a 1.0 4.0 7.0 7.0 5.0 10.0 38 . 0 1 239 . 0 1 221 
3b 0 3 1 0 2 4 44 
3c 1 3 2 3 5 6 23 
3d 12 4 3 10 2 4 3 
3e 2 2 4 10 3 1 10 
SUM 16 16 17 30 17 25 118 
% 6.7 6.7 7.1 12.6 7.1 10.5 49.4 
HH9 3a 1 5 5 8 4 10 29 	414 19.1 
3b 5 11 9 12 1 1 32 
3c 1 7 4 4 3 4 20 
3d 0 10 7 2 4 3 37 
3e 0 6 7 8 3 11 35 
3f 2 4 9 7 6 3 39 
3g 0 5 3 0 4 4 19 
SUM 9 48 44 41 25 36 211 
% 2.2 11.6 10.6 9.9 6.0 8.7 51.0 
HHII 	3a 1 12 7 2 1 6 25 F-311 33.5 
3b 10 1 5 11 3 1 16 
3c 10 12 9 5 2 4 6 
3d 5 3 8 14 2 2 8 
3e 1 4 2 10 0 1 6 
3f 4 6 2 8 3 5 28 
3g 0 4 5 4 2 5 20 
SUM 31 42 38 54 13 24 109 
% 10.0 13.5 12.2 17.4 4.2 7.7 35.0 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 10/12 
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3rd round ON 1/4 ON 1/2 ON 3/4 ON 1/8 ON 1/16 ON OFF SUM % ON 
HHII 	3a 1 12 7 2 1 6 25 311 33.5 
3b 10 1 5 11 3 1 16 
3c 10 12 9 5 2 4 6 
3d 5 3 8 14 2 2 8 
3e 1 4 2 10 0 1 6 
3f 4 6 2 8 3 5 28 
3g 0 4 5 4 2 5 20 
SUM 31 42 38 54 13 24 109 
% 10.0 13.5 12.2 17.4 4.2 7.7 35.0 
HH14 3a 0 13 5 7 8 4 29 800 18.8 
3b 7 4 9 6 5 6 26 
3c 0 5 3 2 3 9 50 
3d 0 11 4 5 2 6 28 
3e 8 4 3 7 2 3 24 
3f 5 8 10 7 0 0 36 
3g 3 3 3 4 3 5 58 
3h 7 5 8 7 3 1 31 
31 0 4 1 0 1 2 54 
3j 0 3 2 0 2 2 44 
3k 4 16 5 10 0 5 36 
31 0 4 1 0 0 0 42 
3m 5 9 6 15 3 4 5 
SUM 39 89 60 70 32 43 463 
% 4.9 11.1 7.5 8.8 4.0 5.4 57.9 
HHI7 3a 5 14 9 7 0 4 17 	j 766 31 . 0 
3b 1 7 13 6 3 2 11 
3c 10 9 11 18 3 0 11 
3d 20 8 8 21 1 4 21 
3e 3 7 9 8 0 0 20 
3f 7 6 8 17 2 5 20 
3g 4 4 1 13 7 2 15 
3h 4 13 7 9 3 4 30 
31 1 10 5 7 4 8 25 
3j 1 5 4 5 4 10 28 
3k 5 7 10 17 1 11 12 
31 0 2 1 1 1 5 47 
3m 0 3 3 4 6 6 35 
SUM 61 95 89 133 35 61 292 
% 8.0 12.4 11.6 17.4 4.6 8.0 38.2 
Table 4.6 BLG mRNA FISH counts for homozygote BLG/7 population page 11/12 
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3rd round ON 1140N 1/20N 3140N 1180N 11160N OFF SUM % 
HH18 3a 0 5 3 1 3 3 10 216 22.6 
3b 0 0 0 0 0 8 12 
3c 5 2 3 2 2 8 12 
3d 1 9 3 4 1 3 11 
3e 2 8 11 6 1 3 11 
3f 3 3 3 2 2 9 13 
3g 0 4 1 4 2 5 12 
SUM 11 31 24 19 11 39 81 
% 5.1 14.4 11.1 8.8 5.1 18.1 37.5 
HH20 3a 0 11 2 1 2 3 16 	14251 23.8 
3b 0 3 2 1 1 9 19 
3c 0 10 6 16 4 6 26 
3d 1 4 3 7 3 2 21 
3e 2 2 1 4 2 3 22 
3f 10 5 8 13 4 3 25 
3g 1 4 6 2 3 5 18 
3h 0 9 7 1 1 2 19 
31 2 2 3 9 2 5 14 
3j 1 4 7 3 1 4 7 
SUM 17 54 45 57 23 42 187 
% 4.0 12.7 10.6 13.4 5.4 9.9 44.0 
Table 4.6 	BLG mRNA FISH counts for homozygote BLG/7 population page 12/12 
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Chapter 5 
Is BLG/7 mosaic expression clonal or instructional? 
5.1 Introduction 
In variably expressing transgenic lines, silencing is frequently seen at the cellular 
level. In some cases, transgene expression levels from individual cells do not vary 
(Graubert et a! 1998). Instead, differences in the number of expressing cells explain 
variable protein production. Qualitative differences in transgene expression generate 
a mosaic pattern of expression revealed by in situ hybridisation (Dobie et a! 1996). 
This phenomenon bears at least a superficial resemblance to Position Effect 
Variegation (PEV) seen in Drosophila (1.7). BLG/7 is one such line exhibiting this 
phenomenon (Dobie et al 1996), and these mice have formed the central focus of the 
work described in this thesis. 
5.1.1 Is BLG/7 mosaicism clonally or instructionally derived? 
The mosaic pattern of expressing and silent cells evident in the mammary tissue of 
BLG/7 mice probed for BLG mRNA expression (Dobie et al 1996) is suggestive of a 
clonal expansion of cells from a progenitor cell after "fixation" of the decision of the 
expression status of the BLG transgene. An alternative explanation is that the 
patterns is the result of an instructional state achieved through inter-cellular 
communication 
Support for clonal origins of mosaic expression patterns 
Drosophila based research has demonstrated that position effect variegation is 
manifested by variable spread of heterochromatin. Once established, the pattern can 
become stable and clonally inherited (Spofford 1976, Paro & Hogness 1991), giving 
rise to the variegated pattern of expression characteristic of the phenomenon. 
Similarities between modifiers of variegation and regulators of homeotic gene 
expression are also suggestive of a clonal maintenance of activational status. It has 
been suggested that the mosaic phenotype is determined during differentiation, at 
least for PEV in Drosophila eye development (Lu eta! 1996). 
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Support for instructional silencing origins of mosaic expression patterns 
The evidence for instructional silencing comes from plant experiments on viral 
defence. Observations of zones of silencing of viral derived sequences preceding the 
zone of infection, alongside absence of any viral RNA upon a second infection 
challenge suggests that a diffusible systemic signal is produced that can move 
between cells and initiate a response (Voinnet & Baulcombe 1997, Jorgensen et a! 
1998). Post-transcriptional silencing and reactivation of a transgenic chitinase gene 
in Nicotiana sylvestris is reported to involve non-clonal events (Kunz et a! 1996). 
Although the promoter used was viral (CaMV 35 S), the variegation appeared to be 
influenced by developmental stage, suggesting that physiological processes can 
affect gene silencing (Kunz et a! 1996). Support for developmental control of 
heterochromatin-mediated silencing is also found in Drosophila, although there is no 
mention of a non-clonal inheritance of expression patterns in this case (Lu et a! 
1998). A non cell autonomous process is suggested responsible for patchwork 
expression in hair follicles of pwklpwk mice (Aubin-Holstein et a! 1998). As there 
are a number of hormones involved in the regulation of mammary gland expansion 
and milk expression (1.8.1), it is possible that some of these exogenous compounds 
could be involved in the generation of BLG/7 variegation. 
5.1.2 How to differentiate between instructional and clonal states 
To differentiate between clonal and instructional origins of the BLGI7 variegated 
cellular expression pattern, cells that share the same clonal history need to be 
marked. X-inactivation is probably the best example of an activation state decision 
initiated early in development and clonally maintained throughout all subsequent 
cellular expansions. A comparison of the expression patterns of cells probed for an 
X-linked marker gene and BLG/7 mRNA should enable dissection of whether the 
two patterns overlap or not in mice doubly hemizygous for both transgenic loci. 
Pattern overlap may also indicate the time-point at which determination of BLG/7 
transcriptional state occurs. For example, if a temporal link between X-inactivation 
and BLG/7 silencing can be established, it would enhance speculation that the two 
phenomena also share mechanistic links. 
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There are several caveats to this experimental approach. A central point is the 
observation that silencing of the X-chromosome occurs at different times in a tissue-
specific manner (Tam et a! 1994, Lu et al 1996), though this does not rule out 
uniform timing of the initial determination event. Any interpretation of results will 
nevertheless have to bear this observation in mind. 
A second potential problem is the experimental evidence that the entire mammary 
gland can be generated from a single cell. It is thus a theoretical possibility that each 
gland is derived from a single mammary progenitor cell, though I do not think that 
this is likely as fully mature mammary glands contain multipotent stem cells 
throughout (Kordon & Smith 1998). 
A third problem is the complexity of the mammary gland, where only a subset of the 
cells express and secrete milk proteins (1.8.1). BLG/7 mRNA will only be visible in 
these cells. An x-linked reporter under the control of a ubiquitous promoter will be 
expressed in all the different cells comprising the mammary gland, rendering reliable 
interpretation of the expression patterns of the reporter and BLG/7 a difficult task. It 
was therefore considered essential to use a reporter under the control of a milk 
protein specific promoter. Mice fitting this description do not exist, so the first 
objective was the making such reporter mice. 
5.2 Experimental Design 
The process of X-inactivation marks the clonal origins of cells, and was chosen for 
exploitation in this project. Mice with an X-linked reporter under milk-protein 
promoter control had to be generated before any other part of the investigation could 
take place (5.1.2). Homozygous reporter mice would be used as controls to check 
that the reporter does not itself variegate, before double transgenic could be made 
containing both the BLG/7 locus and the reporter gene in a hemizygous state. 
Mammary tissue from lactating animals would be gathered and processed (2.3), with 
double mRNA FISH performed (2.4) and the resulting expression patterns analysed 
for coincidence of the reporter and BLG/7 expression profiles. Matching patterns, or 
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patterns that exist within each others boundaries, would confirm that both are the 
result of clonal inheritance of an expression state. 
5.3 Design and assembly of the clonal reporter construct: HBZ 
The targeting construct, HBZ (= HPRT, BLG, LacZ), was made from 3 separate 
components. The targeting vector (M44.8) was a kind gift from Andrew Smith 
(CGR, Univ. Edinburgh). The promoter (from pBJ39), was from the Whitelaw lab 
(Roslin Institute) and the LacZ reporter sequence from a commercial vector (p3Gal 
Basic, Clontech). Figure 5.1 shows the cloning steps and final reporter-targeting 
construct. 
In order to ensure that the reporter construct is integrated as a single copy insert into 
a genomic location that is known to be permissive for transcriptional activity in all 
cells (i.e. the site of a housekeeping gene), embryonic stem cell technology was used 
(Bronson et al 1996). 
Construct Components 
• Reporter: 	LacZ (4.6 Kb) 
• Promoter: 	BLG (4.3 Kb) 
• Targeting Vector: 	genomic HPRT (8.9 Kb, intron 5 0,) in pBS (3 Kb) 
• Target: 	 HPRT (Hypoxanthine Phosphoribosyl Transferase) 
5.3.1 Reporter Choice 
LacZ was chosen as the reporter for marking clonally related cells because it can be 
visualised by staining for protein production and contained a coding sequence of a 
size that allowed probes to be designed for mIRNA FISH. The reporter sequence was 
also commercially available with a Poly A site at the 3' end (Clontech, pGal Basic). 
5.3.2 Promoter Choice 
The milk protein-specific promoter chosen was BLG. BLG was a natural choice 
since the entire functional sequence was available within the group, and has been 
used previously to drive transgenic protein expression in the mammary of both mice 
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Figure 5.1 	Cloning of targeting vector HBZ (HPRT BLG LacZ) 
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and sheep (Archibald et al 1990, Wright et a! 1991, Clark et a! 1993). The promoter 
was a 4.3 Kb Sal 1/Eco RV fragment from pBJ39 (courtesy of CBA Whitelaw, 
Roslin Institute), which was initially inserted into the modified multiple cloning site 
of the reporter plasmid pj3GaI Basic (Clontech). See Figure 5.1. 
5.3.3 Choice of targeting vector 
The targeting vector (M44.8) was a kind gift from Andrew Smith (CGR, Univ. 
Edinburgh) and comprises of approx. 9Kb of genomic HPRT sequence starting from 
the latter half of intron 5 until the end of the gene, inserted into a 3Kb pBS backbone. 
Reporter construct insertion was possible using a unique Sall site in exon 6. 
The targeting vector was chosen for two reasons. One was a good record of efficient 
integration at the target site (A. Smith, personal communication), the other was the 
target gene: HPRT. 
5.3.4 Choice of target gene 
The Hypoxanthine Phosphoribosyl Transferase gene (HPRT) catalyses one of the 
first steps in the purine salvage pathway, is X-linked, expressed at low levels in most 
cell types and is in this respect very much a functional housekeeping gene. 
The position on the X-chromosome and its status as a housekeeping gene are two of 
the four reasons why the gene was chosen as the target for the reporter gene 
integration. The third reason was the ease of selection for a functional knockout of 
the gene using 6-thioguanine, abrogating any need for a positive selectable marker in 
the targeting construct itself. This is a huge advantage as it reduces the size of the 
construct and minimises the length of sequence that bears no homology to the target 
gene, as well as increasing the chance that the reporter will function normally in vivo 
(1.1.4). The fourth and final reason for selecting this gene as a target was the 
availability of a targeting construct with a good record of integration into the HPRT 
site (5.3.3) 
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5.4 Testing HBZ Reporter Competency 
Before undertaking the lengthy process of targeting the reporter construct to HPRT 
in ES cells, it was first tested for expression and induction competency in vitro, using 
HC  1 cells. 
Transient transfections, where the targeting construct HBZ was co-transfected with a 
vector containing neomycing for selection purposes were performed. The positive 
selected cells were pooled, expanded and hormonally induced using lactogenic 
hormones (2.2.2, 2.2.3). Once induction of milk protein genes was completed, the 
cells were stained for presence of LacZ, (2.2.3) with comparisons made between 
cells that had been induced and uninduced. LacZ staining confirmed the 
transcriptional competency and inducibility of the construct (Figure 5.2). Both 
induced and uninduced cells exhibited 13-gal staining, as the HC 11 cells maintain 
basal expression of milk genes even in the uninduced state (Burdon et a! 1994). 
Induction increases the expression of milk-specific genes to between 10-20%, which 
is why this system is used for testing constructs before their introduction into 
animals. The construct was now considered ready for the next stage, introduction and 
targeting into ES cells. 
5.5 Targeting into ES cells and generation of chimeric mice 
The ES cells used were male (RI from 129/01a, passage 14), ensuring that there was 
only one site to be targeted. 
5.5.1 Electroporation and selection for positively targeted cells 
The Qiagen purified targeting vector was linearised using Xhol, and 200 p.g used in 
an electroporation reaction with 2x10 7 ES cells (2.2.5). The cells were then grown 
without selection for 7 days (counting the electroporation day) before 6-thioguanine 
selection was initiated (1.67 .ig/ml). The wait was necessary to ensure that all 
endogenous HPRT had disappeared in the cells where the gene has been correctly 
targeted and disabled. 10 days of selection were sufficient for single colonies to 
appear that could be picked and split into two halves, one for genotyping and the 




Units of Expressing cells 
Treatment of Cells 
Figure 5.2 	Induction of HCII cells tranformed with HBZ construct 
Induced transfected HC1 1 cells stained for LacZ expression 
Representation of differences in number of staining units in induced and uninduced 
transfeceted HC 11 cells 
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The cells destined for genotyping were expanded, spun down and treated with 
proteinase K before being used in a standard PCR reaction to identify cells positive 
for the BLG promoter. 48 colonies were picked in all, 44 were confirmed as positive 
for the transgene promoter by PCR reaction (4 failed to give a PCR result). 
There were of course many more colonies on the plates than the 48 that were picked 
(no more than 6 from each plate), so these plates were methanol fixed and Giemsa 
stained in order that I could estimate the targeting efficiency (2.2.5). 84 colonies 
from 15 plates give a targeting efficiency of 5.6x10 5 , which is close to the efficiency 
seen when a positive selection marker is included (Thomas & Capecchi 1987). 
5.5.2 Southern Blotting confirms targeting 
32 clones were expanded, with some cells from each kept and used to make genomic 
DNA (2.2.6). The genomic DNA was digested with BamHI or HindIII (two sets of 
digests, only clones that provided positive results in both sets of reactions would be 
considered correctly targeted) and RI genomic DNA included as a control. The 
digests were run on a 0.8% agarose gel and Southern Blotted (2.2.6). The blots were 
probed using a 600 bp SphIIBglII fragment from intron 5 of HPRT (Thomas et a! 
1992). Both BamHI and HindIII cut inside the reporter construct, so any positively 
targeted clones should exhibit a lower molecular weight band than the negative 
control, with non-targeted clones exhibiting two bands. 
28 clones were confirmed as correctly targeted by Southern Blotting (Figure 5.3) (the 
remaining 4 clones proved resistant to analysis due to digestion difficulties). 6 of 
these clones were chosen as potential candidates for blastocyst injection, and cells 
were used to make chromosome spreads to check karyotype. The clones picked came 
from different plates to ensure that they were not derived from the same integration 
events, clones HBZ 1, 7, 17, 27, 38 & 47 were used, with HBZ 1, 17 & 47 chosen for 
blastocyst injection. 
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8.6 Kb 	 - 0 
Figure 5.3 	Sothern Blot of BamHI cut HBZ clones 
C = RI control DNA. Rest of lanes are HBZ clones 1 - 27. 
Probe used is 600 bp SphI/BgIll fragment from intron 5 of HPRT (Thomas et a! 
1992) 
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5.5.3 Blastocyst injections and generation of chimeras 
HBZ 1 was the first clone used for blastocyst injections, with 4 chimeric mice 
resulting (agouti coat colour evidence of chimeric origins, Figure 5.4). 
Unfortunately, only 2 of the mice bred, neither providing germline transmission. One 
mouse would not breed, and the other had to be put down due to ill health before 
reaching sexual maturity. 
Circumstances beyond my control meant that attempts to make more chimeras had to 
be discontinued, and no more were generated. This was unfortunate, but the project 
design was such that this risk had been foreseen and additional experimental 
approaches incorporated into the project (chapters 3 & 4). In addition, initial analysis 
was performed on another line that had become available in the lab containing IRES-
Geo targeted to the X-linked PGK gene. 
5.6 An alternative strategy: Exploiting an alternative X-linked 
reporter line containing an IRES-3Geo reporter construct 
targeted to and under PGK gene control control 
We gained access to X-linked reporter mice under a constitutively active promoter 
control, and decided to use them to generate double hemizygous transgenic mice 
containing both the BLG/7 locus and the PGK IRES-I3Geo construct. These were 
designated as MOP mice (Margaret Opsahl PGK). The generation of these mice 
would accomplish two goals: 
. Check that LacZ expression does not interfere with BLG/7 expression 
. Establish the double mRNA FISH protocols 
5.6.1 MOP mice 
PGK IRES-3Geo females (courtesy of D. Strathdee and A.J. Clark) were bred to 
BLG/7 outbred males in order to generate doubly hemizygous females (ear and tail 














Figure 5.4 	HBZ I Chromosome spread and resulting chimeric mice 
Chromosome spread from clone HBZ 1, which was used to make the chimeric 
mice pictured below. 
Chimeric mice resulting from blastocysts injections using clone HBZ 1 as a 
single mouse (Bi) or together with non-transgenic litter mates (132) 
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The failure of chimeric HBZ mice to transmit the targeted insertion through the 
germline has meant that this part of the investigation could not be taken further 
during the course of this project. The generation of the MOP mice ensured that some 
progress could be made, establishing whether LacZ expression can interfere with 
BLG/7 expression and if double RNA FISH can generate a clear image of clonality 
in the mammary gland. It was hoped that even with the obvious background signal 
from non-epithelial cells, that the question of the clonal origins of BLG/7 variegation 
may be addressed in these mice. 
5.6.2 MOP milk results 
Milk and tissue samples were collected at day 11 of lactation from all 35 females. 
Collection and processing of milk and tissue samples took place over a period of 
several weeks. An examination of the levels of transgenic protein expression in the 
milk was made and compared to the results gathered for BLG/7 hemizygous mice 
(Table 4.3). The same non-transgenic control sample was run for both the MOP and 
hemizygous BLG/7 samples. The arithmetic mean of three measurements was used 
in determination of BLG expression levels for each individual sample. The average 
expression from each individual is shown in Table 5.1. The mean BLG expression 
level and spread of expression correlate with that seen for hemizygous BLG/7 (Table 
5.2) 
MICE MEAN SD CV 
(standard deviation) (coefficient of variation) 
MOP 7.88 3.59 45.53 
Hemizygous 
BLG/7 
8.25 3.46 41.98 (outbred Fl 
CBA:C57BL/6)  




MOP 1.1 15.80 16.13 
16.68 
15.90 
MOP 1.2 18.94 19.67 
21.22 
18.87 
MOP 1.3 13.95 14.46 
14.56 
14.88 
MOP 2.1 5.43 5.34 
5.26 
5.33 
MOP 2.2 5.39 5.41 
5.48 
5.36 
MOP 2.3 13.19 12.78 
12.91 
12.23 
MOP 2.4 10.25 10.26 
10.09 
10.45 
MOP 2.5 10.33 9.98 
10.27 
9.34 
MOP 3.1 5.43 6.12 
5.45 
7.47 
MOP 4.3 8.79 8.68 
8.56 
8.71 
MOP 4.4 7.66 7.81 
7.86 
7.92 






MOP 6.3 5.53 6.05 
6.79 
5.83 
MOP 6.4 8.11 8.18 
8.51 
7.93 
MOP 6.5 5.88 6.62 
6.68 
7.29 
MOP 7.2 6.81 7.56 
7.53 
8.33 
MOP 7.4 5.31 5.86 
5.73 
6.54 
MOP 9.1 6.25 7.01 
6.98 
7.79 
MOP 10.1 5.28 5.66 
5.01 
6.68 
MOP 10.2 4.67 5.42 
5.78 
5.81 
MOP 10.3 8.55 8.64 
8.89 
8.48 
MOP 10.8 4.49 4.83 
5.03 
4.97 
MOP 10.9 4.09 4.83 
4.98 
5.43 





MOP 11.1 6.54 6.90 
7.30 
6.86 
MOP 11.5 3.89 4.29 
4.90 
4.06 
MOP 11.7 4.30 4.80 
4.82 
5.27 
MOP 11.8 4.89 5.26 
5.54 
5.36 
MOP 12.4 10.01 10.02 
9.99 
10.06 
MOP 12.5 8.15 8.10 
8.27 
7.89 
MOP 13.2 7.73 7.81 
8.04 
7.65 
MOP 13.7 10.52 10.52 
10.44 
10.61 
MOP 13.8 4.33 4.47 
4.57 
4.51 
MOP 15.2 4.99 4.99 
4.56 
5.42 
MOP 16.1 5.14 5.29 
5.24 
5.50 
Table 5.1 	BLG measurements for MOP mice 
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Figure 5.5 A) SOS PAGE of milk protein samples for MOP mice 
C = non-transgenic control milk, BLG = 13-lactoglobulin standard. Transgenic 









MOP 1.1 - MOP 16.1 
Figure 5.5 B) Bar chart representing individual BLG milk protein yields in mg/ml 
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5.6.3 MOP mRNA FISH 
The MOP mammary tissues were fixed, wax embedded, sectioned and prehybridised 
(2.4.1 - 3). Initial FISH using oligo cocktails for BLG (Cy3) and LacZ (Fluorescein) 
mRNA (2.4.8) failed to pick up any LacZ signal even at 80 nglml (BLG is clearly 
visible at 40 ng/ml). These results and reports from other investigators using the 
PGK mice (C. Neil, personal communication) suggested that LacZ transcription was 
too low in the mammary gland for primary detection and in need of amplification 
steps. 
An antibody to fluorescein, conjugated to fluorescein, was used to amplify the signal 
(2.4.4, 2.4.5, 2.4.7). It took 4 amplification rounds to generate even a weak LacZ 
signal (Figure 5.5), which I considered to be of too poor quality to use to in an 
attempt to eludicate the clonal and temporal determination of BLG/7 silencing. 
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MOP mammary tissue probed with antibody MOP mammary tissue probed for LacZ mRNA 
to Fluorescein without primary probe to LacZ 
Blue cells in both images due to autofluorescence when using DAR filter 
ii
:i 	 42,  
fl- 
MOP mammary showing BLG signal only 	MOP mammary showing BLG & LacZ signal 
Without DAR background 
Figure 5.6 	MOP mammary tissue probed for BLG and LacZ expression. 
Scale: 1cm = 100 lIm. 
Probes used were 5 30'mer (BLG) and 10 30'mer (LacZ) cocktails labelled with either Cy3 
(BLG = red signal) or Fluorescein (LacZ = green signal, amplified using antibodies to 
fluorescein conjugated to fluorescein). Magnification is 10 X. Probe concentration used was 
40 ng/ml. Some epithelial cells express LacZ (green), some express BLG (red). Note that 
alveoli can comprise of cells expressing both genes (i), BLG alone (ii) LacZ alone (iii) or 
neither (iv). Bright yellow fluorescence is caused by autofluorescence of wax residues, easily 




Future experimental strategies & implications of current results 
Each of the experimental chapters (3-5) contains its own discussion section where 
implications of the results are discussed in the context of the experimental findings of 
the particular chapter. This chapter will therefore contain just a brief summary of the 
findings of the project. The remainder of the content will be divided between future 
experimental approaches to expand on the knowledge gained, and putting the results 
into context with the driving force behind much of the transgenic research taking 
place today, understanding human gene function, regulation, disease and devising 
treatment strategies for genetic disorders. 
61 BLG/7 mice are an ideal model system for studying PEV 
BLG/7 is the first line of transgenic mice where the variegated expression was shown 
to coincide with integration close to centromeric heterochromatin and high copy 
number, and suggested to be caused by a mechanism analogous to PEV in 
Drosophila (Dobie et al 1996). My project has extended the knowledge of how this 
particular gene array is regulated at this particular site: 
Variegation is shown to be irrevocably linked to the transgene array at the site of 
insertion, with the extent of variegation open to modification by inbreeding factors 
and multiple minor background-specific loci that probably act in a cumulative 
manner (Chapter 3). 
> The modifier loci operating in an inbred background do not convey 
any heritable epigenetic mark, as demonstrated through outcrossing 
Introduction of a second variegating locus, in the form of generating mice 
homozygous for the BLG/7 locus does not affect the variegating properties of the 
locus inasmuch as variable expression is exhibited by homozygous mice. Curiously, 
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whilst the expected doubling of expression is seen for the minimum expression level, 
maximum expression remains identical for both hemi- and homozygous populations 
(Chapter 4). 
> Protein and mRNA expression in the form of the number of 
expressing cells display the same ratio irrespective of whether the 
hemizyogus or homozygous population is examined. 
> Nuclear FISH reveals that in actively expressing homozygote cells, 
only one of the two BLG/7 loci is active. This is suggestive of some 
form of trans-homology interaction taking place resulting in only one 
of the homologous loci remaining active, a novel phenomenon in 
transgenic mice. 
Targeted ES cells generating an X-linked marker for the clonality of mammary 
epithelial cells have been made and will be used to make transgenic mice (Chapter 5) 
> The successful targeting proved that when using HPRT as a target, no 
positive selection marker is necessary to efficiently generate correctly 
targeted clones. 
> Preliminary investigations using an alternative line of mice confirm 
that the mammary tissue originates from more than a single progenitor 
cell. Poor expression levels of marker RNA adds to the desirability of 
making our own specific reporter line. 
6.2 Future work based on the backcross experimental results of 
Chapter 3 
Although this experimental chapter answers the question the backcross samples were 
intended to address, the work also unexpectedly uncovered a range of new questions. 
The data confirms conclusively that the transgene variegates irrespective of 
background or passage number through the germline, and is therefore an inherent 
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property of the array at the locus of integration. The devastating effects of inbreeding 
depression on all milk protein expression, and the existence of strain-specific 
modifiers in at least one of the two backgrounds added a whole new dimension to the 
investigation. These discoveries prompted further investigations, which provided 
some answers and many new questions. I have outlined how this project could be 
taken forward. 
6.2.1 Continuation of outcrossing experiment 
The loss of the CBA BLG/7 backcross population due to poor breeding performance 
was unfortunate as it meant that the outcrossing experiment was only performed 
using C57BL/6 BLG/7 backcross population. The assumption has therefore had to be 
made that any epigenetic modification in the CBA background would behave in 
exactly the same fashion as in the C57BL16 background. This assumption needs to be 
addressed experimentally by breeding back into the CBA background until the 13th 
generation, and then outcrossing to a C57BL/6 colony to generate first generation 
outcrossed F! BLG/7 mice derived from the CBA line. 
The current C57BL/6 derived outcrossed Fl BLG/7 mice need to be maintained by 
mating to the mixed Fl colony, and sampled at each generation to determine how 
fast the coefficient of variance returns to the level seen in the control outbred F1 
BLG/7 mice. 
6.2.2 Dissection of multiple modifier loci responsible for inbreeding depression 
and strain-specific modification 
The backcross results suggest that there are multiple modifier loci responsible for 
inbreeding depression and strain-specific modification. The mechanism through 
which the modifiers act upon the transgene, and the identities of the loci are currently 
unknown. Based on the known integration site of the transgene, its persistent 
variegated phenotype, and the overall depression of inbred endogenous milk 
proteins, I could speculate that some of the modifiers may be involved in higher 
order chromatin structure and gene regulation. The dissection of at least some of the 
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different modifiers could be attempted by utilising three distinct but complementary 
approaches. 
Genomics 
The creation of genomic libraries for C57BL/6, CBA and Fl mixed background mice 
could be used to investigate differences at the DNA level. These libraries could be 
screened for restriction fragment length polymorphisms (FLP's) identifying regions 
that differ between the populations. Identification of corresponding gene loci and 
sequencing may reveal candidate modifier genes. 
There are several distinct disadvantages to this approach for my purposes. Huge 
amount of data would be generated, and the probability of generating false positive 
results is high. An additional drawback is that this method cannot distinguish 
between differentially expressed or modified genes and proteins. 
Differential Display and Associated Techniques 
My favoured technique for rapid dissection of differently expressed genes in the 
three genotypes would be through differential display (DD). This powerful tool 
allows detection of both qualitative and quantitative differences in mRNA expression 
(Miele et a! 2001). As I am unsure as to what developmental time point the different 
modifiers are active in, sampling of mammary and other tissues would have to take 
place at several different stages (virgin, pregnant, early lactation, mid-lactation etc). 
The method involves RT PCR of the RNA samples, using anchored and random 
primers. Even polymorphisms in expressed transcripts may be detected using this 
technique. The PCR products are radioactively labelled and run on a polyacrylamide 
gel, the resulting bands can then be quantified as well as qualitatively analysed. 
Differentially expressed bands are then excised from the gel and either sequenced 
directly or cloned and then sequenced for identification. A possible additional project 
may be to try to improve the technique by substitution of the radioactive labels with 
fluorescent ones. 
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A complementary approach, although more laborious, would be the use of 
subtractive hybridisation to identify differentially expressed genes. As DD can 
generate quite a high false positive rate, and subtractive hybridisation and DD appear 
to identify positives from two different types of mRNA populations, using both 
systems when tissue material is plentiful makes sense. 
Proteomics 
The final approach would be to look at differences in expression at the protein level. 
A combination of 2D electrophoresis using immobilised pH gradients and 
subsequent use of mass spectrometry to identify excised protein spots would 
complement the approaches above and enable identification of differentially 
modified proteins. Differences in post-translational modification at the protein level 
would not be apparent in any of the previous techniques. Quantification of protein 
products would also be possible, enabling identification of differences in protein 
degradation between the genotypes. 
The combination of the techniques described above should reveal a lot of 
information about differences between the strains of mice at the genomic, cellular 
and protein level. Such a holistic approach may in the future benefit human 
medicine, where there are many inherited diseases whose age of onset and/or 
symptom severity appears to depend on multiple factors. Although there is some 
evidence that lack of correlation between phenotypes and genotypes could be due to 
somatic mutation (Gottlieb et a! 2001), I am confident that the genetic variability 
between individuals can have a large effect in determining the phenotypic 
manifestation of an inherited or acquired illness. Variable phenotypic expression is 
documented for facioscapulohumeral muscular dystrophy (FSHD) (van Deutekom et 
a! 1996) and ICF (immunodeficiency, centromeric instability, facial anomalities) 
(Gimelli et a! 1993). Muscular dystrophy and cardiomyopathy also display variable 
phenotypes, and a candidate modifier gene (Myoferlin) has been identified for these 
conditions (Davis et a! 2000). If we could dissect out the various modifier loci and 
their effect on disease progress, then it may be possible to devise ways of alleviating, 
if not curing, currently incurable and untreatable conditions. 
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6.3 Future work based on the results of the effects of two 
homologous BLG/7 loci on transgene expression in Chapter 4 
Although the experimental work in this chapter has revealed that BLG/7 
homozygotes variegate and exhibit the same maximum expression potential as the 
hemizygote population due to allelic exclusion, there are many questions left 
unanswered as to the mechanisms responsible for this phenomenon. The existence of 
variegating BLG genes capable of doubling output in the homozygous state 
(McClenaghan et a! 1995) argues against variegation per se being the causative agent 
of monoallelic expression in BLG/7 mice. I think that several different mechanistic 
pathways could be involved, whose components may or may not overlap. The future 
work would be to dissect out the components of these pathways. 
6.3.1 Is the epigenetic component leading to monoallelic expression inherited? 
Breeding the homozygous BLG/7 mice to heterozygocity would separate the 
homologous loci and enable investigation into whether the silencing of the one allele 
is heritable (Matzke et a! 2001). If the silencing is heritable, only 50% of the 
offspring will express the transgene, and we would know that the silencing event 
takes place very early in development, before the segregation of the germline. If the 
silencing were not heritable, we would know that the process of inactivation takes 
place later in development. The results will enable estimation of when inactivation 
takes place, and the temporal determination may be able to provide a few clues as to 
what mechanistic pathways may be involved. 
As the mammalian germline is segregated much earlier in development than the plant 
germline, it is considered unlikely that any epigenetic marks not involved in 
imprinting would remain intact, although a recent paper suggests that the murine 
germline may not be as effective as previously thought in erasure of epigenetic marks 
(Kearns et a! 2000). Differences in male and female germline transmission of 
epigenetic features necessitates that any outcrossing of homozygous BLG/7 mice 
must be duplicated to include passage through both male and female transgenic 
parents. 
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6.3.2 Timing of allelic exclusion in BLG/7 homozygous mice 
Variegation in BLG/7 hemizygous mice is maintained through several lactations 
(Dobie et al 1996). As I speculate that allelic exclusion in homozygous BLG/7 mice 
occurs separately and probably later than the process leading to the underlying 
variegation of the locus, this maintenance of expression in hemizygotes through 
several rounds of lactation can be used. I would investigate the timing of the allelic 
exclusion decision (the trans-interaction event) by examining BLG expression in 
serial lactations from homozygous BLG/7 individuals. Variations in BLG/7 protein 
content between lactations would indicate that allelic exclusion occurs during the 
proliferative phase of secretory epithelial cells in early pregnancy and that the 
decision is not maintained between pregnancies. Maintenance of expression levels 
between pregnancies would indicate that allelic exclusion takes place earlier in 
development. 
6.3.3 Spatial distribution of variegated expression pattern 
The images generated by mRNA FISH indicate that the variegated expression pattern 
is highly heterogeneous and remains so throughout the mammary tissue. A more in 
depth investigation into the expression pattern through serial sections of mammary 
tissue would give a very accurate picture of the spatial pattern of expression and 
enable the development of a computer-generated 3D image of the mammary tissue. 
This would be especially useful for double FISH using markers for clonal 
propagation of the mammary epithelial cells (6.4), and would serve the dual purpose 
of determining the clonal history of a single mammary gland as well as the relative 
expression patterns of BLG/7 and the x-inactivation marker. 
6.3.4 Does BLG/7 differ from BLG/45 
Although both BLG/7 and BLG/45 variegate (Dobie et al 1996), there are distinct 
differences between the two transgenic lines. BLG/45 exhibits a much higher level of 
expression, a doubling in homozygote expression levels, and lower levels of 
variegation when compared to BLG/7 mice. A comparison of expression patterns 
through mRNA FISH, and using an X-linked marker for clonal expansion, may be 
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able to tell us something about the mechanistic processes that may or may not link 
the two variegating constructs. 
Crosses between the two lines to generate double transgenics would enable an 
investigation into whether the two loci remain independent of each other, an ideal 
test of the Markov model (1.7.7). 
Crosses to a non-variegating transgenic BLG line (BLG 14, Dobie et a! 1996) could 
also be initiated for both variegating lines in order to investigate the behaviour of 
these genes in the presence of a non-variegating locus. 
6.3.5 Investigation of BLG/7 nuclear localisation 
The nuclear localisation of BLG/7 genomic DNA could be highly informative. 
Double FISH using BLG and probes for various cellular components such as 
heterochromatic proteins, endogenous milk genes etc could cast some light on to the 
nature of the nuclear compartment where the locus (active or silent) resides, and thus 
some of the mechanistic pathways involved in the determination of expression of the 
locus. 
It would also be advantageous for future experimentation to ascertain a more 
accurate localisation of the genomic integration site of the BLG/7 locus. The recently 
completed map of the entire mouse genomic sequence should provide the 
information required to achieve a more specific localisation of the transgene than 
currently available. 
6.3.6 Expression pattern of endogenous milk proteins in nucleus 
The absence of good intronic sequence data for the milk protein genes in mouse 
meant that the ideal controls could not be included in the experiments. A necessary 
future project would be to clone and sequence the introns of the mouse milk protein 
genes in order to design probes for nuclear transcription. Again, the recent 
publication of the mouse genomic sequence may prove useful. 
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Once the sequence data has been gathered, probes can be designed against intronic 
sequences for all the milk protein genes. A systematic mapping of nuclear 
localisation of these endogenous transcripts compared to BLG/7, BLG/45 and 
BLG/14 transcription would be informative when assessing the effect of nuclear 
localisation on expression potential. Comparing the nuclear localisation of BLG 
transcription and/or genomic BLG localisation with heterochromatin-specific 
proteins, transcription complexes etc would enable detailed speculation into what 
factors may affect transcription of a variegating locus as opposed to non-variegating 
loci. 
6.3.7 Endogenous neighbouring gene expression patterns 
As I speculate on the nature of the expression patterns of several of the genes close to 
the transgenic integration site (most notably, Ghr, Prir and IL-7r), it would be natural 
to investigate their expression patterns, in both mammary tissue and elsewhere. This 
would naturally involve nuclear expression to determine whether expression is 
mono- or biallelic. Should any of them exhibit monoallelic expression, this would be 
a strong candidate for the gene responsible for the monoallelic exclusion seen in 
BLG/7 homozygous mice. In order to ensure that the observed expression patterns 
have not been influenced by the BLG/7 integration event (as reported for the Hoxbl 
transposition by Kmita and colleagues in 1999), investigations would have to be 
made using both transgenic and non-transgenic tissue. 
Should monoallelic expression be confirmed for any of these candidate genes, a 
strategy would have to be devised in order to differentiate between the two alleles so 
that parental effects can be investigated(possibly using crosses between m. musculus 
and m. spretus). It would also be interesting to investigate whether the active loci in 
BLG/7 hemi and homozygous mice are linked to the activational status of one or the 
other allele of the monoallelic expressing endogenous gene, and if there is a parental 
preference for the choice of "companion" allele. 
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6.4 Future work based on the results of the investigation into the 
clonal origins of BLG/7 variegated expression patterns in 
Chapter 5 
The successful targeting of HPRT proved that positive selection markers are not 
necessary for efficient HPRT knockout targeting constructs. As only one set of 
confirmed chimereas were generated, the failure of germline transmission should not 
prejudice against the remaining clones. These clones could therefore be used in the 
future. The fact that these cloned cell lines have been kept in storage for over two 
years, would also justify retargeting into fresh ES cells using the original construct. 
MOP mice could also be utilised further, if the mRNA FISH signal could be 
enhanced. Secondary antibodies have been used to increase signal output, but I feel 
that the number of amplification steps needed could cause any interpretation of the 
resulting expression patterns to be questioned. Additional primary oligo probes could 
be designed and added to the probe cocktail to generate a signal comparable to that 
seen for BLG/7. 
Both of the reporter mice mentioned above have relevant uses, both in addressing the 
clonal origins of BLG/7 mosaic expression patterns and the clonality of the 
mammary gland itself. It would be of interest to examine the clonal origins of other 
variegating lines of mice, such as BLG/45 (Dobie et a! 1996), and compare their 
expression patterns with each other and X-inactivation events. Should all have a 
clonal origin, the patterns of expression may also indicate whether they share the 
same temporal origin of determination of expression. This would be very informative 
in elucidating whether all variegation events share a mechanistic link at initiation of 
variegated expression. 
6.5 The position of Position Effect Variegation in human disease 
Position effects are increasingly implicated as a factor in a number of human diseases 
where inappropriate expression or silencing of gene expression cannot be attributed 
to mutation or deletion of the coding and immediate regulatory sequences. 
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6.5.1 The different position effects that can cause human disease phenotypes 
There are several known examples of disease where position effects are attributed 
with a great deal of confidence, and these effects can be quite different. One example 
is the translocation event that positions the MYC oncogene in conjunction with 
immunoglobulin regulatory sequences. This induces the inappropriate MYC 
expression that is responsible for Burkitt's Lymphoma (Milot et al 1996). 
Translocations are not the only source of position effects causing disease phenotypes, 
removal of sequences flanking a gene can also cause position effects due to the 
effects that the new neighbouring sequences may have. Deletion of upstream 
sequences has been shown to be responsible for silencing 3— and a—globin gene 
expression in some families with thalassemias (Milot et a! 1996, Barbour et al 2000). 
PEV in the classical sense is exhibited by some forms of Aniridia, where 
rearrangements 85 Kb or more 3' to the PAX6 gene causes silencing and thus the 
haplo-insufficiency that results in the phenotype (Fantes et a! 1995). 
6.5.2 Position effects in transgenic animals, serendipitous model systems 
Aberrant transgene behaviour can have several underlying causes (1.1 - 1.7), many 
of which are not mutually exclusive. PEV is one such phenomenon, originally 
identified in Drosophila (Muller 1930), and now linked to similar variable gene 
expression in other organisms (Allshire et al 1994, Dobie et al 1996, Iglesias et a! 
1997). Although the term position effect variegation suggests that site of integration 
is the sole source of variable gene expression, transgene position effect variegation 
may be a little more complex. Factors such as copy number, transgene design, 
integrity of insertion product and genetic background may exert an additional 
influence on transgene expression in a manner that may or may not be linked to the 
position effects. These will have to be dissected out before a site can be investigated 
solely for position effects. 
Apart from the obvious links to human disease, understanding PEV is also important 
for the future of such diverse fields as application of gene therapy, 
xenotransplantation and generation of bioreactors for "pharming". Without the 
ability to guarantee stable, heritable and controlled expression of transgenes, neither 
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treatments of genetic diseases through gene therapy nor production of organs for 
human transplant purposes will be possible. Understanding the underlying causes of 
variegated gene expression may help find a way to avoid it. Economic considerations 
make reliable and heritable expression from a transgene desirable in animals or 
plants producing pharmacologically important compounds for harvesting, although 
this is not such a crucial requirement as in the other two applications mentioned 
above. 
6.6 Using knowledge of modifiers of PEV to improve both 
transgenic livestock and treatment of human diseases 
This project has demonstrated that multiple factors can influence BLG/7 expression, 
but that the extent of variegation is open to modification by recessive background-
specific and inbreeding-dependent factors/loci (Chapter 3). 
6.6.1 Using knowledge of modifier loci to improve the performance of 
transgenic animals 
The backcrossing results suggest that poorly performing transgenes may benefit from 
introduction into a mixed genotypic background. Two papers have been published 
demonstrating that known modifiers of PEV can be experimentally manipulated and 
appear to exert an effect on a PEV locus without apparently adversely affecting 
endogenous genes (Festenstein et al 1999, McMorrow et al 2001). This is a viable 
strategy for enhancing the expression of a variegating gene in mice, but the difficulty 
in generating larger transgenic animals renders this strategy unworkable. PEV could 
be avoided by using targeted insertion of transgenes into permissive sites, but ES 
cells are not generally available for animals other than mice. This means that 
transgenic animals are still largely generated through pronuclear injection with 
random insertion of the transgenes, although recent advances indicate that gene 
targeting may be feasible using somatic cells (Clark et a! 2000, Denning et a! 2001). 
A possible strategy to ensure that expression levels are enhanced is to use QTL 
analysis to identify strains and individuals containing traits associated with high 
expression in the tissue where the transgene is to be expressed. If the transgenic 
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protein is to be secreted into the milk, then animals with QTL traits indicative of high 
milk yields, possibly selected for high yields of a particular fraction of the milk 
proteins (caseins versus whey), could be chosen in the hope that the transgene will 
also benefit. Identification of proteins and other factors that generally improve 
expression from a variegating construct could also be used to identify individuals or 
strains with the most advantageous qualitative and quantitative combinations of 
modifying factors. 
6.6.2 Exploiting a knowledge of modifier loci in the treatment of human 
diseases 
The multitude of factors shown to exert an effect on gene expression may explain 
why many human diseases display varied phenotypes despite being caused by the 
same gene. 
Variable expressivity of autosomal dominant diseases is one of the more suggestive 
examples that different combinations of modifier loci exert a variable effect on 
disease phenotype. Polydactyly is one example where there is both variable 
expressivity with differences in phenotypic manifestation and instances of 
incomplete penetrance. The basic genetic basis for this, especially the incomplete 
penetrance, is unknown. As limb development is a multifactorial process, some 
genetic combinations may be able to modify and even prevent the phenotypic 
manifestation of the mutated gene. Differences in modifier loci may explain a 
reported incidence of two siblings with the same ICF (immunodeficiency, 
centromeric instability, facial anomalies) syndrome genotype, only one of which 
exhibited the full-blown genotype (Gimelli et a! 1996). 
Another example of a phenotypically heterogeneous condition is 
fasciocapulohumeral muscular dystrophy (FSHD). The actual gene responsible for 
FSHD has not been identified, but the disease is linked to translocation events 
occurring between defined regions on chromosomes 4 and 10 involving the 
telomeres. This suggests that PEV may be responsible for the disease as the 
translocation breakpoints vary and thus cannot be disrupting the same gene at the 
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breakage site (van Deutekon et a! 1996). FSHD is an autosomal dominant disease, 
with variable clinical severity and age of onset that is evident even within the same 
family (Fisher & Upadhyaya 1997). The phenotype could be linked to variable 
spread of heterochromatin from the telomeres into the disease locus causing variable 
expression of the gene that will differ between individuals. In addition, it is not 
inconceivable that the amount of expression from the unaffected allele, and/or extent 
of heterochromatin spread and silencing of the diseased locus, could be influenced by 
differences in modifier protein combinations that will naturally vary between 
individuals, even if closely related. It could be that the relative strength of repressive 
and activating factors able to act at a particular locus will determine the severity of 
the disease phenotype. A final possibility lies in the identification of one of the 
candidate FSDH genes as a member of a multigene family with related sequences on 
other chromosomes. Other family members may, depending on individual allele 
combinations, be able to substitute for some of the FSHD gene functions and lessen 
the impact of the disease. 
The ability of other gene family members to substitute for each other may explain 
why holoprosencephaly, caused by sonic hedgehog haploinsufficiency, exhibits 
variable phenotypic manifestations is not seen in all hemizygous individuals 
(Kleinjan & van Heyningen 1998). 
6.6.3 A role for somatic mutation in human PEV? 
Although accepting the presence and involvement of phenotypic modifier genes, 
Gottlieb and colleagues (2001) suggest that somatic mosaicism may underlie variable 
expressivity in some human diseases. Androgen insensitivity syndrome (AIS) was 
quoted as a prime example, with heterogeneity of cancer tissues an accessory 
example. In view of AIS being an X-linked disease, my personal feeling is that this 
gene would be more susceptible to somatic-mutation-induced disease phenotypes (as 
are all sex-linked genes), and should be considered an exception rather than a rule. 
AIS is a single locus disease. With many diseases, including non-familial cancers, 
reputed to be multi-locus multi-factorial with environmental conditions impacting on 
phenotype and disease progression, it is my belief that individual variations in both 
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qualitative and quantitative aspects of modifier and "accessory" loci undoubtedly 
contribute to phenotype. 
6.6.4 Using the knowledge of modifier loci for future treatment strategies 
It is my belief the identification of general modifier genes involved in regulation of 
PEV, and linked by animal models to defined human PEV medical conditions, could 
be used to develop alternative treatments. Introduction of proteins that can upregulate 
expression from the variegating locus, or chemically inducing the relevant cells to 
produce more of the modifier protein, could be used to alleviate symptoms in 
conditions where haploinsufficiency in the primary cause of the phenotype. Such 
intervention could provide a safe alternative to gene therapy at a time when targeted 
integration needs the harvesting of stem cell populations from the patient and 
reintroduction of the manipulated stem cells, a process that is lengthy, costly and 
unable to guarantee long-term success at this moment in time. I have no doubts that 
targeted gene therapy will one day become almost as routine as treatment of bacterial 
infections with penicillin and its derivatives, but until that day arrives, alternative 
treatment options must be sought. 
A candidate for testing this approach would be Campomelic dysplacia patients with 
50X9 translocations. Patients with translocations usually exhibit much milder 
clinical symptoms than those with mutations in the 50X9 gene coding region 
(Kleinjan & van Heyningen 1998). One of the phenotypic symptoms is sex reversal, 
which could possibly be re-reversed through upregulation of expression in the testis 
of patients. A more difficult challenge would be targeting of modifier protein 
expression to skeletal cells in order to alleviate the malformations also associated 
with this disease. Once the practicalities of the treatment are sorted out, timing of the 
treatment would be important. I still think that if treatment is initiated early, before 
completion of development and growth phases, it should be successful and 
applicable to a wide range of human conditions. The exceptions would be those 
diseases where development of the affected organs is completed in utero. The 
challenge for these diseases would be early identification of the disease and 
development of a delivery system that does not affect the mother. 
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6.7 Trans-interactions and PEV loci 
The variegating transgene locus of BLG/7 exhibits an unusual property in addition to 
PEV. This property is only manifested in individuals homozygous for the transgene 
locus, with only one of the two loci active in any given cell. This is reminiscent of 
transvection and paramutation phenomena in Drosophila and plants, but differs 
significantly inasmuch as maximum expression levels remain on par with 
hemizygous individuals, as does the number of expressing cells. Transvection can 
lead to up-regulation of expression or, in common with paramutation events, 
silencing of expression from both paired loci. There is no direct evidence yet for 
BLG/7 homologous loci interaction, but the mono-allelic expression is highly 
suggestive of such an event taking place. 
The single locus expression seen in BLG/7 has never before been reported in 
transgenic mammals. Only one similar phenomenon has to my knowledge ever been 
reported for transgenes, and that involved transgenic plants where the experimental 
design was to reproduce transvection interactions (Matzke et a! 2001). The 
infrequent reports of transvection in Drosophila, suggests that homology interactions 
affecting transcription are rare events. Monoallelic expression is of course seen in 
mammals, as the result of imprinting and dosage compensation mechanisms for sex-
chromosome linked genes. Recent reports also suggest that some autosomal genes 
lacking known imprints may be monoallelically expressed (4.5.6), although it is not 
known if any trans-homology interactions are involved in the regulatory process. As 
none of these genes are subject to PEV, BLG/7 homozygous mice may not be the 
best model for this documented intended monoallelic expression from endogenous 
genes. 
6.7.1 Why we need to understand the interactions leading to monoallelic 
expression 
Although reported trans-homology silencing is rare in animals, especially mammals, 
elucidation of the mechanisms responsible could not only prove useful in transgenic, 
but may help explain certain human diseases. Despite a lack of direct evidence, it is 
speculated that trans-homology interactions could play a role in the progression of 
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some autosomal dominant diseases. Anomalies in linkage maps compiled for several 
human diseases, including Huntingdon's Chorea, may be explained through trans-
inactivation of the healthy homologue that is occasionally maintained through 
meiosis (Sabi & Laird 1992). There is even a suggestion that trans-homology 
interactions may be involved in the X-chromosome inactivation process (Marahrens 
1999), and could be a requirement for monoallelic expression from imprinted genes 
(LaSalle & Lalande 1996). Should this be the case, then it suggests that homology 
sensing systems are operational in mammalian systems, and that the monoallelic 
expression pattern of homozygous BLG/7 mice is the result of activation of this 
system. 
Progressive trans-inactivation, where the necessary pairing takes place in a limited 
period during the cell cycle, could be used as a model to explain progressive diseases 
that exhibit variable speed of symptom progression and age of onset. It could be that 
once inactivation takes place the decision is irreversible, such that each round of cell 
division increases the proportion of inactivated cells until there are not enough active 
cells remaining to halt the disease. Candidate diseases include many of the autosomal 
dominant muscular dystrophies, such as fascioscapulohumeral muscular dystrophy 
(FSHD), as well as the aforementioned Huntingdons Disease. The triplet repeat 
expansions characteristic of these diseases (Spiegel 1997) may act as foci for 
heterochromatin formation, and the pairing of the two alleles leading to inactivation 
of the healthy allele in a manner analogous to transvection of the brown gene in 
Drosophila (1.7). 
A single paper was found with evidence to support a role for trans-homology 
interactions in human gene expression control and disease. The paper shows that 
manifestation of type 1 diabetes depends not only on the genes inherited, but also on 
the allelic identity of the non-inherited homologue from the paternal side (Bennett et 
a! 1997). This example combines a trans-homology effect with a parent of origin 
effect, highlighting the complexity of inheritance and the problems that can be 
encountered when trying to match phenotype with genotype. 
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6.8 Using BLG/7 as a model system for complex diseases involving 
both PEV and suspected trans-interactions 
The experimental evidence, especially that gained in chapter 3, suggests strongly that 
BLG/7 variegation is a classical position effect analogous to the Drosophila PEV 
phenomenon. This makes BLG/7 an ideal experimental system for investigating 
general mechanisms affecting PEV in mammals. The monoalleic expression 
resulting from the presence of two homologous transgene loci in BLG/7 is unique, 
and could be used to investigate possible common links between rare dominant 
diseases in mammals. The results could be used to devise a general strategy of 
combating position effects in human disease and improving the performance of 
transgenic animals. 
6.8.1 BLG/7 as a model system for autosomal dominant diseases 
The combination of PEV and possible homologous interactions at the BLG/7 locus in 
homozygous mice does make them a possible model system for studying common 
elements that may link certain dominant autosomal human diseases. These diseases 
could be classified as being caused by a position effect, but instead of translocations 
causing the disease, expansions of repeat sequences within the area occupied by the 
gene and its regulatory components are linked with the disease phenotype. The repeat 
expansions could initiate formation of heterochromatin at the site, which in turn 
could lead to silencing of the whole gene (as demonstrated by Dorer & Henikoff 
1994). Parallels could also be drawn with the dominant brown' mutation seen in 
Drosophila, which can trans-inactivate homologous genes (Dreesen et a! 1991, 
Csink & Henikoff 1996, Dernburg et al 1996). 
Dominant repeat expansion mutations 
A classic example of repeat expansions causing human disease phenotype is the 
fragile X mental retardation syndrome. Here, mutations of the FMR1 gene 
commonly consist of a CGG repeat expansion that coincides with methylation and 
deacetylation of the gene, preventing transcription from the site (Coffee et a! 1999). 
At least 12 human diseases are associated with trinucleotide repeat expansions. Some 
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of these expansions are found in the coding region and the resulting phenotype is 
attributed to gain/loss of function and/or functional knockout or haploinsufficiency. 
6.8.2 Candidate autosomal dominant conditions that may be the result of 
trans-homology interactions. 
My particular interest lies in the autosomal dominant conditions where triplet repeat 
expansions associated with the disease are found outside the coding region. 
Myotonic Dystrophy 
Myotonic dystrophy (DM) is one example, with the CTG expansion in a non-coding 
area with a size varying from 35-2000 copies. DM has 3 clinical forms and exhibits 
huge variations in both phenotypic manifestations and age of onset, with some 
obligate carriers displaying no clinical symptoms at all (Spiegel 1997). I suggest that 
the progressive nature of this muscle-wasting disease, coupled with a generally later 
age of onset in 2/3 clinical forms, indicates the possibility that trans-homology 
interactions between the mutated locus and its normal counterpart during cell 
division may take place. The repeats could form an initiation site for heterochromatin 
formation, whose action may be to tether the locus to constitutive heterochromatic 
sites in the genome and inactivate the gene and/or spread into the whole locus 
denying access to the transcriptional machinery. Pairing during cell division could 
result in the irreversible inactivation of the healthy allele in a manner analogous to 
transvection or paramutation. The outcome of each interaction may depend on the 
balance of modifying factors in the nuclear location at the time of the interaction 
taking place. As a person ages, there is increased chance that a given interaction will 
inactivate the healthy allele, and coupled with the irreversible nature of the 
inactivation could explain the gradual onset of the disease. Variable phenotypes 
could thus be a combination of chance and differences in individual modifier genes 
influencing PEV and/or trans-homology pairing. The maternally transmitted neonatal 
congenital DM could be a combination of maternal germline repeat expansion and/or 
in utero effects that enhance the pairing and inactivation events. 
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Huntingdon Disease 
Huntingdon Disease is another repeat expansion associated disease, but the repeats 
are in the coding region of the gene, with gain of function the suggested cause of the 
phenotype (Spiegel 1997). The progressive nature and generally late age of onset of 
the disease is all the same suggestive of a possible trans-homology effect also 
affecting phenotype. If haplo-insufficiency and/or gain of function was the cause of 
huntingdons disease, I would expect the symptoms to appear earlier in most patients 
and the phenotype to remain stable in an individual. An epigenetic modification as 
one cause of HD is suggested by reports of HD in genotypically normal individuals, 
indicating the possible inheritance of an epigenetically inactivated normal allele 
through the germline that is capable of acting as a HD allele, in a manner analogous 
to paramutation phenomena in plants. 
Both HD and DM share the trait of anticipation, associated with increased repeat 
expansion that may increase heterochromatinisation at the site and strengthen pairing 
interactions and tip the balance in favour of inactivation. Severity and size of the 
repeat expansion are linked in all the triplet expansion diseases, which correlates 
with my theory that the triplet repeats form foci for heterochromatin formation and 
be central to the directional inactivation events through pairing interaction. 
The similarities of the triplet repeat expansion diseases, with variable phenotypes and 
age of onset with gradual worsening of the condition suggests that they may share 
some common triggers. BLG/7 could be used to dissect out candidate genes for these 
triggers and generate a working model for how they act. 
6.9 Concluding Remarks 
The creation of a transgenic line of mice subject to position effect variegation was 
serendipitous. The subsequent identification and characterisation of the trait in 
BLG/7 was due to observation and implementation of scientific methodology. The 
realisation of the importance of the observations of the initial investigations 
prompted further investigations of this transgenic line. 
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My investigations into BLG/7 variegation have revealed this line exhibits a variety of 
traits that are linked to the variegating transgenic locus. This line can be used as a 
unique tool to investigate both multiple modifier loci capable of influencing the 
extent of variegation, and the rare phenomenon of trans-homology interaction 
resulting in mono-allelic expression. 
The first example can be used to devise improvements of product yield from 
transgenic stock, whilst both can be used to model mechanisms of human diseases 
and suggest possible therapeutic interventions. 
BLG/7 is thus a valuable resource, which with careful experimental design and 
execution could push the frontiers of both transgenic research and medicine. 
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Appendix 
A.1) Raw data for inbred and outcrossed milk samples 
Label SD BLG Bcasein AdiBLG Label SD BLG Bcasein Adi.BLG 
ua ua ma/ml ua ua ma/mi 
C57 711 0.02 1.11 1.44 6.24 C57 1 0.03 1.08 1.44 6.16 
C57 712 0.01 0.75 1.48 4.10 C57 2 0.02 0.76 1.43 4.16 
C57 713 0.02 1.08 1.5 5.83 C57 3 0.04 1.05 1.49 4.86 
C57714 0.02 0.91 1.79 4.12 C574 0.03 0.94 1.76 5.43 
C57 715 0.01 0.65 1.4 3.76 C57 5 0.02 0.67 1.41 3.59 
C57716 0.03 1.53 1.66 7.47 C576 0.05 1.39 1.52 7.45 
C57 717 0.02 0.88 1.51 4.72 C57 7 0.03 0.87 1.52 4.89 
C57 718 0.02 0.93 1.44 5.23 C57 8 0.03 0.92 1.45 5.36 
C57 719 0.01 0.98 1.35 5.88 C57 9 0.03 0.97 1.4 4.85 
C4 Bcas 0.02 0 1.62 C4 Bcas 0.04 0 1.63 
C57 711 0.03 1.15 1.47 6.26 C57 17 10 0.03 0.94 1.69 4.48 
C57 712 0.02 0.75 1.45 4.14 C57 1711 0.04 1.47 1.9 6.23 
C57 713 0.03 1.07 1.45 5.90 C57 17 12 0.03 1.12 1.51 5.97 
C57 714 0.03 0.96 1.82 4.22 C57 17 13 0.08 2.45 2.39 8.25 
C57 715 0.02 0.71 1.42 4.00 C57 17 14 0.01 0.23 1.63 1.14 
C57 716 0.05 1.53 1.66 7.37 C57 17 15 0.04 1.75 2.24 6.29 
C57 717 0.03 0.88 1.5 4.69 C57 17 16 0.03 0.88 1.4 5.06 
C57 718 0.03 0.93 1.41 5.28 C57 17 17 0.04 1.27 1.71 5.98 
C57 719 0.02 0.87 1.31 5.31 C57 17 18 0.03 1.22 1.48 6.64 
C4 Bcas 0.06 0 1.6 C4 Bcas 0.04 0 1.61 
C5771 10 0.01 0.53 1.14 3.35 C5771 10 0.03 0.97 1.76 4.63 
C5771 11 0.02 0.96 1.23 5.62 C5771 11 0.05 1.44 1.91 6.33 
C57 71 12 0.02 0.84 1.06 5.71 C57 71 12 0.04 1.11 1.56 5.98 
C57 7113 0.05 1.95 1.76 7.98 C57 7113 0.08 2.47 2.48 8.37 
C57 7114 0.01 0.01 0.6 0.12 C57 7114 0.01 0.39 1.7 1.93 
C57 7115 0.03 1.62 1.92 6.08 C57 7115 0.07 1.77 2.31 6.44 
C57 7116 0.02 0.63 1.07 4.24 C57 7116 0.02 0.89 1.47 5.09 
C57 7117 0.02 0.95 1.22 5.61 C57 7117 0.04 1.26 1.79 5.91 
C5771 18 0.02 1.03 1.15 6.45 C57 71 18 0.04 1.22 1.55 6.61 
C4 Bcas 0.03 0 1.44 C4 Bcas 0.05 0 1.68 
C5717 19 0.06 1.67 1.38 9.80 CBA 14 0.03 1.04 1.53 5.47 
C5717 19 0.05 1.66 1.35 9.96 CBA16 0.03 0.83 1.24 5.39 
C57 1720 0.07 1.05 1.5 5.67 CBA17 0.02 0.8 1.32 4.88 
C57 1720 0.04 0.97 1.43 5.49 C57 3 0.03 1.15 1.57 5.90 
C571721 0.06 1.47 1.21 9.84 C574 0.03 0.91 1.79 4.09 
C5717 21 0.06 1.45 1.2 9.79 C57 9 0.03 0.97 1.36 5.74 
C5717 11 0.06 1.37 1.81 6.13 C57 9 0.03 0.98 1.34 5.89 
c57 17 13 0.06 2.25 2.17 8.40 C57 10 0.02 0.94 1.68 4.50 
C57 17 16 0.03 0.9 1.35 5.40 C57 19 0.04 1.66 1.37 9.75 
CBA 17 9 0.03 0.82 1.25 5.31 C4 Bcas 0.06 0 1.61 
C4 Bcas 0.05 0 1.62 
CBA 10 0.04 1.34 2.21 6.46 
CBA 1 0.02 0.61 1.33 3.26 CBA 12 0.02 0.76 1.79 4.52 
CBA 2 0.01 0.5 1.31 2.71 CBA 15 0.03 0.58 1.41 4.38 
CBA3 0.02 0.56 1.14 3.49 CBA 16 0.03 0.58 1.3 4.75 
CBA4 0.03 1.1 1.63 4.79 CBA 18 0.03 0.56 1.86 3.21 
CBA5 0.03 1.06 1.86 4.05 C57 19 0.05 1.63 2.02 8.59 
CBA6 0.02 0.9 1.85 3.45 C5720 0.03 0.98 1.94 5.38 
CBA8 0.01 0.47 1.35 2.47 C5721 0.03 1.6 1.85 9.21 
C4 Bcas 0.03 0 1.42 C4 Bcas 0.03 0 2.13 
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Label SD BLG Bcasein AdI.BLG Label SD BLG Bcasein Adj.BLG 
uq uq mq/ml uq ug mq/ml 
CBA 1 0.03 0.73 1.82 3.25 CBA 3 0.01 0.59 1.58 3.40 
CBA2 0.02 0.52 1.67 2.52 CBA4 0.02 1.08 2.04 4.82 
CBA7 0.05 1.44 1.77 6.59 CBA5 0.02 1.06 2.27 4.25 
CBA 10 0.05 1.45 1.81 6.49 CBA6 0.02 0.99 2.31 3.90 
CBA 11 0.02 0.56 1.67 2.72 CBA7 0.02 1.44 1.95 6.72 
CBA13 0.03 0.79 1.64 3.90 CBA8 0.01 0.56 1.83 2.78 
CBA 13 0.03 0.79 1.66 3.85 C4 Bcas 0.03 0 1.82 
CBA 14 0.03 0.94 1.42 5.36 
C4 Bcas 0.06 0 1.62 CBA 11 0.02 0.56 1.02 3.07 
CBA 12 0.03 0.86 1.35 3.57 
CBA 1 0.03 0.75 1.81 3.34 CBA 15 0.03 0.83 0.98 4.74 
CBA2 0.02 0.62 1.8 2.77 CBA17 0.02 0.64 0.86 4.17 
CBA3 0.02 0.67 1.49 3.62 C4 Bcas 0.03 0 1.12 
CBA4 0.04 1.06 1.86 4.59 
CBA5 0.04 1.07 2.05 4.20 MP 1.3 0.08 1.33 1.46 10.31 
CBA6 0.04 1.03 2.11 3.93 MP 1.5 0.04 0.81 1.5 6.11 
CBA7 0.05 1.43 1.75 6.58 MP 1.6 0.07 1.07 1.22 9.92 
CBA8 0.02 0.56 1.62 2.78 MP 1.7 0.05 0.78 1.54 5.73 
CBA9 0.03 0.91 1.37 5.35 MP 1.11 0.07 1.09 1.56 7.90 
CBA9 0.03 0.92 1.35 5.49 MP 1.12 0.07 1.02 1.32 8.74 
C4 Bcas 0.04 0 1.61 MP 1.14 0.06 0.98 1.57 7.06 
MP 1.15 0.05 0.94 1.5 7.09 
CBA 10 0.04 1.44 1.81 6.17 MP 3.2 0.06 1.32 1.38 10.82 
CBA 11 0.02 0.66 1.8 2.84 C5 Bcas 0.1 0 1.81 0.00 
CBA12 0.02 1.16 1.62 5.55 
CBA 13 0.02 0.91 1.77 3.98 MP 1.3 0.03 1.34 1.43 10.13 
CBA 14 0.02 0.93 1.43 5.04 MP 1.5 0.03 1.17 2.03 6.23 
CBA 15 0.02 0.99 1.54 4.98 MP 1.6 0.04 1.81 1.96 9.99 
CBA 16 0.02 0.72 1.06 5.26 MP 1.7 0.03 1.12 2.04 5.94 
CBA 17 0.01 0.68 1.14 4.62 MP 1.11 0.05 1.91 2.62 7.88 
CBA 18 0.01 0.73 1.72 3.29 MP 1.12 0.04 1.81 2.05 9.55 
CBA 18 0.01 0.76 1.73 3.40 MP 1.14 0.03 1.67 2.31 7.82 
C4 Bcas 0.03 0 1.55 MP 1.15 0.03 1.49 1.99 8.10 
MP 3.2 0.04 1.62 1.66 11.04 
MP 1.3 0.02 1.25 1.35 10.42 CS Bcas 0.04 0 1.73 0.00 
MP 1.5 0.02 0.99 1.78 6.26 
MP 1.6 0.02 1.23 1.39 9.96 MP 3.3 0.04 0.97 1.7 6.60 
MP 1.7 0.02 0.82 1.57 5.88 MP 5.3 0.03 0.88 1.37 7.43 
MP 1.11 0.03 1.2 1.65 8.18 MP 6.3 0.07 1.62 1.74 10.77 
MP 1.12 0.02 0.9 1.24 8.17 MID 6.4 0.07 1.33 1.7 9.05 
MP 1.14 0.02 0.88 1.46 6.78 MP 6.5 0.07 1.39 2.4 6.70 
MP 1.15 0.01 0.8 1.26 7.14 MP 6.6 0.05 1.06 1.09 11.24 
MP 3.2 0.02 0.98 1.07 10.30 MP 6.7 0.04 0.75 1.27 6.83 
C5 Bcas 0.04 0 1.8 0.00 CS Bcas 0.06 0 1.85 
MID 3.3 0.02 0.74 1.38 6.07 MP 3.3 0.02 1.46 0.81 6.28 
MP 5.3 0.03 1.04 1.59 7.40 MP 5.3 0.02 1.47 0.92 7.08 
MID 6.3 0.03 1.17 1.27 10.42 MP 6.3 0.02 1.29 1.21 10.61 
MID 6.4 0.03 1.11 1.45 8.66 MID 6.4 0.02 1.4 1.03 8.32 
MID 6.5 0.03 1.11 2 6.28 MP 6.5 0.03 2.23 1.36 6.90 
MP 6.6 0.02 0.85 0.89 10.80 MP 6.6 0.02 1.34 1.29 10.89 
MID 6.7 0.02 0.66 1.17 6.38 MP 6.7 0.01 1.27 0.76 6.77 
C5Bcas 0.04 0 1.81 C5Bcas 0.04 0 1.8 
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A.2) Raw data for hemi- and homozygous milk samples 
Label SD BLG Bcasein Adj.BLG Label SD BLG Bcasein Adj.BLG 
ug ug Mg/Ml ug ug Mg/Ml 
Hi 0.04 1.82 1.27 14.33 Hi 0.03 1.83 1.29 14.19 
H2 0.02 0.91 1.07 8.50 H2 0.02 0.98 1.09 8.99 
H3 0.03 1.1 1.34 8.21 H3 0.02 1.11 1.35 8.22 
H4 0.06 2.23 1.23 18.13 H4 0.03 2.19 1.23 17.80 
H5 0.04 1.35 2.1 6.43 H5 0.02 1.32 2.09 6.32 
H6 0.05 1.9 1.69 11.24 H6 0.04 1.89 1.65 11.45 
H7 0.02 0.79 1.51 5.23 H7 0.01 0.79 1.53 5.16 
H8 0.03 0.99 1.33 7.44 H8 0.02 1.04 1.35 7.70 
H9 0.02 0.97 1.2 8.08 H9 0.02 0.93 1.16 8.02 
C5 Bcas 0.05 0 1.6 H10 0.02 0.81 1.44 5.63 
C5Bcas 0.03 0 1.6 
HI 0.02 1.8 1.3 13.76 Hil 0.03 0.72 0.95 7.67 
H2 0.01 0.93 1.03 8.97 H12 0.03 0.59 1.17 5.11 
H3 0.02 1.1 1.36 8.04 H13 0.04 0.97 1.57 6.26 
H4 0.03 2.04 1.06 19.13 H14 0.02 0.49 1.19 4.17 
H5 0.02 0.94 1.7 5.49 H15 0.04 1.19 1.1 10.95 
H6 0.03 1.68 1.46 11.43 H16 0.03 0.72 0.99 7.36 
H7 0.02 0.83 1.54 5.36 H17 0.04 0.95 1.1 8.74 
H8 0.02 1.09 1.36 7.96 H19 0.01 0.4 1.13 3.58 
H9 0.02 0.94 1.19 7.85 H20 0.03 0.93 1.26 7.47 
HiO 0.01 0.78 1.42 5.46 C5 Bcas 0.05 0 1.62 
C5 Bcas 0.02 0 1.59 
H10 0.03 0.83 1.48 5.68 Hil 0.03 1.02 1.24 8.23 
Hil 0.03 0.79 0.99 8.08 H12 0.02 0.87 1.47 5.92 
H12 0.02 0.69 1.2 5.82 H13 0.04 1.11 1.75 6.34 
H13 0.03 0.96 1.51 6.44 H14 0.01 0.63 1.33 4.74 
H14 0.02 0.54 1.25 4.37 H15 0.04 1.11 1.2 9.25 
H15 0.05 1.21 1.1 11.14 H16 0.02 0.96 1.27 7.56 
H16 0.03 0.79 1.01 7.92 H17 0.04 1.22 1.37 8.91 
H17 0.03 0.99 1.02 9.83 H19 0.01 0.55 1.26 4.37 
H19 0.01 0.51 1.12 4.61 H20 0.03 0.98 1.33 7.37 
H20 0.03 0.96 1.25 7.78 C5 Bcas 0.05 0 1.6 
C5 Bcas 0.05 0 1.62 
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Label 	SD BLG Bcasein AdJ.BLG Label SD BLG Bcasein Adj.BLG 
ug ug mg/ml 
HH1 0.05 2.41 1.4 17.21 
HH2 0.05 3.1 2.18 14.22 
HH3 0.04 1.47 1.49 9.87 
HH4 0.05 2.43 2.52 9.64 
HH5 0.06 2.72 2.78 9.78 
HH6 0.05 2.61 2.68 9.74 
HH7 0.04 1.47 1.92 7.66 
HH8 0.04 1.91 1.63 11.72 
HH9 0.02 0.52 0.49 10.61 
C5 Bcas 0.04 0 1.6 
HH1 0.05 3.03 2.31 13.12 
HH2 0.06 3.41 2.66 12.82 
HH3 0.04 1.47 1.59 9.25 
HH4 0.06 2.75 2.82 9.75 
HH5 0.06 2.86 2.93 9.76 
HH6 0.06 3.33 2.88 11.56 
HH7 0.04 1.47 1.92 7.66 
HH8 0.05 2.66 2.24 11.88 
HH9 0.02 0.52 0.56 9.29 
C5 Bcas 0.04 0 1.6 
HH11 0.06 2.28 1.19 22.51 
HH12 0.04 1.28 1.17 12.85 
HH13 0.06 1.98 1.49 15.61 
HH14 0.05 1.47 1.85 9.34 
HH15 0.06 1.95 1.98 11.57 
HH16 0.06 2.07 2.53 9.61 
HH17 0.08 3.29 1.96 19.72 
HH18 0.03 1.02 1.05 11.41 
HH19 0.06 1.65 1.25 15.51 
HH20 0.06 1.97 1.69 13.70 
05 Bcas 0.05 0 1.88 
HH11 0.08 2.94 1.66 17.82 
HH12 0.05 1.69 1.95 8.72 
HH13 0.07 2.41 2.19 11.07 
HH14 0.06 1.84 2.07 8.94 
HH15 0.08 2.77 2.4 11.61 
HH16 0.07 2.54 3.38 7.56 
HH17 0.09 3.45 1.88 18.47 
HH18 0.04 1.29 1.11 11.69 
HH19 0.06 1.68 1.36 12.43 
HH20 0.06 1.97 1.65 12.01 
C5Bcas 0.04 0 1.61 
ug ug mg/ml 
HH1 2.02 1.36 0.44 17.22 
HH2 2.56 1.7 0.67 14.33 
HH3 1.21 1.33 0.62 7.32 
HH4 1.85 1.95 0.4 17.34 
HH5 1.86 1.93 0.41 17.01 
HH6 2.24 1.77 0.41 20.49 
HH7 1.44 1.9 0.52 10.38 
HH8 1.84 1.43 0.64 10.78 
HH9 0.6 0.65 0.26 8.65 
HH11 2.74 1.45 0.65 15.81 
C5 Bcas 0 1.58 0 
HH1 0.04 2.73 2.04 13.63 
HH2 0.06 2.65 1.9 14.21 
HH3 0.03 1.37 1.48 9.43 
HH4 0.05 2.42 2.58 9.56 
HH5 0.06 2.79 2.86 9.94 
HH6 0.06 2.8 2.32 12.30 
HH7 0.03 1.49 1.95 7.78 
HH8 0.04 2.12 1.69 12.78 
HH9 0.01 0.69 0.74 9.50 
HH11 0.04 2.95 1.66 18.10 
C5 Bcas 0.03 0 1.63 
HH 12 0.05 2.35 2.81 9.41 
HH 13 0.05 2.73 2.72 11.29 
HH 14 0.04 2.09 2.56 9.18 
HH 15 0.05 2.91 2.76 11.86 
HH 16 0.05 2.55 3.57 8.04 
HH 17 0.07 3.6 2.12 19.10 
HH 18 0.04 1.59 1.62 11.04 
HH 19 0.03 1.69 1.52 12.51 
HH 20 0.04 2 1.83 12.30 
C5 Bcas 0.04 0 1.8 
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A.3) Raw data for MOP milk samples 
Label SD BLG Bcasein AdJ.BLG Label SD BLG Bcasein AdJ.BLG 
ug ug Mg/Ml ug ug Mg/Ml 
MOP 1.1 0.07 2.25 1.46 15.80 MOP 1.1 0.04 2.01 1.13 16.68 
MOP 1.2 0.08 2.42 1.31 18.94 MOP 1.2 0.05 2.15 0.95 21.22 
MOP 1.3 0.07 2 1.47 13.95 MOP 1.3 0.04 1.74 1.12 14.56 
MOP 2.1 0.03 0.88 1.66 5.43 MOP 2.1 0.02 0.87 1.55 5.26 
MOP 2.3 0.06 1.48 1.15 13.19 MOP 2.2 0.02 0.76 1.3 5.48 
MOP 2.4 0.05 1.32 1.32 10.25 MOP 2.3 0.04 1.46 1.06 12.91 
MOP 2.5 0.04 1.22 1.21 10.33 MOP 2.4 0.03 1.42 1.32 10.09 
MOP 4.3 0.03 0.78 0.91 8.79 MOP 2.5 0.02 1.03 0.94 10.27 
MOP 4.4 0.02 0.62 0.83 7.66 MOP 3.1 0.02 0.75 1.29 5.45 
CS Bcas 0.06 0 1.64 CS Bcas 0.04 0 1.5 
MOP 1.1 0.09 2.26 1.43 15.90 MOP 2.2 0.02 0.75 1.4 5.39 
MOP 1.2 0.09 2.4 1.28 18.87 MOP 3.1 0.02 0.75 1.39 5.43 
MOP 1.3 0.08 1.7 1.15 14.88 MOP 4.3 0.02 0.91 1.07 8.56 
MOP 2.1 0.06 0.88 1.66 5.33 MOP 4.4 0.02 0.82 1.05 7.86 
MOP 2.2 0.04 0.73 1.37 5.36 MOP 10.2 0.02 0.85 1.48 5.78 
MOP 2.3 0.08 1.58 1.3 12.23 MOP 11.1 0.02 0.93 1.43 6.54 
MOP 2.4 0.07 1.34 1.29 10.45 MOP 13.2 0.02 0.96 1.25 7.73 
MOP 2.5 0.05 1.16 1.25 9.34 MOP 15.2 0.01 0.56 1.13 4.99 
MOP 3.1 0.04 0.92 1.24 7.47 MOP 16.1 0.02 0.7 1.37 5.14 
CS Bcas 0.07 0 1.61 C5 Bcas 0.04 0 1.61 
MOP 4.3 0.04 0.97 1.17 8.71 MOP 5.2 0.04 1.42 1.24 11.59 
MOP 4.4 0.03 0.89 1.18 7.92 MOP 6.3 0.02 0.48 0.99 4.91 
MOP 5.2 0.06 1.67 1.51 11.61 MOP 6.4 0.04 1.18 1.5 7.97 
MOP 6.3 0.03 0.59 1.12 5.53 MOP 6.5 0.03 0.79 1.36 5.88 
MOP 6.4 0.05 1.22 1.58 8.11 MOP 7.2 0.03 0.7 1.04 6.81 
MOP 6.5 0.05 1.05 1.65 6.68 MOP 7.4 0.03 0.74 1.41 5.31 
MOP 7.2 0.04 0.94 1.31 7.53 MOP 9.1 0.03 0.71 1.15 6.25 
MOP 7.4 0.03 0.78 1.43 5.73 MOP 10.1 0.02 0.61 1.17 5.28 
MOP 9.1 0.03 0.95 1.43 6.98 MOP 10.2 0.02 0.54 1.17 4.67 
CS Bcas 0.07 0 1.68 C5 Bcas 0.06 0 1.62 
MOP 5.2 0.07 1.94 1.76 11.37 MOP 10.1 0.02 0.6 1.22 5.01 
MOP 6.3 0.03 1.02 1.55 6.79 MOP 10.3 0.05 1.1 1.31 8.55 
MOP 6.4 0.05 1.6 1.94 8.51 MOP 10.8 0.03 0.6 1.36 4.49 
MOP 6.5 0.05 1.35 1.91 7.29 MOP 10.9 0.02 0.47 1.17 4.09 
MOP 7.2 0.05 1.43 1.77 8.33 MOP 10.12 0.01 0.29 1.02 2.90 
MOP 7.4 0.04 1.18 1.86 6.54 MOP 11.1 0.05 1.34 1.87 7.30 
MOP 9.1 0.05 1.33 1.76 7.79 MOP 11.5 0.02 0.55 1.44 3.89 
MOP 10.1 0.03 1.01 1.56 6.68 MOP 11.7 0.02 0.6 1.42 4.30 
MOP 10.2 0.02 0.84 1.49 5.81 MOP 11.8 0.02 0.72 1.5 4.89 













BLG Bcasein Adj./Bcas 
ug 	ug mg/ml 
1.38 1.6 8.89 
0.77 1.58 5.03 
0.7 1.45 4.98 
0.76 1.55 5.06 
0.77 1.62 4.90 
0.72 1.54 4.82 
0.94 1.75 5.54 
1.57 1.62 9.99 
1.46 1.82 8.27 
0 1.65 
Label SD BLG 
ug 
MOP 10.3 0.03 1.29 
MOP 10.8 0.02 0.78 
MOP 10.9 0.02 0.81 
MOP10.12 0.02 0.91 
MOP 11.1 0.03 1.22 
MOP 11.5 0.02 0.61 
MOP 11.7 0.02 0.88 
MOP 11.8 0.02 0.9 
MOP 12.4 0.03 1.53 
























MOP 12.4 0.05 1.43 1.42 10.01 MOP 12.5 0.03 1.2 1.54 
MOP 12.5 0.05 	1.5 1.83 8.15 MOP 13.2 0.03 1.05 1.39 
MOP 13.2 0.05 1.36 1.68 8.04 MOP 13.7 0.03 1.31 1.25 
MOP 13.7 0.05 1.44 1.36 10.52 MOP 13.8 0.01 0.61 1.37 
MOP 13.8 0.03 0.61 1.4 4.33 MOP 15.2 0.02 0.68 1.27 
MOP 13.7 0.04 1.45 1.38 10.44 MOP 16.1 0.03 0.82 1.51 
MOP 13.8 0.03 0.63 1.37 4.57 MOP 5.2 0.04 1.37 1.2 
MOP 15.2 0.02 	0.5 1.09 4.56 MOP 6.3 0.02 0.68 1.18 
MOP 16.1 0.03 0.76 1.44 5.24 MOP 6.4 0.02 1.01 1.29 
C5 Bcas 0.05 	0 1.59 C5 Bcas 0.04 0 1.62 
Statistical Terms 
Mean: 	the sum of all the values divided by the number of values 
Variance: 	average of the squared distance of observations (i.e. sample values) 
from the mean 
Standard Deviation (s.d): the square root of the variance 
Coefficient of variation: 	(s.d./mean) x 100 
Mating regimes for BLG/7 line maintenance 
BLG/7 was made by microinjection of the 16.2 Kb Sal I fragment of the ovine 13 -
lactoglobulin genomic sequence into Fl (CBA: C57BL/6) fertilised eggs (Simons et 
a! 1987). 
G0 BLG/7 founder was bred to F 1 (CBA: C57BL/6). 
F 1 mice are generated by crossing a CBA with a C57BL16, both from inbred colonies 











C.1) Mating regimes for hemi- and homozygous BLG/7 populations 
Hemizygotes: 
BLG/7 hemi (F2) male x Fl (CBA: C57BL16) non- transgenic female 
+ 
BLG/7 hemi (F2) 
Homozygotes: 
BLG/ 7 hemi (F2) x BLG/ 7 hemi (F2) 
+ 
BLG/7 homozygote confirmed by Southern Blotting 
C) 	Maintained as closed homozygous colony 
C.2) Mating regimes for backcrossed BLG/7 populations 
CBA backcross: 
BLGI7 hemi (F2) male x CBA purebred inbred female 
Backcrossed male BLG/7 hemi progeny x CBA purebred inbred 
female 
CBA backcross stopped at generation 16 due to poor breeding performance. 
C57BL/6 backcross: 
C) 	BLG/7 hemi (F2) male x C57BL/6 purebred inbred female 
d) 	Backcrossed male BLG/7 hemi progeny x C57BL/6 purebred inbred 
female 
C57BL/6 backcross currently at generation 20. 
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